{
  "questions": [
    {
      "body": "What is the link between Ctf4 and Chl1 in cohesion establishment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27397686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23334284", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23036200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15226378", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17222391"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_513031343534001D", 
          "o": "CTF4"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_513031343534001D", 
          "o": "CTF4"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1427963", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20695577"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://purl.uniprot.org/uniprot/Q01454", 
          "o": "http://purl.uniprot.org/uniprot/Q01454"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://purl.uniprot.org/uniprot/Q01454", 
          "o": "http://purl.uniprot.org/uniprot/Q01454"
        }, 
        {
          "p": "http://purl.uniprot.org/core/encodedBy", 
          "s": "http://purl.uniprot.org/uniprot/Q01454", 
          "o": "http://linkedlifedata.com/resource/#_513031343534001D"
        }, 
        {
          "p": "http://purl.uniprot.org/core/encodedBy", 
          "s": "http://purl.uniprot.org/uniprot/Q01454", 
          "o": "http://linkedlifedata.com/resource/#_513031343534001D"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://purl.uniprot.org/uniprot/Q01454", 
          "o": "CTF4_YEAST"
        }
      ], 
      "ideal_answer": [
        "Ctf4 links DNA replication with sister chromatid cohesion establishment by recruiting the Chl1 helicase to the replisome. The Eco1 acetyltransferase, helped by factors including Ctf4 and Chl1, concomitantly acetylates the chromosomal cohesin complex to stabilize its cohesive links.", 
        "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3. Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment."
      ], 
      "concepts": [
        "http://www.biosemantics.org/jochem#4264134", 
        "http://amigo.geneontology.org/amigo/term/GO:0034085", 
        "http://amigo.geneontology.org/amigo/term/GO:0034087", 
        "http://amigo.geneontology.org/amigo/term/GO:0034089", 
        "http://www.biosemantics.org/jochem#4265011"
      ], 
      "type": "summary", 
      "id": "587f8324d8d850a152000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Ctf4 Links DNA Replication with Sister Chromatid Cohesion Establishment by Recruiting the Chl1 Helicase to the Replisome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 135, 
          "offsetInEndSection": 441, 
          "text": "The Eco1 acetyltransferase, helped by factors including Ctf4 and Chl1, concomitantly acetylates the chromosomal cohesin complex to stabilize its cohesive links. Here we show that Ctf4 recruits the Chl1 helicase to the replisome via a conserved interaction motif that Chl1 shares with GINS and polymerase \u03b1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 1079, 
          "text": "The Chl1 helicase facilitates replication fork progression under conditions of nucleotide depletion, partly independently of Ctf4 interaction. Conversely, Ctf4 interaction, but not helicase activity, is required for Chl1's role in sister chromatid cohesion. A physical interaction between Chl1 and the cohesin complex during S phase suggests that Chl1 contacts cohesin to facilitate its acetylation. Our results reveal how Ctf4 forms a replisomal interaction hub that coordinates replication fork progression and sister chromatid cohesion establishment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 630, 
          "offsetInEndSection": 858, 
          "text": "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1319, 
          "offsetInEndSection": 1490, 
          "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 430, 
          "offsetInEndSection": 629, 
          "text": "We show here that CTF8, CTF4 and a helicase encoded by CHL1 are required for efficient sister chromatid cohesion in unperturbed mitotic cells, and provide evidence that Chl1 functions during S-phase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 825, 
          "offsetInEndSection": 1002, 
          "text": "Our results suggest that Chl1 and Ctf4 are directly involved in homologous recombination repair rather than acting indirectly via the establishment of sister chromatid cohesion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17222391", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1328, 
          "offsetInEndSection": 1499, 
          "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1327, 
          "offsetInEndSection": 1497, 
          "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 432, 
          "offsetInEndSection": 630, 
          "text": "We show here that CTF8, CTF4 and a helicase encoded by CHL1 are required for efficient sister chromatid cohesion in unperturbed mitotic cells, and provide evidence that Chl1 functions during S-phase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 633, 
          "offsetInEndSection": 860, 
          "text": "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "Sister-chromatid cohesion mediated by the alternative RF-CCtf18/Dcc1/Ctf8, the helicase Chl1 and the polymerase-alpha-associated protein Ctf4 is essential for chromatid disjunction during meiosis II.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 633, 
          "offsetInEndSection": 862, 
          "text": "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Ctf4 Links DNA Replication with Sister Chromatid Cohesion Establishment by Recruiting the Chl1 Helicase to the Replisome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1328, 
          "offsetInEndSection": 1500, 
          "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 829, 
          "offsetInEndSection": 1007, 
          "text": "Our results suggest that Chl1 and Ctf4 are directly involved in homologous recombination repair rather than acting indirectly via the establishment of sister chromatid cohesion..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17222391", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How is primary intestinal lymphangiectasia (PIL) caused?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26962779", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19853733", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23180957", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18294365", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22110841", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26217101", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16292099", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20812055", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26908672", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23626516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26169531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19887697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8650761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24449480", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23229460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18855225", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23316917", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26405709", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25943403"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1418580", 
          "o": "http://linkedlifedata.com/resource/umls/label/A12036259"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A12036259", 
          "o": "PIL"
        }
      ], 
      "ideal_answer": [
        "Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by diffuse or localized dilation and eventual rupture of the enteric lymphatic vessels in mucosa, submucosa, and/or subserosa. Lymph, rich in all kinds of proteins and lymphocytes, leaks into the gastrointestinal tract via the affected lymphatic vessels causing hypoproteinemia and lymphopenia."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008201", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007413", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007410", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007422", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008200", 
        "http://www.disease-ontology.org/api/metadata/DOID:5295", 
        "http://www.disease-ontology.org/api/metadata/DOID:2402"
      ], 
      "type": "summary", 
      "id": "58ca5cba02b8c6095300002b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 390, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare disorder of unknown etiology characterized by diffuse or localized dilation and eventual rupture of the enteric lymphatic vessels in mucosa, submucosa, and/or subserosa. Lymph, rich in all kinds of proteins and lymphocytes, leaks into the gastrointestinal tract via the affected lymphatic vessels causing hypoproteinemia and lymphopenia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962779", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1778, 
          "offsetInEndSection": 1879, 
          "text": "PIL, effusions, and lymphedema can be the features of multisegmental generalized lymphatic dysplasia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962779", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "A number of disorders have been described to cause protein losing enteropathy (PLE) in children. Primary intestinal lymphangiectasia (PIL) is one mechanism leading to PLE.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 286, 
          "text": "Primary intestinal lymphangiectasia is a rare cause of protein-losing enteropathy and usually presents with intermittent diarrhea or malnutrition. Diagnosis depends largely on its pathologic condition demonstrating greatly dilated lymphatics mainly in the lamina propria of the mucosa. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853733", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 592, 
          "offsetInEndSection": 762, 
          "text": "The histopathologic condition of the resected small intestine showed lymphatic dilation limited mainly to the subserosa and mesentery but was not prominent in the mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853733", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 158, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal lymphatics and the development of protein-losing enteropathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22110841", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908672", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "Primary intestinal lymphangiectasia (PIL), so-called Waldmann's disease, is an uncommon condition, characterized by dilated intestinal submucosal and subserosal lymphatics of the gastrointestinal tract.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292099", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 273, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18294365", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 308, 
          "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812055", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing, exsudative gastroenteropathy causing lymphatic obstruction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing enteropathy characterized by tortuous and dilated lymph channels of the small bowel.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24449480", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 186, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare disease of intestinal lymphatics presenting with hypoproteinemia, bilateral lower limb edema, ascites, and protein losing enteropathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 215, 
          "text": "Exudative enteropathy secondary to primary intestinal lymphangiectasia (PIL) is characterized by lymphopenia, hypogammaglobulinemia and hypoalbuminemia resulting from leakage of lymph fluid into the intestinal tract", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855225", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy with lymphatic leakage into the small intestine", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26217101", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing enteropathy characterized by tortuous and dilated lymph channels of the small bowel", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24449480", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare disease of intestinal lymphatics presenting with hypoproteinemia, bilateral lower limb edema, ascites, and protein losing enteropathy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 200, 
          "text": "Primary intestinal lymphangiectasia (PIL), so-called Waldmanns disease, is an uncommon condition, characterized by dilated intestinal submucosal and subserosal lymphatics of the gastrointestinal tract", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292099", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 361, 
          "text": "Primary intestinal lymphangiectasia (Waldmanns disease) is a rare disease characterized by dilated lymphatics in the small bowel leading to an exudative enteropathy with lymphopenia, hypoalbuminemia and hypogammaglobulinemia.We report the case of a 23 year-old male who presented with chronic anemia and in whom primary intestinal lymphangiectasia was diagnosed", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405709", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 187, 
          "offsetInEndSection": 367, 
          "text": "We report a series of 4 children from Chennai, India presenting with anasarca, recurrent diarrhea, hypoproteinemia and confirmatory features of PIL on endoscopy and histopathology.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing, exsudative gastroenteropathy causing lymphatic obstruction. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy characterized by a congenital malformation of the lymphatic vessels of the small intestine causing insufficient drainage and leakage of lymph fluid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy with lymphatic leakage into the small intestine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26217101", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Primary intestinal lymphangiectasia (PIL) or Waldmann's disease is a rare protein-losing gastroenteropathy of unknown etiology.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626516", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are congenital disorders of glycosylation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26873821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26238249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27725718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25840006", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24157261"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Congenital disorders of glycosylation (CDG) are a growing group of inherited metabolic disorders where enzymatic defects in the formation or processing of glycolipids and/or glycoproteins lead to variety of different diseases.\nMore than 100 rare human genetic disorders that result from deficiencies in the different glycosylation pathways are known today.\t\nThe patients have hundreds of misglycosylated products, which afflict a myriad of processes, including cell signaling, cell-cell interaction, and cell migration."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58e115d66fddd3e83e00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Congenital disorder of glycosylation (CDG), formerly representing a group of diseases due to defects in the biosynthetic pathway of protein N-glycosylation, currently covers a wide range of disorders affecting glycoconjugates. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26873821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 219, 
          "text": "Congenital disorders of glycosylation form a rapidly growing group of inherited metabolic diseases. As glycosylation affects proteins all over the organism, a mutation in a single gene leads to a multisystemic disorder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 539, 
          "text": "Glycosylation is an integral part in health and disease, as emphasized by the growing number of identified glycosylation defects. In humans, proteins are modified with a diverse range of glycoforms synthesized in complex biosynthetic pathways. Glycosylation disorders have been described in congenital disorders of glycosylation (CDG) as well as in acquired disease conditions such and non-alcoholic fatty liver disease (NAFLD). A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725718", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 226, 
          "text": "Congenital disorders of glycosylation (CDG) are a growing group of inherited metabolic disorders where enzymatic defects in the formation or processing of glycolipids and/or glycoproteins lead to variety of different diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157261", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 223, 
          "offsetInEndSection": 354, 
          "text": " More than 100 rare human genetic disorders that result from deficiencies in the different glycosylation pathways are known today. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840006", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 719, 
          "offsetInEndSection": 880, 
          "text": "The patients have hundreds of misglycosylated products, which afflict a myriad of processes, including cell signaling, cell-cell interaction, and cell migration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840006", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the additions of the JASPAR 2016 open-access database of transcription factor binding profiles?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26531826"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Compared to the JASPAR CORE collection, JASPAR 2016 has been expanded with 494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and 59 profiles (58 in vertebrates and 1 in fungi) have been updated. The introduced profiles represent an 83% expansion and 10% update when compared to the previous release. The structural annotation of the TF DNA binding domains (DBDs) has been updated following a published hierarchical structural classification. In addition, 130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites were introduced . The new JASPAR release is accompanied by a new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence. Moreover, users are provided with a Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles. JASPAR2016 R/Bioconductor data package is also provided with the data of this release."
      ], 
      "exact_answer": [
        [
          "494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and updated 59 profiles (58 in vertebrates and 1 in fungi)"
        ], 
        [
          "Updated structural annotation of the TF DNA binding domains (DBDs) following a published hierarchical structural classification"
        ], 
        [
          "130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites"
        ], 
        [
          "A new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence"
        ], 
        [
          "A Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles"
        ], 
        [
          "JASPAR2016 R/Bioconductor data package"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "587d2b7efe8a08052f000003", 
      "snippets": [
        {
          "offsetInBeginSection": 267, 
          "offsetInEndSection": 1301, 
          "text": "For this 2016 release, we expanded the JASPAR CORE collection with 494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and updated 59 profiles (58 in vertebrates and 1 in fungi). The introduced profiles represent an 83% expansion and 10% update when compared to the previous release. We updated the structural annotation of the TF DNA binding domains (DBDs) following a published hierarchical structural classification. In addition, we introduced 130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites. This new JASPAR release is accompanied by a new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence. Moreover, we provide the users with a Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles. Finally, we provide the JASPAR2016 R/Bioconductor data package with the data of this release", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26531826", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the protein tafazzin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25688091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25118650", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25598000", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25941633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25919711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17082194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19700766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24714493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26415690", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21068380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16794186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25247053", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24858921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24318983"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0031843", 
          "o": "function"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0031843", 
          "o": "http://linkedlifedata.com/resource/umls/label/A3879881"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A3879881", 
          "o": "function"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0031843", 
          "o": "function"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "http://linkedlifedata.com/resource/umls/label/A12030635"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A12030635", 
          "o": "TAFAZZIN"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "TAZ"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "TAZ"
        }
      ], 
      "ideal_answer": [
        "Tafazzin is a phospholipid transacylase that transfers acyl chains with unsaturated fatty acids from phospholipids to monolysocardiolipin to generate cardiolipin with unsaturated fatty acids on mitochondrial membrane."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011506", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050476", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056889"
      ], 
      "type": "summary", 
      "id": "58d90b968acda3452900000e", 
      "snippets": [
        {
          "offsetInBeginSection": 104, 
          "offsetInEndSection": 282, 
          "text": "Tafazzin is a transacylase that transfers acyl chains with unsaturated fatty acids from phospholipids to monolysocardiolipin to generate cardiolipin with unsaturated fatty acids.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25688091", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Tafazzin (EC 2.3.1.23) is a Phospholipid Transacylase involved in Cardiolipin remodeling on mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: Xq28) in human.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25118650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Tafazzin is a transacylase that affects cardiolipin fatty acid composition and mitochondrial function. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25598000", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941633", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Tafazzin (TAZ) is a phospholipid transacylase that catalyzes the remodeling of cardiolipin, a mitochondrial phospholipid required for oxidative phosphorylation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25919711", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 303, 
          "offsetInEndSection": 479, 
          "text": "Tafazzin expression induced a new enzymatic function in Sf9 cell mitochondria, namely 1-palmitoyl-2-[14C]linoleoyl-phosphatidylcholine:monolysocardiolipin linoleoyltransferase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17082194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 605, 
          "offsetInEndSection": 897, 
          "text": "Among the human isoforms, only full-length tafazzin (FL) and tafazzin lacking exon 5 (Delta5) had transacylase activity, and only these two isoforms were able to restore a normal cardiolipin pattern, normal respiratory activity of mitochondria, and male fertility in tafazzin-deficient flies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 288, 
          "text": "Tafazzin is a mitochondrial transacylase required for cardiolipin remodeling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Tafazzin is a putative enzyme that is involved in cardiolipin metabolism, it may carry mutations responsible for Barth syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17082194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 563, 
          "offsetInEndSection": 790, 
          "text": "Tafazzin is an enzyme that remodels saturated fatty acyl chains within CL to unsaturated fatty acyl chains, loss of function mutations in the TAZ gene encoding tafazzin are causal for the inherited cardiomyopathy Barth syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 197, 
          "text": "The tafazzin gene encodes a phospholipid-lysophospholipid transacylase involved in cardiolipin metabolism, but it is not known why it forms multiple transcripts as a result of alternative splicing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1435, 
          "offsetInEndSection": 1684, 
          "text": "Furthermore, the data show that the expression of human tafazzin in flies creates cardiolipin with a Drosophila pattern, suggesting that the characteristic fatty acid profile of cardiolipin is not determined by the substrate specificity of tafazzin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Tafazzin is a transacylase that affects cardiolipin fatty acid composition and mitochondrial function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25598000", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are assassin bugs?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24438295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25996956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27058599", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25689825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26249492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24884699"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The family Reduviidae (Hemiptera: Heteroptera), or assassin bugs, is among the most diverse families of the true bugs, with more than 6,000 species."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58e12ea66fddd3e83e00000e", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "The complete mitochondrial genome of an assassin bug Peirates arcuatus (Hemiptera: Reduviidae).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24438295", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "First complete mitochondrial genome sequence from the tribelocephaline assassin bugs (Hemiptera: Reduviidae).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996956", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "The complete mitochondrial genome (mitogenome) of Opistoplatys sp. was determined, which was the first representation from the assassin bug subfamily Tribelocephalinae. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 160, 
          "text": "The family Reduviidae (Hemiptera: Heteroptera), or assassin bugs, is among the most diverse families of the true bugs, with more than 6,000 species.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27058599", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Comparative mitogenomics of the assassin bug genus Peirates (Hemiptera: Reduviidae: Peiratinae) ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689825", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Are the genes for marneral biosynthesis scattered in the genome of A. thaliana?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21876149"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Genes for marneral synthesis are organized in an operon-like gene cluster in thale cress (A. thaliana).", 
        "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation. ", 
        "These clusters are unlikely to have arisen by horizontal gene transfer, and the mechanisms behind their formation are poorly understood. Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58eb7898eda5a57672000006", 
      "snippets": [
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1284, 
          "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1057, 
          "offsetInEndSection": 1278, 
          "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 892, 
          "offsetInEndSection": 1063, 
          "text": "Previously in thale cress (Arabidopsis thaliana) we identified an operon-like gene cluster that is required for the synthesis and modification of the triterpene thalianol.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Prediction of operon-like gene clusters in the Arabidopsis thaliana genome based on co-expression analysis of neighboring genes", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561113", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1286, 
          "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1155, 
          "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 258, 
          "offsetInEndSection": 447, 
          "text": "the cyclic hydroxamic acid pathways in maize, the avenacin biosynthesis gene clusters in oat, the thalianol pathway in Arabidopsis thaliana, and the diterpenoid momilactone cluster in rice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561113", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Prediction of operon-like gene clusters in the Arabidopsis thaliana genome based on co-expression analysis of neighboring genes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561113", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is Dupilumab used for treatment of atopic dermatitis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27334730", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27906698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25006719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598956"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58df3e408acda3452900002d", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 149, 
          "text": "Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both type 2 helper T-cell-mediated diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1023, 
          "offsetInEndSection": 1161, 
          "text": "Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Dupilumab for the treatment of atopic dermatitis: A clinical trial review.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 143, 
          "offsetInEndSection": 255, 
          "text": "Dupilumab is a novel monoclonal antibody that was recently studied in adult patients with moderate-to-severe AD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2339, 
          "offsetInEndSection": 2472, 
          "text": "Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006719", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 746, 
          "offsetInEndSection": 978, 
          "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is base J found in the genome of Leishmania tarentolae?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25662217", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25104019", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19114062", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10562569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17329373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20215442"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.", 
        "base j (\u03b2-d-glucosyl-hydroxymethyluracil) replaces 1% of t in the leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.", 
        "j (\u03b2-d-glucosyl-hydroxymethyluracil) replaces 1% of t in the leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. . j is found predominantly in repetitive dna and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in trypanosoma brucei. . ", 
        "Base J (-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei. J is enriched at sites involved in RNA polymerase (RNAP) II initiation and termination. ", 
        "Base J (\u00ce\u00b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei.", 
        "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei."
      ], 
      "exact_answer": [
        [
          "telomeric repeats"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58cf5c5a8acda34529000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25662217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 107, 
          "offsetInEndSection": 266, 
          "text": "Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10562569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 155, 
          "offsetInEndSection": 242, 
          "text": "J is enriched at sites involved in RNA polymerase (RNAP) II initiation and termination.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25104019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25662217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Telomeric localization of the modified DNA base J in the genome of the protozoan parasite Leishmania", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17329373", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 107, 
          "offsetInEndSection": 267, 
          "text": "Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10562569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Base J is a hypermodified DNA base localized primarily to telomeric regions of the genome of Trypanosoma brucei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20215442", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which tool is available for predicting regulatory interactions from ChIP-seq data?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27924029"
      ], 
      "triples": [], 
      "ideal_answer": [
        "CisMapper predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel of tissues. CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue-specific gene expression. CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site of a gene is regulated by a particular binding site of the TF."
      ], 
      "exact_answer": [
        [
          "CisMapper"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "587e0116ae05ffb474000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 741, 
          "text": "We present CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel of tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 742, 
          "offsetInEndSection": 1077, 
          "text": "Using both chromatin conformation capture and differential expression data, we show that CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue-specific gene expression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1078, 
          "offsetInEndSection": 1338, 
          "text": " CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site of a gene is regulated by a particular binding site of the TF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 742, 
          "offsetInEndSection": 1078, 
          "text": "Using both chromatin conformation capture and differential expression data, we show that CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue-specific gene expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where are the unipolar brush cells localized?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17409247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8821458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17223277", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8059339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9023728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11457596", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7978355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16289944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11396855", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8300904", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12814190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9193142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12655510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20937306", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14614902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15940501", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19409228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21190007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16344141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8177517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7673463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7472327", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11044898", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9923978"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0392752", 
          "o": "Localized"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0392752", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0428112"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0428112", 
          "o": "LOCALIZED"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0392752", 
          "o": "Localized"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0392752", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7581226"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7581226", 
          "o": "Localized"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0392752", 
          "o": "http://linkedlifedata.com/resource/umls/label/A6833253"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A6833253", 
          "o": "Localized"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0392752", 
          "o": "Localized"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0392752", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18656681"
        }
      ], 
      "ideal_answer": [
        "Unipolar brush cells (UBCs) are glutamatergic interneurons localized in granule cell regions of the cochlear nucleus and the vestibulocerebellum of cerebellum."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477"
      ], 
      "type": "summary", 
      "id": "58c67bf302b8c60953000026", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "Cerebellar unipolar brush cells (UBCs) are glutamatergic interneurons that receive direct input from vestibular afferents in the form of a unique excitatory synapse on their dendritic brush. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17409247", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 552, 
          "offsetInEndSection": 677, 
          "text": "Immunostained unipolar brush cells were observed in granule cell regions of the cochlear nucleus and the vestibulocerebellum.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8821458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Postsynaptic enrichment of Eps8 at dendritic shaft synapses of unipolar brush cells in rat cerebellum.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223277", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 749, 
          "offsetInEndSection": 874, 
          "text": "In cerebellum, unipolar brush cells (UBCs) were densely Eps8 immunopositive and granule cells were moderately immunostained. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223277", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Postnatal differentiation of unipolar brush cells and mossy fiber-unipolar brush cell synapses in rat cerebellum.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11457596", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 485, 
          "offsetInEndSection": 725, 
          "text": "Knowledge of the ultrastructure of the unipolar brush cell terminals and of the cellular identity of its postsynaptic targets is required to understand how unipolar brush cells contribute to information processing in the cerebellar circuit.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 725, 
          "offsetInEndSection": 1001, 
          "text": "To investigate the unipolar brush cell axon and its targets, unipolar brush cells were patch-clamped in fresh parasagittal slices from rat cerebellar vermis with electrodes filled with Lucifer Yellow and Biocytin, and examined by confocal fluorescence and electron microscopy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "Calretinin-immunoreactive unipolar brush cells in the developing human cerebellum.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16289944", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Unipolar brush cell: a potential feedforward excitatory interneuron of the cerebellum.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1100, 
          "offsetInEndSection": 1160, 
          "text": "Unipolar brush cells are also found in the cochlear nucleus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7978355", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1783, 
          "offsetInEndSection": 1856, 
          "text": "The unipolar brush cells reside nearly exclusively in the granular layer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7978355", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1109, 
          "offsetInEndSection": 1249, 
          "text": "In the monkey cerebellum, unipolar brush cells, localized in the granular layer, were heavily labeled, whereas Golgi cells were devoid of NG", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Unipolar brush cells (UBC) are small, glutamatergic neurons residing in the granular layer of the cerebellar cortex and the granule cell domain of the cochlear nuclear complex", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20937306", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 488, 
          "offsetInEndSection": 727, 
          "text": "Knowledge of the ultrastructure of the unipolar brush cell terminals and of the cellular identity of its postsynaptic targets is required to understand how unipolar brush cells contribute to information processing in the cerebellar circuit", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 729, 
          "offsetInEndSection": 1004, 
          "text": "To investigate the unipolar brush cell axon and its targets, unipolar brush cells were patch-clamped in fresh parasagittal slices from rat cerebellar vermis with electrodes filled with Lucifer Yellow and Biocytin, and examined by confocal fluorescence and electron microscopy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 320, 
          "offsetInEndSection": 521, 
          "text": "While granule cells express solely VGLUT1, there is no report about the VGLUT(s) of the unipolar brush cell (UBC), the second type of glutamatergic interneuron residing in the cerebellar granular layer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14614902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 484, 
          "offsetInEndSection": 759, 
          "text": "Large clusters of labeled nuclei consisting mainly of granule cells and calretinin-positive unipolar brush cells were present in the granular layer, whereas Purkinje cell nuclei were unlabeled, and labeled basket and stellate cell nuclei were scattered in the molecular layer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15940501", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Unipolar brush cells (UBCs) are a class of excitatory interneuron found in the granule cell layer of the vestibulocerebellum", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19409228", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "TBR2-immunopsitive unipolar brush cells are associated with ectopic zebrin II-immunoreactive Purkinje cell clusters in the cerebellum of scrambler mice", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21190007", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "Glutamate receptor subunits at mossy fiber-unipolar brush cell synapses: light and electron microscopic immunocytochemical study in cerebellar cortex of rat and cat.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7673463", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "Properties of transmission at a giant glutamatergic synapse in cerebellum: the mossy fiber-unipolar brush cell synapse.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7472327", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Metabotropic glutamate receptors are associated with non-synaptic appendages of unipolar brush cells in rat cerebellar cortex and cochlear nuclear complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9923978", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "The unipolar brush cells of the rat cerebellar cortex and cochlear nucleus are calretinin-positive: a study by light and electron microscopic immunocytochemistry.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7978355", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Cerebellar choline acetyltransferase positive mossy fibres and their granule and unipolar brush cell targets: a model for central cholinergic nicotinic neurotransmission.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9023728", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 749, 
          "offsetInEndSection": 873, 
          "text": "In cerebellum, unipolar brush cells (UBCs) were densely Eps8 immunopositive and granule cells were moderately immunostained.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223277", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1109, 
          "offsetInEndSection": 1250, 
          "text": "In the monkey cerebellum, unipolar brush cells, localized in the granular layer, were heavily labeled, whereas Golgi cells were devoid of NG.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2164, 
          "offsetInEndSection": 2415, 
          "text": "The results indicate that synaptic excitation of unipolar brush cells by mossy fibers will drive a large population of granule cells, and thus will contribute a powerful form of distributed excitation within the basic circuit of the cerebellar cortex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 227, 
          "offsetInEndSection": 339, 
          "text": "These neurons, here termed unipolar brush cells, are intermediate in size between granule cells and Golgi cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8300904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Extraordinary synapses of the unipolar brush cell: an electron microscopic study in the rat cerebellum.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8059339", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 488, 
          "offsetInEndSection": 728, 
          "text": "Knowledge of the ultrastructure of the unipolar brush cell terminals and of the cellular identity of its postsynaptic targets is required to understand how unipolar brush cells contribute to information processing in the cerebellar circuit.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "The unipolar brush cell: a neglected neuron of the mammalian cerebellar cortex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8300904", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Postnatal differentiation of unipolar brush cells and mossy fiber-unipolar brush cell synapses in rat cerebellum.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11457596", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 729, 
          "offsetInEndSection": 1005, 
          "text": "To investigate the unipolar brush cell axon and its targets, unipolar brush cells were patch-clamped in fresh parasagittal slices from rat cerebellar vermis with electrodes filled with Lucifer Yellow and Biocytin, and examined by confocal fluorescence and electron microscopy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which driver mutations have been identified for Diffuse Intrinsic Pontine Glioma (DIPG)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27048880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26727948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24297113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25182241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27251074"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. Conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) was observed across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n\u2009=\u20092), PIK3CA (n\u2009=\u20092), FGFR1 (n\u2009=\u20092), and MET (n\u2009=\u20091) were also intra-tumorally conserved.  TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.", 
        "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs", 
        "We found conservation of heterozygous K27M mutations in H3F3A (n=4) or HIST1H3B (n=3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). TP53 aberrations (n=3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. ACVR1 (n=2), PIK3CA (n=2), FGFR1 (n=2), and MET (n=1) were also intra-tumorally conserved. ", 
        "found conservation of heterozygous k27m mutations in h3f3a (n\u2009=\u20094) or hist1h3b (n\u2009=\u20093) across all primary , contiguous , and metastatic tumor sites in all dipgs . h3k27m ubiquitously-associated mutations involve alterations in tp53 cell-cycle (tp53/ppm1d) or specific growth factor pathways (acvr1/pik3r1) . reconstruction indicates histone 3 (h3) k27m--including h3.2k27m--mutations potentially arise first and are invariably associated with specific , high-fidelity obligate partners throughout the tumour and its spread , from diagnosis to end-stage disease , suggesting mutual need for tumorigenesis. . aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. . ", 
        "We found conservation of heterozygous K27M mutations in H3F3A (n=4) or HIST1H3B (n=3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n=2), PIK3CA (n=2), FGFR1 (n=2), and MET (n=1) were also intra-tumorally conserved. TP53 aberrations (n=3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). ", 
        "Recurrent mutations within the histone H3 genes H3F3A and HIST1H3B that convert K27 to methionine (H3K27M) and disrupt the global H3K27 methylation landscape and PRC2-dependent silencing, have recently been identified in pediatric high-grade gliomas including Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma multiforme (GBM; Type IV glioma). The spatial and temporal homogeneity of main driver mutations in DIPG implies they will be captured by limited biopsies and emphasizes the need to develop therapies specifically targeting obligate oncohistone partnerships. TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide therapeutic strategy. Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors. Sequencing analysis showed c.83A>T mutations in the H3F3A or HIST1H3B gene in 77\u00a0% of our DIPG cohort. Protein profiling identified 2,305 unique proteins indicating distinct DIPG protein expression patterns compared to other pediatric brain tumors. Two distinct subgroups of DIPG were identified.", 
        "We found conservation of heterozygous K27M mutations in H3F3A (n\u00e2\u0080\u0089=\u00e2\u0080\u00894) or HIST1H3B (n\u00e2\u0080\u0089=\u00e2\u0080\u00893) across all primary, contiguous, and metastatic tumor sites in all DIPGs. Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1).", 
        "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). ", 
        "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs  TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1).", 
        "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs ACVR1 (n\u2009=\u20092), PIK3CA (n\u2009=\u20092), FGFR1 (n\u2009=\u20092), and MET (n\u2009=\u20091) were also intra-tumorally conserved  TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved."
      ], 
      "exact_answer": [
        [
          "K27M in H3F3A"
        ], 
        [
          "HIST1H3B"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58add1d79ef3c34033000008", 
      "snippets": [
        {
          "offsetInBeginSection": 1101, 
          "offsetInEndSection": 1262, 
          "text": "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727948", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1264, 
          "offsetInEndSection": 1361, 
          "text": "ACVR1 (n\u2009=\u20092), PIK3CA (n\u2009=\u20092), FGFR1 (n\u2009=\u20092), and MET (n\u2009=\u20091) were also intra-tumorally conserved", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727948", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1549, 
          "offsetInEndSection": 1691, 
          "text": " TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727948", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 298, 
          "offsetInEndSection": 604, 
          "text": "Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 605, 
          "offsetInEndSection": 755, 
          "text": "These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 397, 
          "offsetInEndSection": 648, 
          "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1238, 
          "offsetInEndSection": 1379, 
          "text": "Moreover, in diffuse intrinsic pontine gliomas (DIPG), recurrent somatic mutations of ACVR1 were found in association with HIST1H3B mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 400, 
          "offsetInEndSection": 650, 
          "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 318, 
          "offsetInEndSection": 668, 
          "text": "Recurrent mutations within the histone H3 genes H3F3A and HIST1H3B that convert K27 to methionine (H3K27M) and disrupt the global H3K27 methylation landscape and PRC2-dependent silencing, have recently been identified in pediatric high-grade gliomas including Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma multiforme (GBM; Type IV glioma).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27251074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1137, 
          "offsetInEndSection": 1239, 
          "text": "Sequencing analysis showed c.83A>T mutations in the H3F3A or HIST1H3B gene in 77\u00a0% of our DIPG cohort.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297113", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 400, 
          "offsetInEndSection": 651, 
          "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Does Jarid2 play a role in early embryo development?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26190104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20075857", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17521633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24374312"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1416528", 
          "o": "JARID2"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5139323833330020", 
          "o": "JARID2"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5139323833330020", 
          "o": "JARID2"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1416528", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20738817"
        }
      ], 
      "ideal_answer": [
        "Yes. Jarid2 coordinates Nanog expression and PCP/Wnt signaling required for efficient ESC differentiation and early embryo development."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D047108", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005314", 
        "http://amigo.geneontology.org/amigo/term/GO:0009790", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063146"
      ], 
      "type": "yesno", 
      "id": "5883781b2305cd7e21000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 107, 
          "offsetInEndSection": 1159, 
          "text": "Unlike other PRC2-deficient embryonic stem cells (ESCs), however, Jarid2-deficient ESCs show a severe differentiation block, altered colony morphology, and distinctive patterns of deregulated gene expression. Here, we show that Jarid2(-/-) ESCs express constitutively high levels of Nanog but reduced PCP signaling components Wnt9a, Prickle1, and Fzd2 and lowered \u03b2-catenin activity. Depletion of Wnt9a/Prickle1/Fzd2 from wild-type ESCs or overexpression of Nanog largely phenocopies these cellular defects. Co-culture of Jarid2(-/-) with wild-type ESCs restores variable Nanog expression and \u03b2-catenin activity and can partially rescue the differentiation block of mutant cells. In addition, we show that ESCs lacking Jarid2 or Wnt9a/Prickle1/Fzd2 or overexpressing Nanog induce multiple ICM formation when injected into normal E3.5 blastocysts. These data describe a previously unrecognized role for Jarid2 in regulating a core pluripotency and Wnt/PCP signaling circuit that is important for ESC differentiation and for pre-implantation development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 909, 
          "offsetInEndSection": 1075, 
          "text": "Consistent with an essential role for PcG proteins in early development, we demonstrate that JARID2 is required for the differentiation of mouse embryonic stem cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20075857", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Jumonij (JMJ)/Jarid2 plays important roles in embryonic development and functions as a transcriptional repressor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17521633", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1083, 
          "offsetInEndSection": 1293, 
          "text": "Thus, these results demonstrate that JARID2 is essential for the binding of PcG proteins to target genes and, consistent with this, for the proper differentiation of embryonic stem cells and normal development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20075857", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "JARID2 is an accessory component of Polycomb repressive complex-2 (PRC2) required for the differentiation of embryonic stem cells (ESCs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24374312", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 954, 
          "offsetInEndSection": 1160, 
          "text": "These data describe a previously unrecognized role for Jarid2 in regulating a core pluripotency and Wnt/PCP signaling circuit that is important for ESC differentiation and for pre-implantation development..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is PUVA therapy indicated for eczema treatment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22738245", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18712324", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17254029", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14699368", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8445063", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7662576", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10321515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23420314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3903677", 
        "http://www.ncbi.nlm.nih.gov/pubmed/708596", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11499537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8088142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9640882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17673386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15611423"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0034172", 
          "o": "PUVA Therapy"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0034172", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0444272"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0444272", 
          "o": "PUVA therapy"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0034172", 
          "o": "PUVA Therapy"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1704892", 
          "o": "PUVA therapy"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0034172", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0107279"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0107279", 
          "o": "Psoralen Ultraviolet A Therapy"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0034172", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20221619"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20221619", 
          "o": "Psoralen Ultraviolet A Therapy"
        }
      ], 
      "ideal_answer": [
        "Yes, PUVA (psoralen plus UVA) therapy is effective for eczema treatment and has relatively few side effects."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011701", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004485"
      ], 
      "type": "yesno", 
      "id": "58bfe70e02b8c60953000019", 
      "snippets": [
        {
          "offsetInBeginSection": 719, 
          "offsetInEndSection": 960, 
          "text": "With bath PUVA treatment, the best results were found in patients with hyperkeratotic eczema (17/22; 77% good clinical response) followed by patients with palmoplantar psoriasis (26/41; 63%) and patients with dyshidrotic eczema (8/16; 50%). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22738245", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 148, 
          "text": "Both oral and bath PUVA with 8-methoxypsoralen (8-MOP) have been shown to be effective in the treatment of chronic palmoplantar eczema. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1175, 
          "offsetInEndSection": 1290, 
          "text": "Oral PUVA is preferable for patients with hyperkeratotic eczema and bath PUVA for patients with dyshidrotic eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 301, 
          "text": "Treatment of hand eczema is dominated by the administration of topical glucocorticosteriods. If topical treatment fails, the best second-line option is ultraviolet (UV) therapy alone or as combination therapy. UVB and PUVA (psoralen plus UVA) therapy is effective and has relatively few side effects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18712324", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 111, 
          "offsetInEndSection": 301, 
          "text": "Although local PUVA has been proven to be effective in the treatment of chronic hand eczema, little is known about the efficacy and safety of local narrowband UVB (TL-01) for this condition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1869, 
          "offsetInEndSection": 2015, 
          "text": "Local narrowband UVB phototherapy regimen is as effective as paint-PUVA therapy in patients with chronic hand eczema of dry and dyshidrotic types.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1631, 
          "offsetInEndSection": 1859, 
          "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Treatment of chronic palmoplantar eczema with local bath-PUVA therapy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Bath-PUVA therapy has been described as successful treatment for palmoplantar eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Systemic PUVA therapy may be useful in the treatment of chronic palmoplantar eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 174, 
          "text": "A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 829, 
          "offsetInEndSection": 1076, 
          "text": "These results indicate that topical PUVA therapy with psoralen in aqueous gel is a useful therapeutic modality for treatment of psoriasis patients, and patients with recalcitrant dermatoses such as palmoplantar psoriasis and hyperkeratotic eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 458, 
          "text": "In order to evaluate environmental influences possibly having an impact on the efficacy of this therapy, smokers and non-smokers suffering from palmoplantar eczema treated with bath-PUVA therapy were compared.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 158, 
          "offsetInEndSection": 210, 
          "text": "PUVA therapy caused acute aggravation of the eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8088142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1073, 
          "offsetInEndSection": 1290, 
          "text": "Hyperkeratotic eczema cleared significantly better with oral than with bath PUVA (P=0.03).CONCLUSION: Oral PUVA is preferable for patients with hyperkeratotic eczema and bath PUVA for patients with dyshidrotic eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "BACKGROUND: Systemic PUVA therapy may be useful in the treatment of chronic palmoplantar eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 835, 
          "offsetInEndSection": 1082, 
          "text": "These results indicate that topical PUVA therapy with psoralen in aqueous gel is a useful therapeutic modality for treatment of psoriasis patients, and patients with recalcitrant dermatoses such as palmoplantar psoriasis and hyperkeratotic eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 819, 
          "offsetInEndSection": 1026, 
          "text": "Vitiligo (60.9%) was the commonest skin disorder treated with PUVA, followed by psoriasis (20.9%), endogenous eczema (11.3%), mycosis fungoides (3.5%), lichen amyloidosis (2.6%) and prurigo nodularis (0.9%).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11499537", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 75, 
          "text": "bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "A 36-year-old female patient was treated with PUVA for dyshidrotic eczema that had not shown sufficient response to topical therapy over the previous months.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8088142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "BACKGROUND: Both oral and bath PUVA with 8-methoxypsoralen (8-MOP) have been shown to be effective in the treatment of chronic palmoplantar eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 909, 
          "offsetInEndSection": 1179, 
          "text": "One patient with hand eczema consistently had detectable 8-MOP levels 1 hour after topical PUVA treatments.CONCLUSION: This report indicates that there is minimal, if any, systemic absorption of 8-MOP after topical PUVA treatment of patients with palmoplantar psoriasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8445063", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1608, 
          "offsetInEndSection": 1963, 
          "text": "In the narrowband UVB-treated side, the tolerance of all the patients to the treatment was good all patients well-tolerated the treatment with the exception of mild xerosis that responded to topical emollients.Local narrowband UVB phototherapy regimen is as effective as paint-PUVA therapy in patients with chronic hand eczema of dry and dyshidrotic types", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Bath-PUVA therapy has been described as successful treatment for palmoplantar eczema", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1648, 
          "offsetInEndSection": 1875, 
          "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Systemic PUVA therapy may be useful in the treatment of chronic palmoplantar eczema", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 710, 
          "text": "However, few data are available on the effectiveness of local bath-PUVA therapy in palmoplantar eczema.Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment.After fungal or bacterial infection had been excluded in all patients, hands or feet or both were soaked for 15 minutes in warm water containing 1 mg/L 8-methoxypsoralen", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1333, 
          "offsetInEndSection": 1504, 
          "text": "No phototoxic reactions were observed.Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "Treatment of chronic palmoplantar eczema with local bath-PUVA therapy", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Bath-PUVA therapy has been described as successful treatment for palmoplantar eczema. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1642, 
          "offsetInEndSection": 1870, 
          "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 369, 
          "offsetInEndSection": 566, 
          "text": "OBJECTIVE: Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1416, 
          "offsetInEndSection": 1563, 
          "text": "CONCLUSION: Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 45, 
          "text": "Topical PUVA therapy for chronic hand eczema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9640882", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 711, 
          "text": "However, few data are available on the effectiveness of local bath-PUVA therapy in palmoplantar eczema.Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment.After fungal or bacterial infection had been excluded in all patients, hands or feet or both were soaked for 15 minutes in warm water containing 1 mg/L 8-methoxypsoralen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1333, 
          "offsetInEndSection": 1505, 
          "text": "No phototoxic reactions were observed.Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1648, 
          "offsetInEndSection": 1876, 
          "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 86, 
          "offsetInEndSection": 250, 
          "text": "However, our own observations showed that patients with palmoplantar eczema of the dyshidrotic or hyperkeratotic type responded only partially to bath-PUVA therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1608, 
          "offsetInEndSection": 1964, 
          "text": "In the narrowband UVB-treated side, the tolerance of all the patients to the treatment was good all patients well-tolerated the treatment with the exception of mild xerosis that responded to topical emollients.Local narrowband UVB phototherapy regimen is as effective as paint-PUVA therapy in patients with chronic hand eczema of dry and dyshidrotic types.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14699368", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1374, 
          "offsetInEndSection": 1558, 
          "text": "No phototoxic reactions were observed.CONCLUSION: Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 835, 
          "offsetInEndSection": 1083, 
          "text": "These results indicate that topical PUVA therapy with psoralen in aqueous gel is a useful therapeutic modality for treatment of psoriasis patients, and patients with recalcitrant dermatoses such as palmoplantar psoriasis and hyperkeratotic eczema..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "Treatment of chronic palmoplantar eczema with local bath-PUVA therapy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1132, 
          "offsetInEndSection": 1248, 
          "text": "Oral PUVA is preferable for patients with hyperkeratotic eczema and bath PUVA for patients with dyshidrotic eczema..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1375, 
          "offsetInEndSection": 1509, 
          "text": "Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 356, 
          "text": "However, few data are available on the effectiveness of local bath-PUVA therapy in palmoplantar eczema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1642, 
          "offsetInEndSection": 1871, 
          "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 114, 
          "offsetInEndSection": 445, 
          "text": "In order to investigate the effectiveness of topical PUVA-bath therapy (PUVA-soak therapy) on chronic palmoplantar dermatoses, 30 patients with plaque-type psoriasis, pustular psoriasis, endogenous eczema, dyshidrotic eczema and hyperkeratotic dermatitis of the palms and soles were treated over 8 weeks with PUVA-soak using 8-MOP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10321515", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 542, 
          "text": "Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is DECKO?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26493208"
      ], 
      "triples": [], 
      "ideal_answer": [
        "DECKO (Double Excision CRISPR Knockout) is a dual CRISPR tool, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064113"
      ], 
      "type": "summary", 
      "id": "58837ba62305cd7e21000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "DECKO: Single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1213, 
          "offsetInEndSection": 1443, 
          "text": "We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 132, 
          "offsetInEndSection": 559, 
          "text": " We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously. The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "DECKO: Single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 340, 
          "text": "We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 340, 
          "offsetInEndSection": 545, 
          "text": "The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 340, 
          "text": "We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 342, 
          "offsetInEndSection": 748, 
          "text": "The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.We apply DECKO to deleting the promoters of one protein-coding gene and two oncogenic lncRNAs, UCA1 and the highly-expressed MALAT1, focus of many previous studies employing RNA interference approaches", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1062, 
          "offsetInEndSection": 1408, 
          "text": "These clones have reductions in steady-state MALAT1 RNA levels of up to 98 % and display reduced proliferation rates.We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 341, 
          "text": "We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 342, 
          "offsetInEndSection": 749, 
          "text": "The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.We apply DECKO to deleting the promoters of one protein-coding gene and two oncogenic lncRNAs, UCA1 and the highly-expressed MALAT1, focus of many previous studies employing RNA interference approaches.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1062, 
          "offsetInEndSection": 1409, 
          "text": "These clones have reductions in steady-state MALAT1 RNA levels of up to 98 % and display reduced proliferation rates.We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "DECKO: Single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1181, 
          "offsetInEndSection": 1412, 
          "text": "We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List genes associated with hypolipidemia.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26546829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24751931", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22247256", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22062970"
      ], 
      "triples": [], 
      "ideal_answer": [
        "PCSK9\nAPOB \nANGPTL3\nANGPTL4\nMTP"
      ], 
      "exact_answer": [
        [
          "PCSK9"
        ], 
        [
          "APOB"
        ], 
        [
          "ANGPTL3"
        ], 
        [
          "ANGPTL4"
        ], 
        [
          "MTP"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58dfd83a6fddd3e83e000003", 
      "snippets": [
        {
          "offsetInBeginSection": 622, 
          "offsetInEndSection": 788, 
          "text": " Conversely familial hypobetalipoproteinemia is caused by inactivation of the PCSK9 gene which increases the number of LDL receptors and decreases plasma cholesterol.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546829", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 789, 
          "offsetInEndSection": 985, 
          "text": "Mutations in the genes APOB, and ANGPTL3 and ANGPTL4 (that encode angiopoietin-like proteins which inhibit lipoprotein lipase activity) can further cause low levels of apoB containing lipoproteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546829", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 19, 
          "offsetInEndSection": 329, 
          "text": "Several mutations in the apoB, proprotein convertase subtilisin/kexin type 9 (PCSK9), and MTP genes result in low or absent levels of apoB and LDL-cholesterol in plasma, which cause familial hypobetalipoproteinemia and abetalipoproteinemia. Mutations in the ANGPTL3 gene cause familial combined hypolipidemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24751931", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 222, 
          "text": "Mutations of the ANGPTL3 gene have been associated with a novel form of primary hypobetalipoproteinemia, the combined hypolipidemia (cHLP), characterized by low total cholesterol and low HDL-cholesterol levels. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247256", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1189, 
          "offsetInEndSection": 1437, 
          "text": "These results demonstrated that in a cohort of subjects with severe primary hypobetalipoproteinemia the prevalence of ANGPTL3 gene mutations responsible for a combined hypolipidemia phenotype is about 10%, whereas mutations of APOB gene are absent.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247256", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 142, 
          "offsetInEndSection": 354, 
          "text": "Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1703, 
          "offsetInEndSection": 2022, 
          "text": "Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I-containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the enzymatic activity of PARL?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21355049", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21415861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19859837", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17938163"
      ], 
      "triples": [], 
      "ideal_answer": [
        "the mitochondrial protease presenilin-associated rhomboid-like (PARL). Rhomboids are a recently discovered family of widely distributed intramembrane serine proteases."
      ], 
      "exact_answer": [
        [
          "PARL are serine proteases"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58dfe6b56fddd3e83e000004", 
      "snippets": [
        {
          "offsetInBeginSection": 743, 
          "offsetInEndSection": 970, 
          "text": "Here we demonstrate that the mitochondrial protease presenilin-associated rhomboid-like (PARL) can affect the proteolytic processing of PINK1 and that normal PINK1 localization and stability requires PARL's catalytic activity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21355049", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 210, 
          "text": "The mitochondrial rhomboid protease Parl governs apoptosis, morphology, metabolism and might be implicated in Parkinson's disease, but the structural basis of its activity and complex regulation remain unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21415861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 43, 
          "offsetInEndSection": 248, 
          "text": ". In this study, we evaluated the mRNA levels of presenilins-associated rhomboid-like protein (PARL) and mitochondrial content and enzyme activity from skeletal muscle isolated from insulin-resistant rats.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19859837", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Rhomboids are a recently discovered family of widely distributed intramembrane serine proteases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17938163", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Do brown fat cells produce heat?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24567786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25466254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23818608", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22654830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21196229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16594742", 
        "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2039657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3083882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1550210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9277366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22796012", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19641492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/5262992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26910308", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26496384", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27528697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24129212", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15058310", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23834768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21982742", 
        "http://www.ncbi.nlm.nih.gov/pubmed/541897", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6819159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26322018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24046370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25068090", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21123942", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8042786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6315457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27528872", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6148836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25642708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27552974", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26912151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26749900"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0018837", 
          "o": "Heat"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0018837", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0066521"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0066521", 
          "o": "Heat"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0018837", 
          "o": "Heat"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0018837", 
          "o": "Heat"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0018837", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18591807"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18591807", 
          "o": "heat"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0018837", 
          "o": "Heat"
        }
      ], 
      "ideal_answer": [
        "Yes, brown fat cells produce heat."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052437", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002001", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005223", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006359"
      ], 
      "type": "yesno", 
      "id": "58ca906a02b8c6095300002e", 
      "snippets": [
        {
          "offsetInBeginSection": 271, 
          "offsetInEndSection": 512, 
          "text": "WAT and BAT are both involved in energy balance. WAT is mainly involved in the storage and mobilization of energy in the form of triglycerides, whereas BAT specializes in dissipating energy as heat during cold- or diet-induced thermogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24567786", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 76, 
          "offsetInEndSection": 288, 
          "text": "Because brown adipose\u00a0tissue (BAT) dissipates energy in the form of heat, increasing energy expenditure by augmenting BAT-mediated thermogenesis may represent an approach to counter obesity and its complications.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25466254", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 254, 
          "text": "Classic brown fat and inducible beige fat both dissipate chemical energy in the form of heat through the actions of mitochondrial uncoupling protein 1. This nonshivering thermogenesis is crucial for mammals as a defense against cold and obesity/diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818608", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 105, 
          "offsetInEndSection": 245, 
          "text": "Mitochondrial uncoupling protein 1 in brown fat cells produces heat by dissipating the energy generated by fatty acid and glucose oxidation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22654830", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 36, 
          "text": "Brown fat biology and thermogenesis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Brown fat (brown adipose tissue, BAT) primary function is to produce heat. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 165, 
          "offsetInEndSection": 353, 
          "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1226, 
          "offsetInEndSection": 1487, 
          "text": "Calorimetric measurements from cell suspensions showed that ATP increased basal heat production of isolated brown fat cells by approximately 40% but had no effect on the greater than fivefold increase in heat production seen with maximal adrenergic stimulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9277366", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Classic brown fat and inducible beige fat both dissipate chemical energy in the form of heat through the actions of mitochondrial uncoupling protein 1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818608", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 182, 
          "text": "Brown adipocytes oxidize fatty acids to produce heat in response to cold or to excessive energy intake; stimulation of brown fat development and function may thus counteract obesity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21982742", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1032, 
          "offsetInEndSection": 1285, 
          "text": "The occurrence of Types 1 and/or 6 cells that has been revealed in 65 out of the total 180 samples (36%), suggests that the oxidation of fat for the thermogenesis proceeds in the brown fat tissue and that brown fat cells partially undergo fat depletion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 354, 
          "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 126, 
          "offsetInEndSection": 333, 
          "text": "In response to cold, both classical brown fat and the newly identified \"beige\" or \"brite\" cells are activated by \u03b2-adrenergic signaling and catabolize stored lipids and carbohydrates to produce heat via UCP1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "The ability of brown adipocytes (fat cells) to dissipate energy as heat shows great promise for the treatment of obesity and other metabolic disorders", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26496384", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Inappropriate heat dissipation ignites brown fat thermogenesis in mice with a mutant thyroid hormone receptor \u03b11", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24046370", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 64, 
          "text": "Brown fat and vascular heat dissipation: The new cautionary tail", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25068090", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 255, 
          "offsetInEndSection": 458, 
          "text": "Brown adipose produces heat as a defense against hypothermia and obesity, and the appearance of brown-like adipocytes within white adipose tissue depots is associated with improved metabolic phenotypes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21123942", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1764, 
          "offsetInEndSection": 1902, 
          "text": "In the same manner, marked ability to produce a considerable amount of heat was evidenced in  brown fat tissue of children and teenagers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 355, 
          "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1616, 
          "offsetInEndSection": 1739, 
          "text": "It is inferred that brown-adipose-tissue heat production is reduced during (and probably also some time after) anesthesia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8042786", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Parallel measurements of heat production and thermogenin content in brown fat cells during cold acclimation of rats.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3083882", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 39, 
          "offsetInEndSection": 287, 
          "text": "The classical white adipose tissue builds up energy in the form of triglycerides and is useful for preventing fatigue during periods of low caloric intake and the brown adipose tissue instead of inducing fat accumulation can produce energy as heat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528872", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 126, 
          "offsetInEndSection": 334, 
          "text": "In response to cold, both classical brown fat and the newly identified \"beige\" or \"brite\" cells are activated by \u03b2-adrenergic signaling and catabolize stored lipids and carbohydrates to produce heat via UCP1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 103, 
          "offsetInEndSection": 245, 
          "text": "White adipose tissue stores energy reserves as fat, whereas the metabolic function of brown adipose tissue is lipid oxidation to produce heat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23834768", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "The main function of brown adipose tissue (BAT) is to produce heat in response to cold.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6148836", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Brown adipocytes oxidize fatty acids to produce heat in response to cold or caloric overfeeding.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129212", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Brown fat (brown adipose tissue, BAT) primary function is to produce heat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 293, 
          "text": "Adipose tissue plays an active role in energy balance because it is not only a lipid storing and mobilizing tissue but consists of functionally specialized tissues able to produce heat (in brown adipose tissue) and to produce or release a vast number of so called adipokines or adipocytokines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15058310", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Brown adipose tissue (BAT), a specialized fat that dissipates energy to produce heat, plays an important role in the regulation of energy balance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25642708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Brown adipose cells are specialized to dissipate chemical energy in the form of heat, as a physiological defence against cold and obesity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641492", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1286, 
          "offsetInEndSection": 1430, 
          "text": "In the present study, the thermogenesis of human brown fat tissue was suggested chiefly with regard to the occurrence of Types 1 and/or 6 cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1764, 
          "offsetInEndSection": 1901, 
          "text": "In the same manner, marked ability to produce a considerable amount of heat was evidenced in  brown fat tissue of children and teenagers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Adult humans have heat-producing and energy-consuming brown adipose tissue in the clavicular region of the neck.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26749900", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Brown and beige adipocytes expend chemical energy to produce heat and are therefore important in regulating body temperature and body weight.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552974", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2005, 
          "offsetInEndSection": 2203, 
          "text": "In human perirenal brown fat tissue, darkly stained fat-depleted cells (D) occupy, with other cell types (CR, CR'), an important part in the reversible heat production cycle of the brown fat tissue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2039657", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Brown fat is a specialized fat depot that can increase energy expenditure and produce heat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26912151", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a mimotope vaccine?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25379726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23161490", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22936035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19088033", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15634921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16685414", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17445956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25990849", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17597331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19846865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20493257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24106273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21919618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27622022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7534789", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19111573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20827761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16634806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11122460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19344285", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19695868", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16814270"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/11094", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/354401"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/354401", 
          "o": "Vaccines"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/11094", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3254401"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3254401", 
          "o": "Vaccines"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0042210", 
          "o": "Vaccine"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0042210", 
          "o": "http://linkedlifedata.com/resource/umls/label/A11798658"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A11798658", 
          "o": "Vaccine"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/11094", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/354410"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/354410", 
          "o": "Vaccine"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0042210", 
          "o": "Vaccine"
        }
      ], 
      "ideal_answer": [
        "A mimotope vaccine contains peptide mimics of specific antigen epitopes, which alter the antigen presentation and/or T cell activation to increase the expansion of tumor-specific T cells and are able to induce polyclonal antibodies response."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064166", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014612", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016233"
      ], 
      "type": "summary", 
      "id": "58d388958acda34529000006", 
      "snippets": [
        {
          "offsetInBeginSection": 1704, 
          "offsetInEndSection": 1980, 
          "text": "These data are proof of principle that by performing affinity selection on neutralizing antibodies, our VLP technology can identify peptide mimics of non-linear epitopes and that these mimotope based VLP vaccines provide protection against pathogens in relevant animal models.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 657, 
          "text": "A major hurdle in vaccine development is the difficulty in identifying relevant target epitopes and then presenting them to the immune system in a context that mimics their native conformation. We have engineered novel virus-like-particle (VLP) technology that is able to display complex libraries of random peptide sequences on a surface-exposed loop in the coat protein without disruption of protein folding or VLP assembly. This technology allows us to use the same VLP particle for both affinity selection and immunization, integrating the power of epitope discovery and epitope mimicry of traditional phage display with the high immunogenicity of VLPs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1165, 
          "offsetInEndSection": 1630, 
          "text": "Our data suggest that the improved tumor immunity results from the expansion of mimotope-elicited tumor-specific T cells that have increased avidity for the tumor antigen. The enhanced T cells are phenotypically distinct and enriched for T-cell receptors previously correlated with improved antitumor immunity. These results suggest that incorporation of native antigen into clinical mimotope vaccine regimens may improve the efficacy of antitumor T-cell responses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 683, 
          "offsetInEndSection": 911, 
          "text": "One strategy for overcoming these mechanisms is vaccination with mimotopes, or peptide mimics of tumor antigens, which alter the antigen presentation and/or T cell activation to increase the expansion of tumor-specific T cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 296, 
          "text": "The high molecular weight melanoma-associated antigen (HMW-MAA) is an attractive target for immunotherapy of malignant melanoma. We have recently generated a vaccine based on the HMW-MAA mimotope 225D9.2+ that was able to induce anti-HMW-MAA antibodies with antitumor activity in vitro. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19088033", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 268, 
          "text": "Peptide mimics of a conformational epitope that is recognized by a mAb with antitumor activity are promising candidates for formulations of anticancer vaccines. These mimotope vaccines are able to induce a polyclonal Ab response focused to the determinant of the mAb. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15634921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 386, 
          "text": "Carbohydrate mimetic peptides of tumor associated carbohydrate antigens (TACA) are T-cell-dependent antigens and, therefore, immunization with these surrogates is predicted to overcome the low immunogenicity of carbohydrate antigens. Consistent with this hypothesis, we show that among the potential immune cells involved, peptide immunization led to an increase in T-cell populations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16685414", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 802, 
          "text": "To explore the mimotope vaccine approach against infectious bursal disease virus (IBDV), five IBDV-specific monoclonal antibodies (mAbs) were prepared and their binding peptides were screened against a phage-displayed 12-mer peptide library. After three rounds of biopanning, 12 phages were selected for each mAbs and their specificity to IBDV was verified by sandwich and competitive inhibition ELISAs. Seven phages per mAb were sequenced and their amino acid sequences were deduced. The five representative sequences of mimotopes corresponding mAbs were determined. An artificial gene, designated 5epis (5 epitopes) and consisting of the five mimotopes arranged in tandem (F1-F7-B34-2B1-2G8) with four GGGS spacers, was chemically synthesized and cloned into a prokaryotic expression plasmid pET28b. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17445956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 729, 
          "offsetInEndSection": 862, 
          "text": "The mimotope vaccine was then generated by coupling the most suitable candidate mimotope to tetanus toxoid as an immunogenic carrier.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15634921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 790, 
          "offsetInEndSection": 973, 
          "text": "We hypothesized that boosting the mimotope vaccine with the native tumor antigen would focus the T-cell response elicited by the mimotope toward high affinity, tumor-specific T cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 585, 
          "offsetInEndSection": 672, 
          "text": "Following the mice immunization, phage-based mimotope vaccine induced humoral immunity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25990849", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 695, 
          "offsetInEndSection": 796, 
          "text": "In this article we focus on cancer vaccines for antibody production, in particular mimotope vaccines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21919618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 226, 
          "text": "Vaccines that incorporate peptide mimics of tumor antigens, or mimotope vaccines, are commonly used in cancer immunotherapy and function by eliciting increased numbers of T cells that cross-react with the native tumor antigen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106273", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 795, 
          "offsetInEndSection": 978, 
          "text": "We hypothesized that boosting the mimotope vaccine with the native tumor antigen would focus the T-cell response elicited by the mimotope toward high affinity, tumor-specific T cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17597331", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 161, 
          "offsetInEndSection": 267, 
          "text": "These mimotope vaccines are able to induce a polyclonal Ab response focused to the determinant of the mAb.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15634921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1501, 
          "offsetInEndSection": 1628, 
          "text": "We therefore suggest that mimotope gene vaccines are potential candidates for epitope-specific immunotherapy of type I allergy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19111573", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Conformational B-cell epitopes on the HCV E2 protein recognized by human antibodies were characterized by the use of a peptide mimotope named K1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20827761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 590, 
          "offsetInEndSection": 677, 
          "text": "Following the mice immunization, phage-based mimotope vaccine induced humoral immunity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25990849", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 700, 
          "offsetInEndSection": 801, 
          "text": "In this article we focus on cancer vaccines for antibody production, in particular mimotope vaccines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21919618", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe clinical manifestation of the Mal de debarquement syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26559820", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25726862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27730651", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25809585", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26252893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26346344", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25331814", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8336953", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3631419", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22231864", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24594496", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25076935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23202153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23209584", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23219828", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23091536", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17046477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25570942"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1608983", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18471215"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18471215", 
          "o": "Mal de debarquement syndrome"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1608983", 
          "o": "Mal de debarquement"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1608983", 
          "o": "Mal de debarquement"
        }
      ], 
      "ideal_answer": [
        "Mal de debarquement syndrome (MdDS) is a disorder of chronic self-motion perception that occurs though entrainment to rhythmic background motion, such as from sea voyage, and involves the perception of low-frequency rocking that can last for months or years."
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:225", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"
      ], 
      "type": "summary", 
      "id": "588f9b7eed9bbee70d000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 409, 
          "text": "Mal de debarquement (MdD) is a subjective perception of self-motion after exposure to passive motion, in most cases sea travel, hence the name. Mal de debarquement occurs quite frequently in otherwise healthy individuals for a short period of time (several hours). However, in some people symptoms remain for a longer period of time or even persist and this is then called mal de debarquement syndrome (MdDS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559820", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "OBJECTIVE: Mal de debarquement syndrome (MdDS) is a balance disorder that typically starts after an extended exposure to passive motion, such as a boat or plane ride. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27730651", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Mal de debarquement syndrome (MdDS) is a rare and poorly understood condition of perceived continual motion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809585", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 271, 
          "text": "BACKGROUND: Mal de debarquement syndrome (MdDS) is a disorder of chronic self-motion perception that occurs though entrainment to rhythmic background motion, such as from sea voyage, and involves the perception of low-frequency rocking that can last for months or years. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252893", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 335, 
          "text": "It is characterized by abnormal sensation of motion/balance reported after travel by air, land, and sea; being reexposed to motion/activity relieves it. Symptoms may last from minutes to years. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346344", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Persistent mal de debarquement syndrome: a motion-induced subjective disorder of balance.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631419", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Mal de debarquement syndrome (MdDS) is a disorder of phantom perception of self-motion of unknown cause. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22231864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Mal de debarquement (MDD) is a common, benign, and self-limited syndrome suffered by many people after disembarkation from an oceangoing vessel.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046477", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Persistent mal de debarquement syndrome: a motion-induced subjective disorder of balance.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631419", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is Melioidosis caused by the bacterium\u00a0Burkholderia pseudomallei?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26935879", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22176696", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25803046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19156200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24065633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17676990", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24736221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19276877", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17563759", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27219859", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22564963", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27427979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27694236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19538822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18691413", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20532233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20142364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22473609", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11495298", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20169062", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15380526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17062053", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17582188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15191392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12803798", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19679240", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14604083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12139670", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24067292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9753000", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26495852", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25943405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22442327", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26526925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26542622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25689538", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24962103", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25442759", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24392083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24603493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25653950", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26311902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27472421", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26710411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18855560", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26607593"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0025229", 
          "o": "Melioidosis"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0025229", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0432241"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0432241", 
          "o": "MELIOIDOSIS"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0025229", 
          "o": "Melioidosis"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0025229", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0084485"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0084485", 
          "o": "Melioidosis"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1025638", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3197303"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3197303", 
          "o": "Melioidosis"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/semanticnetwork/id/T007", 
          "o": "Bacterium"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0004611", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7567988"
        }
      ], 
      "ideal_answer": [
        "Burkholderia pseudomallei is the causative agent of melioidosis"
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016957", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019121", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008554"
      ], 
      "type": "yesno", 
      "id": "58caf88c02b8c60953000031", 
      "snippets": [
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 284, 
          "text": "Burkholderia pseudomallei, the causative agent of melioidosis,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935879", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "What drives the occurrence of the melioidosis bacterium Burkholderia pseudomallei in domestic gardens?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803046", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Landscape changes influence the occurrence of the melioidosis bacterium Burkholderia pseudomallei in soil in northern Australia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156200", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176696", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Melioidosis, caused by the gram-negative bacterium Burkholderia pseudomallei, is a common cause of community-acquired sepsis in Southeast Asia and Northern Australia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27219859", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Melioidosis is a suppurative chronic infection caused by a gramnegative bacterium, Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17582188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Melioidosis is an infection caused by the gram-negative bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17062053", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "Melioidosis is an infectious disease caused by a saprophytic bacterium, Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12803798", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Melioidosis is an infectious disease caused by the Gram-negative bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19679240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Melioidosis is a pyogenic infection with high mortality caused by the bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24067292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Melioidosis is a tropical infectious disease caused by the gram-negative bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14604083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Melioidosis is a potentially fatal disease caused by the bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15380526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Melioidosis is a rare tropical disease caused by infection with the bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12139670", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "The mechanisms involved in the pathogenesis of melioidosis, caused by the intracellular bacterium Burkholderia pseudomallei, are unclear.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9753000", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Melioidosis is an emerging tropical infection caused by the intracellular bacterium Burkholderia pseudomallei, and is associated with high mortality rates.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15191392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Melioidosis is an increasingly recognised cause of sepsis and death across South East Asia and Northern Australia, caused by the bacterium Burkholderia pseudomallei", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495852", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Melioidosis, an infection caused by the gram-negative bacterium Burkholderia pseudomallei, is an important cause of pneumonia, skin infection, sepsis, and death in Southeast Asia and Australia, but is exceedingly rare in North America", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943405", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 179, 
          "offsetInEndSection": 391, 
          "text": "The Gram-negative bacterium Burkholderia pseudomallei is able to survive and replicate within leukocytes and causes melioidosis, an important cause of pneumonia-derived community-acquired sepsis in Southeast Asia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20142364", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "Melioidosis, a lethal tropical infection that is endemic in southeast Asia and northern Australia, is caused by the saprophytic Gram-negative bacterium Burkholderia pseudomallei", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691413", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Melioidosis is an emerging infectious disease caused by the soil bacterium Burkholderia pseudomallei", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Melioidosis is a tropical disease of high mortality caused by the environmental bacterium, Burkholderia pseudomallei", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26526925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Melioidosis is an infectious disease caused by Burkholderia pseudomallei, a bacterium endemic in Southeast Asia and northern Australia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26542622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Melioidosis is a life-threatening infection caused by the Gram-negative bacterium Burkholderia pseudomallei, mainly found in Southeast Asia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689538", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is a dreadful disease common in South-East Asia and Northern Australia and is characterized by chronic suppurative lesions and pneumonia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962103", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Melioidosis is an emerging infectious disease of humans and animals in the tropics caused by the soil bacterium Burkholderia pseudomallei. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176696", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Melioidosis is a potentially fatal disease caused by the bacterium Burkholderia pseudomallei. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22473609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Melioidosis, infection caused by the Gram-negative bacterium Burkholderia pseudomallei, is a common cause of sepsis in northeast Thailand. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Melioidosis is a potentially fatal disease caused by the bacterium, Burkholderia pseudomallei. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17563759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "BACKGROUND: The soil-dwelling saprophyte bacterium Burkholderia pseudomallei is the cause of melioidosis, a severe disease of humans and animals in southeast Asia and northern Australia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Melioidosis is an endemic disease caused by the bacterium Burkholderia pseudomallei. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 424, 
          "text": "Melioidosis is a severe infection caused by the gram-negative bacterium, Burkholderia pseudomallei, that is endemic in Southeast Asia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676990", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Melioidosis, infection caused by the Gram-negative bacterium Burkholderia pseudomallei, is a common cause of sepsis in northeast Thailand.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Melioidosis is a clinically diverse disease caused by the facultative intracellular Gram-negative bacterium, Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25653950", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 277, 
          "offsetInEndSection": 411, 
          "text": "Melioidosis is a severe infection caused by the gram-negative bacterium, Burkholderia pseudomallei, that is endemic in Southeast Asia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676990", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 178, 
          "text": "Melioidosis, a lethal tropical infection that is endemic in southeast Asia and northern Australia, is caused by the saprophytic Gram-negative bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691413", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 213, 
          "text": "Melioidosis, a severe human disease caused by the bacterium Burkholderia pseudomallei, has a wide spectrum of clinical manifestations ranging from acute septicemia to chronic localized illness or latent infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "Melioidosis, an often fatal infectious disease in Northeast Thailand, is caused by skin inoculation, inhalation or ingestion of the environmental bacterium, Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27472421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Melioidosis is an infection caused by Gram-negative bacterium, Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26710411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 215, 
          "text": "Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is a dreadful disease common in South-East Asia and Northern Australia and is characterized by chronic suppurative lesions and pneumonia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962103", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Largely due to its recognition as a biological threat agent, current knowledge on melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, has increased tremendously over the last years.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276877", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Melioidosis is an endemic disease caused by the bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Melioidosis is a potentially fatal disease caused by the bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22473609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Melioidosis is a potentially fatal disease caused by the bacterium, Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17563759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Melioidosis is a disease of humans and animals that is caused by the saprophytic bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Melioidosis is an emerging infectious disease of humans and animals in the tropics caused by the soil bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176696", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 174, 
          "text": "The soil-dwelling saprophyte bacterium Burkholderia pseudomallei is the cause of melioidosis, a severe disease of humans and animals in southeast Asia and northern Australia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Melioidosis is an often fatal infectious disease affecting humans and animals in tropical regions and is caused by the saprophytic environmental bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 147, 
          "offsetInEndSection": 352, 
          "text": "We have recently shown that during melioidosis, a severe infection caused by the gram-negative bacterium Burkholderia pseudomallei, TLR2 but not TLR4 impacts the immune response of the intact host in vivo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855560", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1767, 
          "offsetInEndSection": 1924, 
          "text": "It is caused by the bacterium Burkholderia pseudomallei, which can infect many organs of the body, including the brain, and results in neurological symptoms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24736221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Melioidosis is a frequent cause of severe sepsis in Southeast Asia caused by the gram-negative bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22564963", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "What drives the occurrence of the melioidosis bacterium Burkholderia pseudomallei in domestic gardens?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803046", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "The Gram-negative bacterium Burkholderia pseudomallei is the causative agent of melioidosi", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065633", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 175, 
          "text": "The environmental bacterium Burkholderia pseudomallei causes the infectious disease melioidosis with a high case-fatality rate in tropical and subtropical regions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27427979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Burkholderia pseudomallei is a soil-dwelling bacterium and the cause of melioidosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27694236", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "Melioidosis, an infectious disease caused by the Gram-negative bacterium Burkholderia pseudomallei,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538822", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 144, 
          "text": "Melioidosis is a frequently fatal infectious disease caused by the soil dwelling Gram-negative bacterium Burkholderia pseudomallei. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532233", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "Burkholderia pseudomallei, an environmental bacterium that causes the deadly disease melioidosis, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27303718", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Melioidosis is an important public health problem in Southeast Asia and Northern Australia. This disease is caused by the gram-negative bacilli, Burkholderia pseudomallei", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11495298", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 184, 
          "offsetInEndSection": 301, 
          "text": "Melioidosis, caused by Burkholderia pseudomallei, is an important cause of community-acquired sepsis in Southeast-Asi", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169062", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Melioidosis is a potentially fatal disease caused by the saprophytic bacterium Burkholderia pseudomallei", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24145517", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Melioidosis is a disease of humans caused by opportunistic infection with the soil and water bacterium Burkholderia pseudomallei.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624016", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mechanism of action of verubecestat?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27807285", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27933948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27934506", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27023706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27678025"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Verubecestat (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity)."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"
      ], 
      "type": "summary", 
      "id": "589a246a78275d0c4a000031", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 601, 
          "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 195, 
          "text": "Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 315, 
          "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Verubecestat is an inhibitor of \u03b2-secretase being evaluated for the treatment of Alzheimer's disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Verubecestat is an inhibitor of \u03b2-secretase being evaluated for the treatment of Alzheimer's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1201, 
          "offsetInEndSection": 1446, 
          "text": "After giving an update on the development and current status of new AD therapeutics, this review will focus on BACE inhibitors and, in particular, will discuss the prospects of verubecestat (MK-8931), which has reached phase III clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 314, 
          "offsetInEndSection": 591, 
          "text": "Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain A\u03b2 levels in rats and nonhuman primates and CSF A\u03b2 levels in humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 299, 
          "offsetInEndSection": 599, 
          "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 314, 
          "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 599, 
          "offsetInEndSection": 938, 
          "text": "Chronic treatment of rats and monkeys with verubecestat achieved exposures >40-fold higher than those being tested in clinical trials in AD patients yet did not elicit many of the adverse effects previously attributed to BACE inhibition, such as reduced nerve myelination, neurodegeneration, altered glucose homeostasis, or hepatotoxicity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 514, 
          "offsetInEndSection": 883, 
          "text": "Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the \u03b2-secretase cleaving enzyme (BACE) (verubecestat), three anti-A\u03b2 monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 196, 
          "text": "Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1209, 
          "offsetInEndSection": 1454, 
          "text": "After giving an update on the development and current status of new AD therapeutics, this review will focus on BACE inhibitors and, in particular, will discuss the prospects of verubecestat (MK-8931), which has reached phase III clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 315, 
          "offsetInEndSection": 592, 
          "text": "Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain A\u03b2 levels in rats and nonhuman primates and CSF A\u03b2 levels in humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How are triple negative gliomas characterized?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23288644", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26061753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22890969", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21889777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26989023", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23831947"
      ], 
      "triples": [], 
      "ideal_answer": [
        "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative (IDH-/p53-/1p19q-), this last subgroup having the worst prognosis.", 
        "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis.", 
        "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. ", 
        "of these markers - 1p/19q deletions , mgmt methylation status , and mutations in the idh1 gene - are so potent that a new brain tumor subtype , the \"triple negative\" glioma (1p/19q intact , mgmt unmethylated , idh1 non-mutated) has entered common parlance . ", 
        "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance. ", 
        "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance. ", 
        "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. (Funded by the National Institutes of Health and others. Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance.", 
        "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations", 
        "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58bac5e822d3005309000012", 
      "snippets": [
        {
          "offsetInBeginSection": 1107, 
          "offsetInEndSection": 1310, 
          "text": "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21889777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 696, 
          "offsetInEndSection": 878, 
          "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 838, 
          "offsetInEndSection": 1255, 
          "text": "Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1026, 
          "offsetInEndSection": 1282, 
          "text": "Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288644", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 513, 
          "text": "Few data are available in the literature regarding the relationship between IDH mutations and HIF expression in low-grade gliomas (LGGs), especially in a recently described aggressive molecular subtype: \"triple negative\" (IDH non mutated, 1p 19q non codeleted, p53 expression negative) gliomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989023", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 691, 
          "offsetInEndSection": 872, 
          "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1021, 
          "offsetInEndSection": 1278, 
          "text": "Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288644", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 696, 
          "offsetInEndSection": 876, 
          "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 696, 
          "offsetInEndSection": 877, 
          "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 220, 
          "offsetInEndSection": 514, 
          "text": "Few data are available in the literature regarding the relationship between IDH mutations and HIF expression in low-grade gliomas (LGGs), especially in a recently described aggressive molecular subtype: \"triple negative\" (IDH non mutated, 1p 19q non codeleted, p53 expression negative) gliomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989023", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is ectopia lentis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25797933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25939784", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19200529"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0013581", 
          "o": "Ectopia lentis"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0013581", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0052649"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0052649", 
          "o": "Ectopia Lentis"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1026597", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3153153"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3153153", 
          "o": "Ectopia Lentis"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0013581", 
          "o": "Ectopia lentis"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0013581", 
          "o": "http://linkedlifedata.com/resource/umls/label/A12012342"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A12012342", 
          "o": "Ectopia lentis"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0013581", 
          "o": "Ectopia lentis"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0013581", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0078970"
        }
      ], 
      "ideal_answer": [
        "Ectopia Lentis is dislocation of the optic lens in the eye."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004479"
      ], 
      "type": "summary", 
      "id": "58dc2c698acda3452900001f", 
      "snippets": [
        {
          "offsetInBeginSection": 242, 
          "offsetInEndSection": 268, 
          "text": "bilateral lens dislocation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25797933", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 239, 
          "text": "Clinical manifestations include mental retardation, dislocation of the optic lens (ectopia lentis)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25939784", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Ectopia lentis is a genetically heterogeneous condition that is characterized by the subluxation of the lens resulting from the disruption of the zonular fibers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200529", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can glyburide reduce cerebral edema?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26268138", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24193798", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24671831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25422710", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23633925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17673715", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24552576", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26463916"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017628", 
          "o": "glyburide"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017628", 
          "o": "http://linkedlifedata.com/resource/umls/label/A10769058"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A10769058", 
          "o": "GLYBURIDE"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/4815", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3163336"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3163336", 
          "o": "GLYBURIDE"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017628", 
          "o": "glyburide"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017628", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0064005"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0064005", 
          "o": "Glyburide"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/4815", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/1842549"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/1842549", 
          "o": "Glyburide"
        }
      ], 
      "ideal_answer": [
        "Yes. Glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing and attenuating cerebral edema."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001929", 
        "http://www.biosemantics.org/jochem#4275786", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005905", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275786", 
        "http://www.disease-ontology.org/api/metadata/DOID:4724"
      ], 
      "type": "yesno", 
      "id": "588482f5e56acf517600000a", 
      "snippets": [
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 411, 
          "text": "Preclinical studies have shown that a continuous infusion of glyburide blocks edema formation and improves outcome. We hypothesize that treatment with RP-1127 (Glyburide for Injection) reduces formation of brain edema in patients after large anterior circulation infarction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1298, 
          "offsetInEndSection": 1486, 
          "text": "CONCLUSIONS: GAMES-RP was designed to provide critical information regarding glyburide for injection in patients with large hemispheric stroke and will inform the design of future studies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Glyburide is associated with attenuated vasogenic edema in stroke patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 134, 
          "offsetInEndSection": 382, 
          "text": "Glyburide is reported to prevent brain swelling in preclinical rodent models of ischemic stroke through inhibition of a non-selective channel composed of sulfonylurea receptor 1 and transient receptor potential cation channel subfamily M member 4. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 936, 
          "offsetInEndSection": 1323, 
          "text": "RESULTS: We report that IV glyburide was associated with T2 fluid-attenuated inversion recovery signal intensity ratio on brain MRI, diminished the lesional water diffusivity between days 1 and 2 (pseudo-normalization), and reduced blood MMP-9 level.CONCLUSIONS: Several surrogate markers of vasogenic edema appear to be reduced in the setting of IV glyburide treatment in human stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Pilot study of intravenous glyburide in patients with a large ischemic stroke.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193798", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "BACKGROUND AND PURPOSE: Preclinical and retrospective clinical data indicate that glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing edema and improving outcome after focal ischemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193798", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 222, 
          "text": "Preclinical data suggest that glyburide, an inhibitor of SUR1-TRPM4, is effective in preventing edema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 48, 
          "text": "Glyburide in Treating Malignant Cerebral Edema. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25422710", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Glyburide in Treating Malignant Cerebral Edema. Blocking Sulfonyl Urea One (SUR1) Receptors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25422710", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 242, 
          "text": "The sulfonylurea receptor 1-regulated NC(Ca-ATP) channel is upregulated in rodent models of stroke with block of the channel by the sulfonylurea, glibenclamide (glyburide), significantly reducing mortality, cerebral edema, and infarct volume.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17673715", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1534, 
          "offsetInEndSection": 1678, 
          "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 552, 
          "offsetInEndSection": 901, 
          "text": "In this focused review, we explore preclinical data linking Sur1 channel formation to development of edema and reference evidence suggesting that the antidiabetic sulfonylurea drug glyburide (a Sur1 inhibitor) is an inexpensive and well-tolerated agent that can be clinically tested to reduce or prevent malignancy and/or treatment-associated edema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Potential of glyburide to reduce intracerebral edema in brain metastases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552576", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 107, 
          "offsetInEndSection": 209, 
          "text": "Preclinical data suggest that glyburide, an inhibitor of SUR1-TRPM4, is effective in preventing edema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Inhibition of sulfonylurea receptor 1 (SUR1) by glyburide has been shown to decrease edema after subarachnoid hemorrhage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1563, 
          "offsetInEndSection": 1706, 
          "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 938, 
          "offsetInEndSection": 1189, 
          "text": "RESULTS: We report that IV glyburide was associated with T2 fluid-attenuated inversion recovery signal intensity ratio on brain MRI, diminished the lesional water diffusivity between days 1 and 2 (pseudo-normalization), and reduced blood MMP-9 level. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 223, 
          "text": "Preclinical data suggest that glyburide, an inhibitor of SUR1-TRPM4, is effective in preventing edema. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Exploratory analysis of glyburide as a novel therapy for preventing brain swelling.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Inhibition of sulfonylurea receptor 1 (SUR1) by glyburide has been shown to decrease edema after subarachnoid hemorrhage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 555, 
          "offsetInEndSection": 904, 
          "text": "In this focused review, we explore preclinical data linking Sur1 channel formation to development of edema and reference evidence suggesting that the antidiabetic sulfonylurea drug glyburide (a Sur1 inhibitor) is an inexpensive and well-tolerated agent that can be clinically tested to reduce or prevent malignancy and/or treatment-associated edema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1531, 
          "offsetInEndSection": 1675, 
          "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 134, 
          "offsetInEndSection": 381, 
          "text": "Glyburide is reported to prevent brain swelling in preclinical rodent models of ischemic stroke through inhibition of a non-selective channel composed of sulfonylurea receptor 1 and transient receptor potential cation channel subfamily M member 4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1159, 
          "offsetInEndSection": 1282, 
          "text": "Several surrogate markers of vasogenic edema appear to be reduced in the setting of IV glyburide treatment in human stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 241, 
          "offsetInEndSection": 399, 
          "text": "We hypothesize that treatment with RP-1127 (Glyburide for Injection) reduces formation of brain edema in patients after large anterior circulation infarction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1545, 
          "offsetInEndSection": 1690, 
          "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Glyburide is associated with attenuated vasogenic edema in stroke patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the function of gasdermin D?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27281216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27932073", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26611636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26482951"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1539620", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20719561"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20719561", 
          "o": "gasdermin D"
        }
      ], 
      "ideal_answer": [
        "The gasdermin-N domains of the gasdermin proteins can bind membrane lipids, phosphoinositides and cardiolipin to produce membrane-disrupting cytotoxicity."
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/GSDMD_MOUSE", 
        "http://www.uniprot.org/uniprot/GSDMD_HUMAN"
      ], 
      "type": "summary", 
      "id": "58e2467a6fddd3e83e000012", 
      "snippets": [
        {
          "offsetInBeginSection": 33, 
          "offsetInEndSection": 161, 
          "text": "gasdermin D (GSDMD) protein to trigger pyroptosis, a lytic form of cell death that is crucial for immune defences and diseases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27281216", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 329, 
          "offsetInEndSection": 584, 
          "text": "Here we show that the gasdermin-N domains of the gasdermin proteins GSDMD, GSDMA3 and GSDMA can bind membrane lipids, phosphoinositides and cardiolipin, and exhibit membrane-disrupting cytotoxicity in mammalian cells and artificially transformed bacteria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27281216", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is TOPAZ1?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26358182", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22069478"
      ], 
      "triples": [], 
      "ideal_answer": [
        "TOPAZ1 (Testis and Ovary-specific PAZ domain gene 1) is a germ cell specific factor that is essential for male meiotic progression. Topaz1 is supposed to have a role during gametogenesis and may be involved in the piRNA pathway and contribute to silencing of transposable elements and maintenance of genome integrity. It is highly conserved in vertebrates."
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/TOPZ1_BOVIN"
      ], 
      "type": "summary", 
      "id": "587d016ed673c3eb14000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "TOPAZ1, a germ cell specific factor, is essential for male meiotic progression", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358182", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Topaz1 (Testis and Ovary-specific PAZ domain gene 1) is a germ cell specific gene highly conserved in vertebrates", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358182", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 239, 
          "offsetInEndSection": 423, 
          "text": "Topaz1 is supposed to have a role during gametogenesis and may be involved in the piRNA pathway and contribute to silencing of transposable elements and maintenance of genome integrity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358182", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "TOPAZ1, a novel germ cell-specific expressed gene conserved during evolution across vertebrates", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069478", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which are the symptoms of glucose-6-phosphate dehydrogenase (G6PD) deficiency?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25079187", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24711919", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16450734", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21336800", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11842483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25949934", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23640458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10698963", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25116429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19086137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24372186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11271380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24865682", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18094574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/750548", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18450407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24891465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22829586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22139979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21302115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24636884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20684792", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12737943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11261779", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20194698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10980404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20065266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11233775", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23874768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19769422", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10745013", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9088998", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21784438", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26275698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11793482", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25807896", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26840990", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23961874"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://purl.uniprot.org/uniprot/P11413", 
          "o": "http://purl.uniprot.org/uniprot/P11413"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017757", 
          "o": "G6PD"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_503131343133004B", 
          "o": "G6PD"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_503131343133004B", 
          "o": "G6PD"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017757", 
          "o": "http://linkedlifedata.com/resource/umls/label/A8256485"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", 
          "o": "http://purl.uniprot.org/uniprot/P11413"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", 
          "o": "Glucose-6-phosphate 1-dehydrogenase"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://purl.uniprot.org/uniprot/P11413", 
          "o": "G6PD_HUMAN"
        }
      ], 
      "ideal_answer": [
        "Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) is the most common red blood cell (RBC) enzyme disorder. The decrease as well as the absence of the enzyme increase RBC vulnerability to oxidative stress caused by exposure to certain medications or intake of fava beans. Among the most common symptoms of this condition are:\n1) acute hemolysis, \n2) chronic hemolysis, \n3) neonatal hyperbilirubinemia."
      ], 
      "exact_answer": [
        [
          "acute hemolysis"
        ], 
        [
          "chronic hemolysis"
        ], 
        [
          "neonatal hyperbilirubinemia"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005955", 
        "http://www.disease-ontology.org/api/metadata/DOID:2862", 
        "http://amigo.geneontology.org/amigo/term/GO:0004345", 
        "http://www.uniprot.org/uniprot/G6PD_CRIGR", 
        "http://www.uniprot.org/uniprot/G6PD_DIDVI", 
        "http://www.uniprot.org/uniprot/G6PD_TAKRU", 
        "http://www.uniprot.org/uniprot/G6PD_MACRO", 
        "http://www.uniprot.org/uniprot/G6PD_BOSIN", 
        "http://www.uniprot.org/uniprot/G6PD_HUMAN", 
        "http://www.uniprot.org/uniprot/G6PD_ECO57", 
        "http://www.uniprot.org/uniprot/G6PD_HELPY", 
        "http://www.uniprot.org/uniprot/G6PD_HELPJ", 
        "http://www.uniprot.org/uniprot/G6PD_HAEIN", 
        "http://www.uniprot.org/uniprot/G6PD_GLUOX", 
        "http://www.uniprot.org/uniprot/G6PD_ENCCU", 
        "http://www.uniprot.org/uniprot/G6PD_EMENI", 
        "http://www.uniprot.org/uniprot/G6PD_ECOLI", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005954", 
        "http://www.uniprot.org/uniprot/G6PD_AGGAC", 
        "http://www.uniprot.org/uniprot/G6PD_ZYMMO", 
        "http://www.uniprot.org/uniprot/G6PD_NOSP7", 
        "http://www.uniprot.org/uniprot/G6PD_CYBJA", 
        "http://www.uniprot.org/uniprot/G6PD_BUCAI", 
        "http://www.uniprot.org/uniprot/G6PD_BUCAP", 
        "http://www.uniprot.org/uniprot/G6PD_CERCA"
      ], 
      "type": "list", 
      "id": "58c6665602b8c60953000024", 
      "snippets": [
        {
          "offsetInBeginSection": 14, 
          "offsetInEndSection": 466, 
          "text": "Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) is the most common red blood cell (RBC) enzyme disorder. The decrease as well as the absence of the enzyme increase RBC vulnerability to oxidative stress caused by exposure to certain medications or intake of fava beans. Among the most common clinical manifestations of this condition, acute hemolysis, chronic hemolysis, neonatal hyperbilirubinemia, and an asymptomatic form are observed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25079187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 330, 
          "text": "Red blood cells carry oxygen in the body and Glucose-6-Phosphate Dehydrogenase protects these cells from oxidative chemicals. If there is a lack of Glucose-6-Phosphate Dehydrogenase, red blood cells can go acute hemolysis. Convulsion is a rare presentation for acute hemolysis due to Glucose-6-Phosphate Dehydrogenase deficiency. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24711919", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 376, 
          "offsetInEndSection": 851, 
          "text": "By far the most common form worldwide is the Glucose-6-phosphate deficiency. In the most frequent variants of this disease hemolysis occurs only during stress, imposed for example by infection, \"oxidative\" drugs or after ingestion of fava beans. The most serious clinical complication of the Glucose-6-phosphate deficiency is the rarely observed neonatal icterus. Some enzyme variants can cause chronic hemolysis which is described as chronic nonsperocytic hemolytic anemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16450734", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 194, 
          "offsetInEndSection": 367, 
          "text": "One limitation of primaquine is that, at certain doses, primaquine can cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24891465", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common human enzymopathy that affects cellular redox status and may lower flux into nonoxidative pathways of glucose metabolism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 279, 
          "offsetInEndSection": 505, 
          "text": "The 6PGD deficiency was associated with a variable reticulocyte count and recurrent increased unconjugated bilirubinemia without anemia in the propositus, while no clinical or hematological symptoms were evident in her mother.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11233775", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2121, 
          "offsetInEndSection": 2644, 
          "text": "The authors of this article make 5 particular recommendations: (1) Anyone suspected of G6PD deficiency should be screened; (2) exposure to oxidative stressors in these individuals should be avoided; (3) these patients should be informed of risks along with signs and symptoms of an acute hemolytic crisis; (4) the clinician should be able to identify both laboratory and clinical signs of hemolysis; and finally, (5) if an acute hemolytic crisis is identified, the patient should be admitted for close observation and care.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19769422", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 639, 
          "offsetInEndSection": 816, 
          "text": "None of the patients with or without G6PD deficiency showed symptoms, signs, or laboratory findings indicating hemolysis before administration of the drug and 4 days thereafter.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9088998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "Kinetic and electrophoretic properties of 230--300 fold purified preparations of glucose-6-phosphate dehydrogenase (G6PD) from red cells of donors and patients with acute drug hemolytic anemia due to G6PD deficiency were studied.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive disorder in which haemolytic anaemia is the major symptom.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11271380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive genetic defect that can cause hemolytic crisis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 110, 
          "offsetInEndSection": 245, 
          "text": "However, its use is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk for haemolytic anaemia).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25807896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 61, 
          "offsetInEndSection": 192, 
          "text": "The role of glucose-6-phosphate dehydrogenase (G6PD) deficiency in the development of stroke in children with SCA is controversial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840990", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by a mutation in the G6PD gene on Xq28.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25807896", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Has the gorilla genome been determined?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27435933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27034376", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22398555", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11592477"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, the gorilla genome has been sequenced."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58dfec676fddd3e83e000006", 
      "snippets": [
        {
          "offsetInBeginSection": 494, 
          "offsetInEndSection": 638, 
          "text": "Starting with human, chimpanzee, gorilla, and orangutan genomes, our software generated an exhaustive data set of 292 ALs (\u223c1 kb each) in \u223c3 h. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27435933", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 101, 
          "offsetInEndSection": 258, 
          "text": "We generated a high-quality assembly of the gorilla genome using single-molecule, real-time sequence technology and a string graph de novo assembly algorithm", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034376", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 301, 
          "text": "Here we present the assembly and analysis of a genome sequence for the western lowland gorilla, and compare the whole genomes of all extant great ape genera.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22398555", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "DNA sequencing reveals that the genomes of the human, gorilla and chimpanzee share more than 98% homology.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592477", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is vemurafenib used for thyroid cancer?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27460442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25467940", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26176686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27754804", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26284586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26735176", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27432558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24262022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27127178", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26751190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27554612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24756795", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23489023", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24987354", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22649416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26636651"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220", 
          "o": "VEMURAFENIB"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C3192263", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20020623"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20020623", 
          "o": "VEMURAFENIB"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/4224011"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/4224011", 
          "o": "VEMURAFENIB"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/chembl/synonym/691867_Vemurafenib_USAN", 
          "o": "Vemurafenib"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C3192263", 
          "o": "http://linkedlifedata.com/resource/umls/label/A19613644"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A19613644", 
          "o": "Vemurafenib"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C3192263", 
          "o": "http://linkedlifedata.com/resource/umls/label/A19649207"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A19649207", 
          "o": "Vemurafenib"
        }
      ], 
      "ideal_answer": [
        "Yes. Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013964", 
        "http://www.disease-ontology.org/api/metadata/DOID:3963", 
        "http://www.disease-ontology.org/api/metadata/DOID:1781"
      ], 
      "type": "yesno", 
      "id": "58848ea5e56acf517600000e", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 314, 
          "text": "Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2338, 
          "offsetInEndSection": 2559, 
          "text": "INTERPRETATION: Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1685, 
          "offsetInEndSection": 1840, 
          "text": "CONCLUSIONS: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 459, 
          "text": "The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine-refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30-40%.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467940", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Use of vemurafenib in anaplastic thyroid carcinoma: a case report.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1212, 
          "offsetInEndSection": 1361, 
          "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 399, 
          "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 361, 
          "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 400, 
          "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1220, 
          "offsetInEndSection": 1369, 
          "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1237, 
          "offsetInEndSection": 1415, 
          "text": "Metformin or rapamycin adjuvant treatment may provide clinical benefits with minimal side effects to BRAFV600E-positive advanced thyroid cancer patients treated with vemurafenib.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 362, 
          "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1515, 
          "offsetInEndSection": 1727, 
          "text": "Our data demonstrate that vemurafenib induces ER stress response-mediated autophagy in thyroid cancer and autophagy inhibition may be a beneficial strategy to sensitize BRAF-mutant thyroid cancer to vemurafenib..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 552, 
          "offsetInEndSection": 729, 
          "text": "Combination of vemurafenib and metformin decreased cell viability and increased apoptosis in both BCPAP papillary thyroid cancer cells and 8505c anaplastic thyroid cancer cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1010, 
          "offsetInEndSection": 1092, 
          "text": "Vemurafenib induced a high level of autophagy in BRAF-mutant thyroid cancer cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are mutations in the C9orf72  gene associated with macular degeneration?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27619540", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26303227", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22300873", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22366791", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22892647", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27632209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23934648", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24521566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24442578", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23053135", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24064469", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22673113"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1428691", 
          "o": "C9orf72"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1428691", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20715582"
        }
      ], 
      "ideal_answer": [
        "Amyotrophic lateral sclerosis (ALS) is characterized by motor neurone loss resulting in muscle weakness, spasticity and ultimately death. 5-10% are caused by inherited mutations, most commonly C9ORF72, SOD1, TARDBP and FUS."
      ], 
      "exact_answer": "no", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008268", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057135", 
        "http://www.disease-ontology.org/api/metadata/DOID:4448", 
        "http://www.disease-ontology.org/api/metadata/DOID:14245", 
        "http://www.disease-ontology.org/api/metadata/DOID:10871", 
        "http://www.disease-ontology.org/api/metadata/DOID:8466", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012162"
      ], 
      "type": "yesno", 
      "id": "58e11bf76fddd3e83e00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 296, 
          "offsetInEndSection": 710, 
          "text": "Over the years, however, growing evidence from clinical, pathological and genetic findings has suggested that ALS and FTD belong to the same clinic-pathological spectrum disorder. This concept has been further supported by the identification of the most common genetic cause for both diseases, an aberrantly expanded hexanucleotide repeat GGGGCC/ CCCCGG sequence located in a non-coding region of the gene C9orf72.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27619540", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 223, 
          "text": "Amyotrophic lateral sclerosis (ALS) is characterized by motor neurone loss resulting in muscle weakness, spasticity and ultimately death. 5-10% are caused by inherited mutations, most commonly C9ORF72, SOD1, TARDBP and FUS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26303227", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 902, 
          "offsetInEndSection": 1125, 
          "text": "In this article, we will review the brief characterizations of the C9ORF72 gene, the expansion mutations, the related disorders, and their features, followed by a discussion of the deficiency knowledge of C9ORF72 mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23934648", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2374, 
          "offsetInEndSection": 2520, 
          "text": "Mutations in the C9ORF72 gene may be a major cause not only of frontotemporal dementia with motor neuron disease but also of late onset psychosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Frontotemporal lobar degeneration (FTLD) is a genetically heterogenous syndrome and has been associated most recently with a hexanucleotide repeat expansion within the C9ORF72 gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892647", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 200, 
          "text": "An expanded GGGGCC hexanucleotide repeat in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal lobar degeneration associated with TDP-43 pathology (FTLD-TDP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053135", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Novel TARDBP sequence variant and C9ORF72 repeat expansion in a family with frontotemporal dementia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892647", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 914, 
          "offsetInEndSection": 1027, 
          "text": "There was, as expected, a significant association between C9ORF72 mutations and presence of motor neuron disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Expansion of a hexanucleotide repeat in the C9ORF72 gene has been identified as the most common pathogenic mutation in families with autosomal dominant frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064469", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a genotype-phenotype correlation study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064469", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis, and may be the most common genetic cause of both neurodegenerative diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24442578", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 260, 
          "text": "studies recently identified a GGGGCC hexanucleotide repeat expansion in a non-coding region of the chromosome 9 open-reading frame 72 gene (C9ORF72) as the cause of chromosome 9p-linked amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22228244", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 208, 
          "text": "GGGGCC hexanucleotide repeat expansion in the C9ORF72 gene was recently identified as an important cause of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia in Caucasian populations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22673113", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the Genome 10K Project?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25689317", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22897955"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The Genome 10K Project was established in 2009 by a consortium of biologists and genome scientists determined to facilitate the sequencing and analysis of the complete genomes of 10,000 vertebrate species."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58dff3f06fddd3e83e000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "The Genome 10K Project was established in 2009 by a consortium of biologists and genome scientists determined to facilitate the sequencing and analysis of the complete genomes of 10,000 vertebrate species.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689317", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "The Genome 10K project aims to sequence the genomes of 10,000 vertebrates, representing approximately one genome for each vertebrate genus", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897955", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene controls the expression of GATA-1 isoforms?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24453067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20304827", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12202480"
      ], 
      "triples": [], 
      "ideal_answer": [
        "A transcriptional network has been reported, in which PU.1 positively regulates GATA-1 expression in mast cell development.", 
        "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. ", 
        "In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation.", 
        "In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development.  This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript.", 
        "Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s.", 
        "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development."
      ], 
      "exact_answer": [
        [
          "PU.1"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58e75d483e8b6dc87c000005", 
      "snippets": [
        {
          "offsetInBeginSection": 127, 
          "offsetInEndSection": 272, 
          "text": "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 190, 
          "offsetInEndSection": 320, 
          "text": "In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 454, 
          "offsetInEndSection": 611, 
          "text": "This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1035, 
          "offsetInEndSection": 1186, 
          "text": "Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12202480", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 886, 
          "offsetInEndSection": 1034, 
          "text": "Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1587, 
          "offsetInEndSection": 1813, 
          "text": "Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27)..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12202480", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is MIRA-seq?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25881900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27009155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26384656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25623529"
      ], 
      "triples": [], 
      "ideal_answer": [
        "MIRA-seq is a reliable, genome-scale DNA methylation analysis platform for scoring DNA methylation differences at CpG-rich genomic regions. The method is not limited by primer or probe design and is cost effective."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018899", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019175", 
        "http://amigo.geneontology.org/amigo/term/GO:0044027", 
        "http://amigo.geneontology.org/amigo/term/GO:0044029", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000070593", 
        "http://amigo.geneontology.org/amigo/term/GO:0044728", 
        "http://amigo.geneontology.org/amigo/term/GO:1905642"
      ], 
      "type": "summary", 
      "id": "588fd7cded9bbee70d000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 53, 
          "text": "MIRA-seq for DNA methylation analysis of CpG islands.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 620, 
          "offsetInEndSection": 834, 
          "text": "MIRA-seq is a reliable, genome-scale DNA methylation analysis platform for scoring DNA methylation differences at CpG-rich genomic regions. The method is not limited by primer or probe design and is cost effective.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Using MIRA-seq, we have characterized the DNA methylome of metastatic melanoma and normal melanocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26384656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 353, 
          "offsetInEndSection": 538, 
          "text": "Global gene expression was measured by RNA-Seq, while an epigenetic basis for expression differences was examined by methylated CpG island recovery assay sequencing (MIRA-Seq) analysis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 355, 
          "offsetInEndSection": 540, 
          "text": "Global gene expression was measured by RNA-Seq, while an epigenetic basis for expression differences was examined by methylated CpG island recovery assay sequencing (MIRA-Seq) analysis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 54, 
          "text": "MIRA-seq for DNA methylation analysis of CpG islands.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 576, 
          "offsetInEndSection": 715, 
          "text": "MIRA-seq is a reliable, genome-scale DNA methylation analysis platform for scoring DNA methylation differences at CpG-rich genomic regions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 928, 
          "offsetInEndSection": 1129, 
          "text": "Despite extensive breed differences in the transcriptome, MIRA-Seq unveiled relatively similar patterns of genome-wide DNA methylation between breeds, with an overall hypomethylation of gene promoters.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1141, 
          "offsetInEndSection": 1470, 
          "text": "Methylated CpG island recovery assay sequencing (MIRA-Seq) revealed numerous methylation peaks spread across the genome, combined with an overall hypomethylation of gene promoter regions, and a remarkable similarity, except for 20 regions along the genome, between the fibroblasts collected at the two ages from the same animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25623529", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How does Ssu72 mediate gene looping?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26119342", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17803944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16319194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24945319", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12704082"
      ], 
      "triples": [], 
      "ideal_answer": [
        "In RNAP II transcription, promoter and terminator regions are juxtaposed and the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation. These interactions are transcription-dependent, require the Ssu72 and Pta1 components of the CPF 3'-end processing complex, and require the phosphatase activity of Ssu72.", 
        "tfiib crosslinks to both the promoter and terminator regions of the pma1 and blm10 genes, and its association with the terminator, but not the promoter, is adversely affected by e62k and by depletion of the ssu72 component of the cpf 3' end processing complex, and is independent of tbp.", 
        "The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing", 
        "Investigation of chromosome folding in mutants confirms roles for RSC, \"gene looping\" factor Ssu72, Mediator, H3K56 acetyltransferase Rtt109, and the N-terminal tail of H4 in folding of the yeast genome. The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP. We propose a model for RNAP II transcription in which promoter and terminator regions are juxtaposed, and that the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation. The first 300 amino acids of Pta1 are sufficient for interactions with Ssu72, which is needed for pre-mRNA cleavage. ", 
        "Investigation of chromosome folding in mutants confirms roles for RSC, \"gene looping\" factor Ssu72, Mediator, H3K56 acetyltransferase Rtt109, and the N-terminal tail of H4 in folding of the yeast genome. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP. We propose a model for RNAP II transcription in which promoter and terminator regions are juxtaposed, and that the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation. The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing  These interactions are transcription-dependent, require the Ssu72 and Pta1 components of the CPF 3'-end processing complex, and require the phosphatase activity of Ssu72. Furthermore, different regions of Pta1 interact with the CPF subunits Ssu72, Pti1, and Ysh1, supporting the idea that Pta1 acts as a scaffold to organize CPF."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58af14ae717cd3f655000001", 
      "snippets": [
        {
          "offsetInBeginSection": 688, 
          "offsetInEndSection": 891, 
          "text": "Investigation of chromosome folding in mutants confirms roles for RSC, \"gene looping\" factor Ssu72, Mediator, H3K56 acetyltransferase Rtt109, and the N-terminal tail of H4 in folding of the yeast genome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26119342", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 661, 
          "offsetInEndSection": 819, 
          "text": "Furthermore, different regions of Pta1 interact with the CPF subunits Ssu72, Pti1, and Ysh1, supporting the idea that Pta1 acts as a scaffold to organize CPF.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 820, 
          "offsetInEndSection": 937, 
          "text": "The first 300 amino acids of Pta1 are sufficient for interactions with Ssu72, which is needed for pre-mRNA cleavage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1237, 
          "offsetInEndSection": 1392, 
          "text": "These findings suggest that the amino terminus of Pta1 has an inhibitory effect and that this effect can be neutralized through the interaction with Ssu72.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 512, 
          "offsetInEndSection": 799, 
          "text": "TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 585, 
          "offsetInEndSection": 756, 
          "text": " These interactions are transcription-dependent, require the Ssu72 and Pta1 components of the CPF 3'-end processing complex, and require the phosphatase activity of Ssu72.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16319194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 757, 
          "offsetInEndSection": 1027, 
          "text": "We propose a model for RNAP II transcription in which promoter and terminator regions are juxtaposed, and that the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16319194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 469, 
          "offsetInEndSection": 661, 
          "text": "The pta1-Delta75 mutant is defective for snoRNA termination, RNA polymerase II C-terminal domain Ser5-P dephosphorylation, and gene looping but is fully functional for mRNA 3'-end processing. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1168, 
          "offsetInEndSection": 1325, 
          "text": "We conclude that Swd2.2 opposes condensin-mediated chromosome condensation by facilitating the function of the two CPF-associated phosphatases PP1 and Ssu72.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24945319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 983, 
          "offsetInEndSection": 1286, 
          "text": "Based on the interactions of Ssu72 and Sub1 with both the Pta1 of CPF and the TFIIB component of the initiation complex, we present a model describing how these novel connections between the transcription and 3' end processing machineries might facilitate transitions in the RNAP II transcription cycle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12704082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 937, 
          "offsetInEndSection": 1128, 
          "text": "By the degron-mediated depletion of Pta1, we show that the removal of this essential region leads to a loss of Ssu72, yet surprisingly, in vitro cleavage and polyadenylation remain efficient.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 469, 
          "offsetInEndSection": 660, 
          "text": "The pta1-Delta75 mutant is defective for snoRNA termination, RNA polymerase II C-terminal domain Ser5-P dephosphorylation, and gene looping but is fully functional for mRNA 3'-end processing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the number of described human nuclear mutations less than 50000?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20569258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24077912", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22948725"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No, The number of known mutations in human nuclear genes, underlying or associated with human inherited disease, has now exceeded 100,000 in more than 3700 different genes (Human Gene Mutation Database)."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58e26ede6fddd3e83e000015", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "The number of known mutations in human nuclear genes, underlying or associated with human inherited disease, has now exceeded 100,000 in more than 3700 different genes (Human Gene Mutation Database).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 368, 
          "text": "The Human Gene Mutation Database (HGMD\u00ae) is a comprehensive collection of germline mutations in nuclear genes that underlie, or are associated with, human inherited disease. By June 2013, the database contained over 141,000 different lesions detected in over 5,700 different genes, with new mutation entries currently accumulating at a rate exceeding 10,000 per annum.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24077912", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 607, 
          "offsetInEndSection": 778, 
          "text": "By March 2012, the database contained in excess of 123,600 different lesions (HGMD Professional release 2012.1) detected in 4,514 different nuclear genes, with new entries", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22948725", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of peptide aptamers?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25966787", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25963836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15037656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18243349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23579184", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18314488", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25801767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24478452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16751801", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25230811", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19295259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16581027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18195017", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12842895", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15231297", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11071782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10439043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18265211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12530529", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23785412", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17574575", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8755498", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9222505", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20653933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19895821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15952909", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25699094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22949372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22503683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19377984", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18186614", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25238402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19320493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19377988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19377987", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17189388", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21224349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11641783", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16731923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21838684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18336207"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/595798", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3218865"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3218865", 
          "o": "Peptide Aptamers"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1567956", 
          "o": "Aptamers, Peptide"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1567956", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17937093"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A17937093", 
          "o": "Aptamers, Peptide"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/595798", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3111176"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3111176", 
          "o": "Aptamers, Peptide"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1567956", 
          "o": "Aptamers, Peptide"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1567956", 
          "o": "Aptamers, Peptide"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1567956", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17888724"
        }
      ], 
      "ideal_answer": [
        "Peptide aptamers are artificial short peptides which are able to specifically bind to defined functional domains, track, and inhibit a given target molecule with high affinity, even molecules with poor immunogenicity or high toxicity. They represent a remarkable alternative to antibodies in many different applications."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052158", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010455"
      ], 
      "type": "summary", 
      "id": "58d131218acda34529000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Peptide aptamers: The versatile role of specific protein function inhibitors in plant biotechnology.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 215, 
          "offsetInEndSection": 485, 
          "text": " These artificial short peptides are able to specifically bind, track, and inhibit a given target molecule with high affinity, even molecules with poor immunogenicity or high toxicity, and represent a remarkable alternative to antibodies in many different applications. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 488, 
          "offsetInEndSection": 696, 
          "text": "To inhibit the oncogenic action of Stat3 in tumor cells, we have selected short peptides, so-called peptide aptamers, which specifically interact with defined functional domains of this transcription factor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15037656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 347, 
          "text": "Aptasensors utilize aptamers as bioreceptors. Aptamers are highly efficient, have a high specificity and are reusable. Within the biosensor the aptamers are immobilized to maximize their access to target molecules. Knowledge of the orientation and location of the aptamer and peptide during binding could be gained through computational modeling. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963836", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 607, 
          "offsetInEndSection": 743, 
          "text": "Understanding orientation and location of the binding region for a peptide-aptamer complex is critical in their biosensor applicability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963836", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2171, 
          "offsetInEndSection": 2435, 
          "text": " Our study clearly demonstrates the ability of MD simulations to obtain molecular insights for peptide-aptamer binding, and to provide details on the orientation and location of binding between the peptide-aptamer that can be instrumental in biosensor development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963836", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "Peptide aptamers are artificial short peptides that potentially interfere with the biological roles of their target proteins; however, this technology has not yet been applied to plant functional genomics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 252, 
          "offsetInEndSection": 436, 
          "text": "To extend such strategies we selected peptide aptamers binding to PrP from a combinatorial peptide library presented on the Escherichia coli thioredoxin A (trxA) protein as a scaffold.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574575", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1277, 
          "text": "These peptide aptamers retained their binding properties to PrPc and, depending on peptide sequence and C-terminal modification, interfered with endogenous PrPSc conversion upon expression in prion-infected cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574575", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 566, 
          "offsetInEndSection": 706, 
          "text": "Binding to the nonfarnesylated peptide was at least 10-fold weaker, showing that the aptamers can recognize the hydrophobic farnesyl moiety.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9222505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12530529", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 190, 
          "offsetInEndSection": 351, 
          "text": "Typically, peptide aptamers are generated by screening a randomized peptide expression library, displayed from the Escherichia coli thioredoxin A (TrxA) protein.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12530529", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Peptide aptamers define distinct EB1- and EB3-binding motifs and interfere with microtubule dynamics.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24478452", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 382, 
          "text": "Reverse analysis with peptide aptamers involves isolating aptamers that interact with a specific protein and monitoring the resulting aptamer-induced phenotype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18265211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 504, 
          "text": "Peptide aptamers are combinatorial protein reagents that bind to targets with a high specificity and a strong affinity thus providing a molecular tool kit for modulating the function of their targets in vivo.Here we report the isolation of a peptide aptamer named swiggle that interacts with the very short (21 amino acid long) intracellular domain of membrane type 1-metalloproteinase (MT1-MMP), a key cell surface protease involved in numerous and crucial physiological and pathological cellular events", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20653933", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Peptide aptamers are simple structures, often made up of a single-variable peptide loop constrained within a constant scaffold protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19895821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 286, 
          "offsetInEndSection": 461, 
          "text": "Peptide aptamers are small peptide sequences that have been selected to recognise a predetermined target protein domain and are potentially able to interfere with its function", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15952909", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "Aptamers, including DNA, RNA and peptide aptamers, are a group of promising recognition units that can specifically bind to target molecules and cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25699094", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Aptamers are a group of molecules, which can specifically bind, track, and inhibit target molecules, comprising DNA aptamers, RNA aptamers, and peptide aptamers", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "Peptide aptamers: The versatile role of specific protein function inhibitors in plant biotechnology", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Peptide aptamers are small proteins containing a randomized peptide sequence embedded into a stable protein scaffold, such as Thioredoxin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 534, 
          "offsetInEndSection": 822, 
          "text": "Peptide aptamers can subsequently be used to guide the discovery of small molecule drugs specific for these molecular surfaces.Here, we present a high-throughput screening assay that identifies small molecules that displace interactions between proteins and their cognate peptide aptamers", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377984", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 154, 
          "offsetInEndSection": 443, 
          "text": "These peptide aptamers are target-specific peptides expressed within a protein scaffold engineered from the human protease inhibitor stefin A. The scaffold provides stability to the inserted peptides and increases their binding affinity owing to the resulting three-dimensional constraints", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18186614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 57, 
          "text": "Isolation of Peptide aptamers to target protein function.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377987", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189388", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21224349", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11641783", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1590, 
          "offsetInEndSection": 1776, 
          "text": "These data highlight the utility of peptide aptamers to identify novel binding interfaces and highlight a role for MAP1B in DAPK-1-dependent signaling in autophagy and membrane blebbing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18195017", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 588, 
          "text": "Therapeutic application depends on binding specificities and affinities, as well as on the production and purification characteristics of the peptide aptamers and their delivery into cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18314488", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 209, 
          "offsetInEndSection": 407, 
          "text": "While antibodies are known to recognize the sequence and conformation of protein surface features (epitopes), very little is known about the precise interactions between aptamers and their epitopes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8755498", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18314488", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 423, 
          "offsetInEndSection": 575, 
          "text": "The use of small peptide aptamers to competitively inhibit protein interaction and function is becoming increasingly recognized as a powerful technique.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24478452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1373, 
          "offsetInEndSection": 1533, 
          "text": "For the first time, we show that trxA-based peptide aptamers can be targeted to the secretory pathway, thereby not losing the affinity for their target protein.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574575", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 902, 
          "offsetInEndSection": 1047, 
          "text": "Moreover, the aptamers appeared to be able to bind peptides with different solution conformations, implying an induced fit mechanism for binding.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8755498", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Peptide aptamers are small proteins containing a randomized peptide sequence embedded into a stable protein scaffold, such as Thioredoxin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Peptide aptamers are the newest in the class of \"genetic\" agents that aid in the analysis of cellular processes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18265211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Peptide aptamers: The versatile role of specific protein function inhibitors in plant biotechnology.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 637, 
          "offsetInEndSection": 892, 
          "text": "Here we present a detailed protocol for the creation of a peptide aptamer plasmid library, selection of peptide aptamers using the LiRP scaffold in a yeast two-hybrid system, and the screening of those peptide aptamers for a ligand-regulated interaction..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377988", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the clinical symptoms of left ventricular noncompaction?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27274374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23196658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25290726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24132556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23117287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22773171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22949776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10824732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11858389", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9005281", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24826276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22009732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20860157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17479651", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23258208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19218740", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15458689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23633270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22235038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21987083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23843353", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24231893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23914034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20347493"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "Symptoms"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0788385"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0788385", 
          "o": "SYMPTOMS"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "Symptoms"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "http://linkedlifedata.com/resource/umls/label/A11838788"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A11838788", 
          "o": "Symptoms"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7164206"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7164206", 
          "o": "Symptoms"
        }
      ], 
      "ideal_answer": [
        "The clinical symptoms of left ventricular noncompaction are:\n1) heart failure, \n2) systemic thromboembolic events, \n3) ventricular arrhythmias and\n4) sudden cardiac death."
      ], 
      "exact_answer": [
        [
          "heart failure"
        ], 
        [
          "systemic thromboembolic events", 
          "systemic thromboembolism"
        ], 
        [
          "ventricular arrhythmias"
        ], 
        [
          "sudden cardiac death"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:0060480", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016277", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018487", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018754"
      ], 
      "type": "list", 
      "id": "58d8e9bd8acda3452900000b", 
      "snippets": [
        {
          "offsetInBeginSection": 188, 
          "offsetInEndSection": 377, 
          "text": "Perioperative management of the patient with LVNC might be challenging due to the clinical symptoms of heart failure, systemic thromboembolic events, and fatal left ventricular arrhythmias.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274374", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 249, 
          "text": "Left ventricular noncompaction cardiomyopathy is a rare type of congenital cardiomyopathy characterized by prematurely arrested compaction of the endocardial and myocardial fibers and the progressive deterioration of left ventricular contractility. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196658", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 313, 
          "offsetInEndSection": 590, 
          "text": "Clinical features associated with LVNC vary in asymptomatic and symptomatic patients, and include the potential for heart failure, conduction defects (eg, left bundle branch block), supraventricular and ventricular arrhythmias, thromboembolic events, and sudden cardiac death. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25290726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1146, 
          "offsetInEndSection": 1328, 
          "text": "The clinical presentations are variable ranging from asymptomatic patients to patients who develop ventricular arrhythmias, thromboembolism, heart failure, and sudden cardiac death. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24132556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 372, 
          "offsetInEndSection": 546, 
          "text": "The clinical presentation and the natural history of LVNC are highly variable, ranging from no symptoms to congestive heart failure, arrhythmias, and systemic thromboemboli. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 451, 
          "offsetInEndSection": 606, 
          "text": "The clinical manifestations of the disease are variable, ranging from no symptoms to signs of heart failure, systemic emboli, and ventricular arrhythmias. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22773171", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 281, 
          "offsetInEndSection": 414, 
          "text": "We describe the case of a 62-year-old woman who presented with symptoms of heart failure secondary to left ventricular noncompaction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Multiple left ventricular thrombi in a patient with left ventricular noncompaction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 578, 
          "text": "We present three children with myocardial noncompaction: one male with isolated left ventricular noncompaction, another with right ventricular noncompaction and dysplastic tricuspid valve, and the last with left ventricular noncompaction, ventricular septal defect and coarctation of aorta, to stress especially the different clinical forms of the disorder and the importance of early diagnosis, as it may result in a fatal outcome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17479651", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 443, 
          "text": "Left ventricular noncompaction has a heterogeneous clinical presentation that includes arrhythmia and sudden cardiac death.We retrospectively reviewed all children diagnosed with left ventricular noncompaction at Texas Childrens Hospital from January 1990 to January 2009", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633270", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Left ventricular noncompaction is a cardiomyopathy characterized by excessive trabeculation of the left ventricle, progressive myocardial dysfunction, and early mortality", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633270", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 283, 
          "offsetInEndSection": 417, 
          "text": "We describe the case of a 62-year-old woman who presented with symptoms of heart failure secondary to left ventricular noncompaction. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1094, 
          "offsetInEndSection": 1273, 
          "text": "Left ventricular noncompaction (LVNC) and dilated CMP are the most common cardiac phenotypes reported and can lead to symptoms of heart failure as well as ventricular arrhythmias.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843353", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Multiple left ventricular thrombi in a patient with left ventricular noncompaction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 295, 
          "text": "Left ventricular noncompaction has a heterogeneous clinical presentation that includes arrhythmia and sudden cardiac death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633270", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 360, 
          "offsetInEndSection": 513, 
          "text": "Clinical symptoms include signs of left ventricular systolic dysfunction even to the point of heart failure, ventricular arrhythmias, and embolic events.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10824732", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the Glasgow Coma score?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26295284", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25834958", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23022643", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11332457"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Glasgow coma sore is used to determine injury severity on admission to a hospital emergency department or by the duration of unconsciousness."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015600"
      ], 
      "type": "summary", 
      "id": "58cdbbd102b8c60953000045", 
      "snippets": [
        {
          "offsetInBeginSection": 423, 
          "offsetInEndSection": 543, 
          "text": " Injury severity was determined by the Glasgow Coma Scale (GCS) score on admission or by the duration of unconsciousness", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26295284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 678, 
          "text": "Severity analysis was based on the Glasgow Coma Scale and Injury Severity Scor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25834958", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 663, 
          "offsetInEndSection": 775, 
          "text": "The strongest correlations were found between the Glasgow coma score and quality of life (r\u00a0= 0.236, P\u00a0= 0.0001)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23022643", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1245, 
          "offsetInEndSection": 1420, 
          "text": "By accepting the Glasgow Coma Scale as a gold standard for classification of the level of coma, we can confirm satisfactory measuring qualities for the Vienna Vigilance Score.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332457", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 14, 
          "offsetInEndSection": 399, 
          "text": "Our aim in this study was to assess whether the new Glasgow Coma Scale, Age, and Systolic Blood Pressure (GAP) scoring system, which is a modification of the Mechanism, Glasgow Coma Scale, Age, and Arterial Pressure (MGAP) scoring system, better predicts in-hospital mortality and can be applied more easily than previous trauma scores among trauma patients in the emergency department", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21831280", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Andexanet Alfa is an antidote of which clotting factor inhibitors?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26449414", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26627486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26686866", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26872887", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27147456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27399455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25494843", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27895055", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27913536", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27697443", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27575436", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27659071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27082776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26069913", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27789605", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26519420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25816811", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25387210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25516695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25431993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26559317"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0003295", 
          "o": "antidote"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0003295", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17973253"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A17973253", 
          "o": "Antidote"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/930", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/30155"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/30155", 
          "o": "Antidote"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0003295", 
          "o": "antidote"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/99104", 
          "o": "Coagulation factor inhibitor"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/99104", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/743388"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0003295", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17925206"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A17925206", 
          "o": "Antidote [EPC]"
        }
      ], 
      "ideal_answer": [
        "Andexanet alfa is a specific reversal agent for Factor Xa inhibitors.", 
        "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", 
        "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. In Phase III trials in healthy volunteers, andexanet alfa reduced anti-FXa activity by more than 90%, reduced the concentration of unbound direct FXa inhibitor, and inhibited thrombin generation. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. ", 
        "andexanet alfa is a factor xa (fxa) decoy that binds to direct and indirect inhibitors in phase iii trials in healthy volunteers , andexanet alfa reduced anti-fxa activity by more than 90% , reduced the concentration of unbound direct fxa inhibitor , and inhibited thrombin generation . andexanet is an antidote targeted to reverse the oral direct factor xa inhibitors as well as the indirect inhibitor enoxaparin. . ", 
        "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. ", 
        "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.: rivaroxaban, apixaban and edoxaban). Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors. Antidotes that experimentally reverse the anti-coagulant effect of dabigatran (Idarucizumab; BI 655075; Boehringer Ingelheim); of rivaroxaban, apixaban, or edoxaban (Andexanet alfa, r-Antidote, PRT064445; Portola Pharmaceuticals) or of all DOACs (Aripazine, PER-977, ciraparantag; Perosphere Inc.) are discussed. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly. Andexanet alfa (PRT064445), a specific reversal agent against factor Xa inhibitors, showed a complete reversal of anticoagulant activity of apixaban and rivaroxaban within minutes after administration without adverse effects in two recently completed parallel phase III trials ANNEXA-A and ANNEXA-R respectively.", 
        "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. ", 
        "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Andexanet alfa is a factor Xa (FXa) decoy that binds to direct and indirect FXa inhibitors.", 
        "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", 
        "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly."
      ], 
      "exact_answer": [
        [
          "Factor Xa", 
          "Xa"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019774", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000925"
      ], 
      "type": "factoid", 
      "id": "5880b073c872c95565000003", 
      "snippets": [
        {
          "offsetInBeginSection": 642, 
          "offsetInEndSection": 789, 
          "text": "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449414", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1095, 
          "offsetInEndSection": 1229, 
          "text": "Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26627486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "Andexanet alfa is a specific reversal agent for Factor Xa inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 238, 
          "offsetInEndSection": 440, 
          "text": "In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1198, 
          "offsetInEndSection": 1330, 
          "text": "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872887", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 746, 
          "offsetInEndSection": 1034, 
          "text": "Andexanet alfa is a factor Xa (FXa) decoy that binds to direct and indirect FXa inhibitors. In Phase III trials in healthy volunteers, andexanet alfa reduced anti-FXa activity by more than 90%, reduced the concentration of unbound direct FXa inhibitor, and inhibited thrombin generation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147456", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 734, 
          "offsetInEndSection": 938, 
          "text": "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1308, 
          "offsetInEndSection": 1601, 
          "text": "Recent results from phase 3/4 studies demonstrate efficacy for an antidote to dabigatran (idarucizumab, a monoclonal antibody fragment with specificity for dabigatran) and an antidote to factor Xa inhibitors (andexanet alfa, a recombinant and inactive form of factor Xa that binds inhibitors).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27913536", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "176\u2003Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1190, 
          "offsetInEndSection": 1322, 
          "text": "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872887", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 638, 
          "offsetInEndSection": 785, 
          "text": "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449414", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 282, 
          "text": "Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 195, 
          "offsetInEndSection": 352, 
          "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 354, 
          "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559317", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 959, 
          "offsetInEndSection": 1212, 
          "text": "Specific reversal agents are currently under development (idarucizumab for dabigatran, andexanet alfa for Xa inhibitors, and PER977 for both Xa- and thrombin inhibitors), which will facilitate clinical management of severe bleeding and emergency surgery", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25431993", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 355, 
          "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 739, 
          "offsetInEndSection": 981, 
          "text": "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.: rivaroxaban, apixaban and edoxaban).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 284, 
          "text": "Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1077, 
          "offsetInEndSection": 1389, 
          "text": "Andexanet alfa (PRT064445), a specific reversal agent against factor Xa inhibitors, showed a complete reversal of anticoagulant activity of apixaban and rivaroxaban within minutes after administration without adverse effects in two recently completed parallel phase III trials ANNEXA-A and ANNEXA-R respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27082776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1673, 
          "offsetInEndSection": 1968, 
          "text": "New antidotes are being explored, including a mouse monoclonal antibody to dabigatran; andexanet alfa, a potential universal factor Xa inhibitor reversal agent; and a synthetic small molecule (PER977) that may be effective for the reversal of factor Xa inhibitors and direct thrombin inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 65, 
          "text": "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559317", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 699, 
          "offsetInEndSection": 857, 
          "text": "Currently, two potential reversal agents for oral direct factor Xa inhibitors (andexanet alfa and ciraparantag) are at various stages of clinical development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27895055", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "176\u2003Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1315, 
          "offsetInEndSection": 1608, 
          "text": "Recent results from phase 3/4 studies demonstrate efficacy for an antidote to dabigatran (idarucizumab, a monoclonal antibody fragment with specificity for dabigatran) and an antidote to factor Xa inhibitors (andexanet alfa, a recombinant and inactive form of factor Xa that binds inhibitors).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27913536", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the main cause of the Patau syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21344634", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18253026", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14506431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11885075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24993362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20584846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18467377", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20537076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17603803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12762245", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12393964", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6458983", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19408854", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20641042", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23622175", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24564826", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23613355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23949924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26034714", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2348978", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2325123", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25459971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24340511"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0152095", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18670259"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18670259", 
          "o": "syndrome patau"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0152095", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0574493"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0574493", 
          "o": "Patau syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0152095", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18474937"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18474937", 
          "o": "Patau syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0152095", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18577308"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0152095", 
          "o": "Trisomy 13"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0152095", 
          "o": "Trisomy 13"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0152095", 
          "o": "Trisomy 13"
        }
      ], 
      "ideal_answer": [
        "Patau syndrome is caused by trisomy 13."
      ], 
      "exact_answer": [
        [
          "Trisome 13"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:11665", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002882"
      ], 
      "type": "factoid", 
      "id": "58da111c8acda34529000010", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "Trisomy 13, or Patau syndrome is a rare chromosomal disorder characterized by a triad of cleft lip and palate, postaxial polydactyly and microcephaly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344634", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 213, 
          "offsetInEndSection": 308, 
          "text": "Mosaic trisomy 13 is very rare, it occurs in only 5% of all patients with trisomy 13 phenotype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344634", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "Among full autosomal trisomies, only trisomies of chromosome 21 (Down syndrome), 18 (Edwards syndrome) and 13 (Patau syndrome) are compatible with postnatal survival. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18253026", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "We describe the management of the eyelid anomaly associated with Patau syndrome. Trisomy 13 is the genotype of the syndrome's phenotype. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14506431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 226, 
          "offsetInEndSection": 400, 
          "text": "This article identifies the causes and manifestations of most of these trisomies: trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), and trisomy 21 (Down syndrome). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11885075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 248, 
          "text": "WHS is caused by a deletion of 4p16, while Patau syndrome is caused by trisomy for some or all regions of chromosome 13.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12393964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Patau syndrome is a chromosomal disorder associated with multiple malformations caused by inheritance of an extra chromosome (trisomy 13).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20537076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004-2011", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23949924", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 640, 
          "text": "To determine whether older paternal age increases the risk of fathering a pregnancy with Patau (trisomy 13), Edwards (trisomy 18), Klinefelter (XXY) or XYY syndrome.Case-control: cases with each of these syndromes were matched to four controls with Down syndrome from within the same congenital anomaly register and with maternal age within 6 months.Data from 22 EUROCAT congenital anomaly registers in 12 European countries.Diagnoses with observed or (for terminations) predicted year of birth from 1980 to 2005, comprising live births, fetal deaths with gestational age \u2265 20 weeks and terminations after prenatal diagnosis of the anomaly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20584846", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 231, 
          "text": "Congenital diaphragmatic hernia (CDH) occurs in 5-10% associated with chromosomal abnormalities like, Pallister Killian syndrome, Trisomy 18, and certain deletions.. Association of CDH with trisomy 13 (Patau syndromes) is very rare", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26034714", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 250, 
          "text": "WHS is caused by a deletion of 4p16, while Patau syndrome is caused by trisomy for some or all regions of chromosome 13. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12393964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Patau syndrome is a chromosomal disorder associated with multiple malformations caused by inheritance of an extra chromosome (trisomy 13). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20537076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Ocular abnormalities in Patau syndrome (chromosome 13 trisomy syndrome).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2348978", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Trisomy 13 (Patau's syndrome): a rare case of survival into adulthood.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2325123", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 241, 
          "text": "BACKGROUND: Whilst maternal age is an established risk factor for Patau syndrome (trisomy 13), Edwards syndrome (trisomy 18) and Down syndrome (trisomy 21), the aetiology and contribution of genetic and environmental factors remains unclear.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467377", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 249, 
          "text": "WHS is caused by a deletion of 4p16, while Patau syndrome is caused by trisomy for some or all regions of chromosome 13.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12393964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "Patau syndrome, trisomy 13, is the third commonest autosomal trisomy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 61, 
          "text": "Patau syndrome (trisomy 13) is very rare in live-born babies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17603803", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the main abnormality that arises with Sox9 locus duplication?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25077096", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24040047", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18056774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18391513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25010117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22678921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11420125"
      ], 
      "triples": [], 
      "ideal_answer": [
        "SOX9 duplication can cause XX sex reversal.  SOX9 duplication has been found to be a rare cause of 46,XX testicular DSD in humans.", 
        "Autosomal XX sex reversal caused by duplication of SOX9", 
        "The 46,XX testicular disorder of sex development (DSD), also known as 46,XX male syndrome, is a rare form of DSD and clinical phenotype shows complete sex reversal from female to male. A complex network of genes determines sex in mammals. Differentiation of testicular tissue in 46,XX individuals is seen either in XX males, the majority of them with SRY gene, or in individuals, usually SRY(-), with ovotesticular disorder of sex development (OT-DSD). SOX9 is one of the genes that play critical roles in male sexual differentiation.", 
        "Autosomal XX sex reversal caused by duplication of SOX9. Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal. We report here evidence supporting that SOX9 duplication can cause XX sex reversal. Fluorescent in situ hybridization (FISH) with a BAC clone containing the SOX9 gene demonstrated that the SOX9 gene is duplicated on the rearranged chromosome 17. SOX9 duplication linked to intersex in deer. ", 
        "Thus, SOX9 duplication is the most likely cause for the sex reversal in this case because it plays an important role in male sex determination and differentiation. The SRY-box 9 (SOX9) gene has several important functions during testis development and differentiation in males, and overexpression of SOX9 leads to the male development of 46,XX gonads in the absence of SRY.", 
        "Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal. In addition, SOX9 duplication has been found to be a rare cause of 46,XX testicular DSD in humans."
      ], 
      "exact_answer": [
        [
          "Autosomal XX sex reversal"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58af1cb3717cd3f655000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 55, 
          "text": "Autosomal XX sex reversal caused by duplication of SOX9", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 82, 
          "offsetInEndSection": 180, 
          "text": "Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 182, 
          "offsetInEndSection": 264, 
          "text": "We report here evidence supporting that SOX9 duplication can cause XX sex reversal", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 691, 
          "text": "Fluorescent in situ hybridization (FISH) with a BAC clone containing the SOX9 gene demonstrated that the SOX9 gene is duplicated on the rearranged chromosome 17", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 43, 
          "text": "SOX9 duplication linked to intersex in deer", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040047", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 358, 
          "text": "Whole genome sequencing and quantitative real-time PCR analyses revealed a triple dose of the SOX9 gene, allowing insights into a new genetic defect in a wild animal", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 575, 
          "offsetInEndSection": 672, 
          "text": "In addition, SOX9 duplication has been found to be a rare cause of 46,XX testicular DSD in humans", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25077096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Extended pedigree with multiple cases of XX sex reversal in the absence of SRY and of a mutation at the SOX9 locus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391513", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1152, 
          "offsetInEndSection": 1307, 
          "text": "Together, these findings implicate a mutation at a sex-determining locus other than SRY and SOX9 as the cause for the XX sex reversal trait in this family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 56, 
          "text": "Autosomal XX sex reversal caused by duplication of SOX9.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Sox9 duplications are a relevant cause of Sry-negative XX sex reversal dogs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010117", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 182, 
          "offsetInEndSection": 265, 
          "text": "We report here evidence supporting that SOX9 duplication can cause XX sex reversal.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 82, 
          "offsetInEndSection": 181, 
          "text": "Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 916, 
          "offsetInEndSection": 1081, 
          "text": "Duplications of the locus DSS can lead to a failure of testicular development and a duplication of the region containing SOX9 has been implicated in XX sex reversal.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11420125", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Extended pedigree with multiple cases of XX sex reversal in the absence of SRY and of a mutation at the SOX9 locus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391513", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "XX male sex reversal with genital abnormalities associated with a de novo SOX3 gene duplication.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678921", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is Musclin a secretory peptide?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26449458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24734231", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23940802", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19244276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17189616"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, musclin has been described as a muscle-derived secretory peptide."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58df779d6fddd3e83e000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 60, 
          "text": "Musclin is a novel skeletal muscle-derived secretory factor,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17950246", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Musclin has been described as a muscle-derived secretory peptide, responsive to insulin in vivo, and inducing insulin resistance in vitro.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189616", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Musclin is a type of muscle-secreted cytokine and its increased gene expression induces insulin resistance in type 2 diabetes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Musclin is a novel skeletal muscle-derived factor found in the signal sequence trap of mouse skeletal muscle cDNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24734231", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Musclin is a novel skeletal muscle-derived secretory factor found in the signal sequence trap of mouse skeletal muscle cDNAs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940802", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Musclin is a novel skeletal muscle-derived secretory factor that was isolated by our group. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19244276", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What tissue is commonly affected in Marfan's syndrome", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26272787", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8240311", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19554831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14304236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23304566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9401003", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17620463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26281765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16400220", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21866385", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26494287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21723458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10050736", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9316048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9068910", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21308160"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0024796", 
          "o": "Marfan Syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0024796", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0431931"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0431931", 
          "o": "MARFAN SYNDROME"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0024796", 
          "o": "Marfan Syndrome"
        }
      ], 
      "ideal_answer": [
        "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents.", 
        "marfan syndrome (ms) is a connective tissue disorder that affects thousands of adolescents .", 
        "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents ", 
        "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents. ", 
        "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents"
      ], 
      "exact_answer": [
        [
          "connective tissue"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:14323", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008382"
      ], 
      "type": "factoid", 
      "id": "58dd0dde8acda34529000027", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26272787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 636, 
          "text": "Fibrillin-1 mutations have also been found in several other related connective tissue disorders, such as severe neonatal Marfan syndrome, dominant ectopia lentis, familial ascending aortic aneurysm, isolated skeletal features of Marfan syndrome, and Shprintzen-Goldberg syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401003", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Marfans syndrome is an Autosomal dominant disorder of the connective tissues resulting in abnormalities of the musculoskeletal system, cardiovascular system and eyes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16400220", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "Marfan syndrome (MFS) is a systemic disorder of the connective tissue with pleiotropic manifestations due to heterozygous FBN1 mutations and consequent upregulation of TGF\u03b2 signaling in affected tissues", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21866385", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 257, 
          "text": "Marfan syndrome (MFS) is an autosomal dominant disorder of connective tissue, caused by mutations of the microfibrillar protein fibrillin-1, that predisposes affected individuals to aortic aneurysm and rupture and is associated with increased TGF\u03b2 signaling", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26494287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "Marfan syndrome is an autosomal dominant connective tissue disorder commonly due to mutation of the fibrillin-1 (FBN-1) gene that causes disruption of elastic fibers in large- and medium-size arteries and predisposes to aneurysm formation and arterial dissection", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21723458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 85, 
          "offsetInEndSection": 236, 
          "text": "Children affected by the Marfan syndrome carry a mutation in one of their two copies of the gene that encodes the connective tissue protein fibrillin-1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23304566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "Marfan's syndrome is an autosomal dominant disorder of connective tissue, commonly involving the cardiovascular, ocular, and skeletal systems. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10050736", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "Marfan syndrome is an autosomal dominant connective tissue disorder commonly due to mutation of the fibrillin-1 (FBN-1) gene that causes disruption of elastic fibers in large- and medium-size arteries and predisposes to aneurysm formation and arterial dissection. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21723458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Marfan's syndrome is an autosomal dominant disorder of connective tissue, commonly involving the cardiovascular, ocular, and skeletal systems.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10050736", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Marfan's syndrome is a heritable connective tissue disorder that has been associated with intracranial aneurysms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9316048", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Marfan's syndrome is an inherited disorder of connective tissue associated with characteristic abnormalities of the skeletal, ocular, and cardiovascular systems.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9068910", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 785, 
          "offsetInEndSection": 939, 
          "text": "Therefore, Marfan's syndrome is termed a fibrillinopathy, along with other connective tissue disorders with subtle differences in clinical manifestations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21308160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "The Marfan syndrome is an inherited disorder of the connective tissue which is mainly caused by a mutation in the fibrillin-1 gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19554831", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Marfan syndrome is an inherited multisystemic connective-tissue disease that is caused by a mutation of the fibrillin-1 gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17620463", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 311, 
          "offsetInEndSection": 497, 
          "text": " Mutations in the fibrillin-1 gene give rise to Marfan syndrome, a connective tissue disorder with clinical complications in the cardiovascular, skeletal, ocular and other organ systems.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26281765", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "To which disease does the loss of CD28 expression by liver-infiltrating T cells contribute?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24726754"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.", 
        "loss of cd28 expression by liver-infiltrating t cells contributes to pathogenesis of primary sclerosing cholangitis.", 
        "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. "
      ], 
      "exact_answer": [
        [
          "Primary sclerosing cholangitis"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008107", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058625", 
        "http://www.uniprot.org/uniprot/CD28_HUMAN", 
        "http://www.uniprot.org/uniprot/CD28_FELCA", 
        "http://www.uniprot.org/uniprot/CD28_CHICK", 
        "http://www.uniprot.org/uniprot/CD28_MOUSE", 
        "http://www.uniprot.org/uniprot/CD28_RABIT", 
        "http://www.uniprot.org/uniprot/CD28_BOVIN", 
        "http://www.uniprot.org/uniprot/CD28_RAT"
      ], 
      "type": "factoid", 
      "id": "58853922e56acf5176000016", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726754", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726754", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726754", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Are cutaneous porphyrias inherited with a recessive pattern?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15868463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12859407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11202049"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No, cutaneous porphyrias are inherited in a dominant (not recessive) pattern."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58e11b9b6fddd3e83e00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 464, 
          "offsetInEndSection": 728, 
          "text": "Five of the porphyrias are low-penetrance autosomal dominant conditions in which clinical expression results from additional factors that act by increasing demand for haem or by causing an additional decrease in enzyme activity or by a combination of these effects", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 57, 
          "text": "Molecular mechanisms of dominant expression in porphyria.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "Variegate porphyria (VP) is an autosomal-dominant disorder that is caused by inheritance of a partial deficiency of the enzyme protoporphyrinogen oxidase (EC 1.3.3.4). It is characterized by cutaneous photosensitivity and/or various neurological manifestations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12859407", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "The acute porphyrias constitute a group of metabolic disorders engaging enzymes in the haem synthetic chain and generally following dominant inheritance patterns.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11202049", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease is treated with ZMapp?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26798032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26861827", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27067649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26962157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27274814", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25171469", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26946569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27732819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27465308", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26311869", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25414384", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25760722", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27521366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25648530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27676206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25648233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25694097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25387576", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25352204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25404321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25260583", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25465382", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26191408", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27683818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27279622"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0012634", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0049608"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0049608", 
          "o": "Disease"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1022004", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3147522"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3147522", 
          "o": "Disease"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0012634", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18683747"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18683747", 
          "o": "disease"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0012634", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0015569"
        }
      ], 
      "ideal_answer": [
        "ZMapp is a combination of antibodies for treatment of Ebola virus disease."
      ], 
      "exact_answer": [
        [
          "Ebola virus disease"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:4", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
      ], 
      "type": "factoid", 
      "id": "5880e417713cbdfd3d000001", 
      "snippets": [
        {
          "offsetInBeginSection": 424, 
          "offsetInEndSection": 691, 
          "text": "This includes agents belonging to various therapeutic classes, namely direct antiviral agents (favipiravir and BCX4430), a combination of antibodies (ZMapp), type I interferons, RNA interference-based drugs (TKM-Ebola and AVI-7537), and anticoagulant drugs (rNAPc2). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798032", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Recent successes with monoclonal antibody cocktails ZMapp(TM) and MIL77 against Ebola virus (EBOV) infections have reignited interest in antibody-based therapeutics. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067649", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 147, 
          "offsetInEndSection": 708, 
          "text": "The human-mouse chimeric monoclonal antibody (mAb) cocktail ZMapp, previously shown to be efficacious in EBOV (variant Kikwit) lethally infected nonhuman primates (NHPs) when administration was initiated up to 5 days, was used in some patients during the outbreak. We show that a two-antibody cocktail, MIL77E, is fully protective in NHPs when administered at 50 mg/kg 3 days after challenge with a lethal dose of EBOV variant Makona, the virus responsible for the ongoing 2014-2015 outbreak, whereas a similar formulation of ZMapp protected two of three NHPs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "The growing promise of plant-made biologics is highlighted by the success story of ZMapp\u2122 as a potentially life-saving drug during the Ebola outbreak of 2014-2016. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274814", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "Background Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Several patients with Ebola virus disease (EVD) managed in the United States have received ZMapp monoclonal antibodies, TKM-Ebola small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27521366", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 648, 
          "offsetInEndSection": 838, 
          "text": "Also there is no specific vaccine and treatment for Ebola virus; however, many candidate vaccines and antiviral-drugs such as ZMapp and TKM-Ebola are being developed for Ebola virus disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648530", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 757, 
          "offsetInEndSection": 869, 
          "text": "ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1233, 
          "offsetInEndSection": 1489, 
          "text": "Going forward, this work now provides a basis for strategic selection of next-generation antibody cocktails against Ebola and related viruses and a model for predicting the impact of ZMapp on potential escape mutations in ongoing or future Ebola outbreaks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404321", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 635, 
          "offsetInEndSection": 742, 
          "text": "Some potential therapeutic materials including ZMapp were supplied and the treated people got over the EVD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648233", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1580, 
          "offsetInEndSection": 1876, 
          "text": "Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311869", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 426, 
          "offsetInEndSection": 666, 
          "text": "This review explores some of the more prominent recent advances in the biofarming of viral vaccines and therapies, including the recent use of ZMapp for Ebolavirus infection, and explores some possible future applications of the technology.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25465382", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 757, 
          "offsetInEndSection": 868, 
          "text": "ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1581, 
          "offsetInEndSection": 1877, 
          "text": "Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311869", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 369, 
          "text": "For example, several patients of the present Ebola virus outbreak in West Africa were treated with ZMapp, a cocktail of three monoclonal antibodies which are expressed in Nicotiana benthamiana.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191408", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Can methylenetetrahydrofolate reductase (MTHFR) gene mutations cause homocystinuria?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24461181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23533858", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21626167", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20236116", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17349292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17457696", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10980581", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16629766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10679944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9781030", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27130656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9490685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12673793", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10923034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11181567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9453374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11592438", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23095199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14656017", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2629632", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20532821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8124871", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22521626"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0066357", 
          "o": "MTHFR"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5034323839380027", 
          "o": "MTHFR"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5034323839380027", 
          "o": "MTHFR"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5135534E573500F", 
          "o": "MTHFR"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/drugbank/molecule/3917", 
          "o": "Methylenetetrahydrofolate reductase"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://linkedlifedata.com/resource/drugbank/molecule/3917", 
          "o": "http://purl.uniprot.org/uniprot/P42898"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://purl.uniprot.org/uniprot/P42898", 
          "o": "MTHR_HUMAN"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://purl.uniprot.org/uniprot/P42898", 
          "o": "http://purl.uniprot.org/uniprot/P42898"
        }
      ], 
      "ideal_answer": [
        "Yes, several methylenetetrahydrofolate reductase (MTHFR) gene mutations can cause homocystinuria and hyperhomocysteinemia."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.uniprot.org/uniprot/MTHR_MOUSE", 
        "http://www.uniprot.org/uniprot/MTHR_HUMAN", 
        "http://www.uniprot.org/uniprot/MTHR_BOVIN", 
        "http://www.uniprot.org/uniprot/MTHR_MACFA", 
        "http://www.disease-ontology.org/api/metadata/DOID:9263", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006712", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154"
      ], 
      "type": "yesno", 
      "id": "58d8d0cc8acda34529000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Methylenetetrahydrofolate reductase (MTHFR) deficiency is a rare autosomal recessive disorder. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461181", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 136, 
          "offsetInEndSection": 391, 
          "text": "Several mutations seen in methylenetetrahydrofolate reductase (MTHFR) give rise to the formation of hyperhomocysteinemia and homocystinuria, a considerable risk factor for cardiovascular and cerebrovascular disorders, by leading to enzymatic inactivation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533858", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 551, 
          "offsetInEndSection": 764, 
          "text": "At admission, he had significantly elevated plasma and urine levels of total homocysteine, significantly decreased levels of folate in serum and cerebrospinal fluid, and a normal blood concentration of methionine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461181", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 529, 
          "offsetInEndSection": 814, 
          "text": "Response to treatment demonstrated B(6)-non-responsive homocystinuria. Molecular study showed compound heterozygous T353\u00a0N and D444\u00a0N mutations of the cystathionine beta-synthase (CBS) gene, and also a C667T homozygous mutation of the methylenetetrahydrofolate-reductase (MTHFR) gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626167", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1121, 
          "offsetInEndSection": 1374, 
          "text": "Our case is atypical because of the absence of thromboembolism and the mild phenotype, in spite of being B(6)-non-responsive, and the association of a rare compound heterozygous mutation of the CBS gene and also an homozygous mutation of the MTHFR gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626167", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 457, 
          "text": "Methylenetetrahydrofolate reductase (MTHFR) is a key regulatory enzyme in folate and homocysteine metabolism. Research performed during the past decade has clarified our understanding of MTHFR deficiencies that cause homocystinuria or mild hyperhomocysteinemia. Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 320, 
          "text": "Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the regulation of plasma homocysteine levels. MTHFR deficiency, an autosomal recessive disorder, results in homocystinuria and hypomethioninaemia and presents with highly variable symptoms affecting many organs but predominantly the central nervous system. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17457696", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 309, 
          "offsetInEndSection": 431, 
          "text": "Rare mutations in the MTHFR gene have been associated with autosomal recessive MTHFR deficiency leading to homocystinuria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 227, 
          "offsetInEndSection": 414, 
          "text": "Five patients suspected of having non-classical homocystinuria due to MTHFR deficiency were examined with respect to their symptoms, MTHFR enzyme activity and genotypes of the MTHFR gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1171, 
          "offsetInEndSection": 1417, 
          "text": "The results of our study render the full-length characterisation of affected alleles in severe homocystinuria and moderate hyperhomocysteinaemia due to MTHFR deficiency and provide a basis for investigating the regulation of the human MTHFR gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10980581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 260, 
          "offsetInEndSection": 455, 
          "text": "Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 385, 
          "text": "Different MTHFR mutations lead either to severe homocystinuria as a multisystem disorder or to moderate hyperhomocysteinaemia, which is a common risk factor for disorders ranging from cardiovasculopathy to spina bifida.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10980581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 435, 
          "offsetInEndSection": 712, 
          "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 807, 
          "offsetInEndSection": 1094, 
          "text": "On the contrary, thermolabile MTHFR caused by the 677C-->T mutation, was frequently observed among homocystinuria patients, especially among those with thromboembolic complications: three of six homocystinuria patients who had suffered from a thromboembolic event had thermolabile MTHFR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 438, 
          "offsetInEndSection": 715, 
          "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 438, 
          "offsetInEndSection": 714, 
          "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 278, 
          "text": "The most common genetic cause of hyperhomocysteinemia is the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 444, 
          "text": "The 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592438", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "Hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) gene mutation have been postulated as a possible cause of recurrent miscarriage (RM)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 276, 
          "offsetInEndSection": 403, 
          "text": "The 677C>T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinaemia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14656017", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 438, 
          "offsetInEndSection": 716, 
          "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "AIM: Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2629632", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 216, 
          "text": "Severe deficiency of methylenetetrahydrofolate reductase (MTHFR) with homocystinuria can result in early demise or later-onset neurological impairment, including developmental delay, motor dysfunction, and seizures. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Deficiency of 5,10-methylenetetrahydrofolate reductase (MTHFR) leads to deficient remethylation of homocysteine and is one of the causes of homocystinuria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8124871", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 270, 
          "offsetInEndSection": 369, 
          "text": "Neurological disturbances have been described in homocystinuria caused by severe MTHFR deficiency. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22521626", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 445, 
          "text": "The 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592438", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 110, 
          "offsetInEndSection": 261, 
          "text": "Research performed during the past decade has clarified our understanding of MTHFR deficiencies that cause homocystinuria or mild hyperhomocysteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 276, 
          "offsetInEndSection": 404, 
          "text": "The 677C>T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinaemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14656017", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 279, 
          "text": "The most common genetic cause of hyperhomocysteinemia is the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 262, 
          "offsetInEndSection": 457, 
          "text": "Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 812, 
          "offsetInEndSection": 1099, 
          "text": "On the contrary, thermolabile MTHFR caused by the 677C-->T mutation, was frequently observed among homocystinuria patients, especially among those with thromboembolic complications: three of six homocystinuria patients who had suffered from a thromboembolic event had thermolabile MTHFR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What happens to H2AX upon DNA bouble strand breaks?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27158526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24682951", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22704343", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21511815"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR).  Phosphorylated H2AX (\u03b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress. DNA double-strand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin", 
        " phosphorylated h2ax (\u03b3h2ax) is rapidly concentrated in chromatin domains around dna double-strand breaks (dsbs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress.", 
        "Defective or inefficient DNA double-strand break (DSB) repair results in failure to preserve genomic integrity leading to apoptotic cell death, a hallmark of systemic lupus erythematosus (SLE). The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR). A sequence variant of histone H2A called H2AX is one of the key components of chromatin involved in DNA damage response induced by different genotoxic stresses. DNA double-strand breaks (DSBs) can induce chromosomal aberrations and carcinogenesis and their correct repair is crucial for genetic stability.", 
        "Histone H2AX phosphorylation as a measure of DNA double-strand breaks and a marker of environmental stress and disease activity in lupus. DSBs were quantified in peripheral blood mononuclear cell subsets from patients with SLE, healthy controls, and patients with rheumatoid arthritis (RA) by measuring phosphorylated H2AX (phospho-H2AX) levels with flow cytometry. Most hydrogen peroxide-induced histone H2AX phosphorylation is mediated by ATR and is not dependent on DNA double-strand breaks. The nuclear foci of phosphorylated histone H2AX (H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR). These results suggest that a major fraction of H2AX induced by oxidative stress is not associated with DSBs. ", 
        "Defective or inefficient DNA double-strand break (DSB) repair results in failure to preserve genomic integrity leading to apoptotic cell death, a hallmark of systemic lupus erythematosus (SLE). Phosphorylated H2AX (\u00ce\u00b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress.", 
        "DSBs were quantified in peripheral blood mononuclear cell subsets from patients with SLE, healthy controls, and patients with rheumatoid arthritis (RA) by measuring phosphorylated H2AX (phospho-H2AX) levels with flow cytometry DNA double-strand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin", 
        " Phosphorylated H2AX (\u03b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR)"
      ], 
      "exact_answer": [
        [
          "it is rapidly concentrated"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58af16ea717cd3f655000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Histone H2AX phosphorylation as a measure of DNA double-strand breaks and a marker of environmental stress and disease activity in lupus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158526", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 542, 
          "offsetInEndSection": 768, 
          "text": "DSBs were quantified in peripheral blood mononuclear cell subsets from patients with SLE, healthy controls, and patients with rheumatoid arthritis (RA) by measuring phosphorylated H2AX (phospho-H2AX) levels with flow cytometry", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Most hydrogen peroxide-induced histone H2AX phosphorylation is mediated by ATR and is not dependent on DNA double-strand breaks.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682951", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682951", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1030, 
          "offsetInEndSection": 1243, 
          "text": "These results suggest that a major fraction of \u03b3H2AX induced by oxidative stress is not associated with DSBs. Single-stranded DNA arisen from stalled replication forks can cause the ATR-mediated induction of \u03b3H2AX", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682951", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704343", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "A sequence variant of histone H2A called H2AX is one of the key components of chromatin involved in DNA damage response induced by different genotoxic stresses", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704343", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 389, 
          "text": " Phosphorylated H2AX (\u03b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704343", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "DNA double-strand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511815", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 583, 
          "text": "he cellular response to DSBs depends on damage signaling including the phosphorylation of the histone H2AX (\u03b3H2AX). However, a lack of \u03b3H2AX formation in heterochromatin (HC) is generally observed after DNA damage induction. Here, we examine \u03b3H2AX and repair protein foci along linear ion tracks traversing heterochromatic regions in human or murine cells and find the DSBs and damage signal streaks bending around highly compacted DNA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511815", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can valproic acid prolong survival of glioblastoma patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26420896", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26925628", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25648357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26194676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25066904", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24328881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27889835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22168970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21880994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23523186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18751431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26786929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26976976"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0042291", 
          "o": "valproic acid"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0042291", 
          "o": "http://linkedlifedata.com/resource/umls/label/A10769673"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A10769673", 
          "o": "VALPROIC ACID"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/11118", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3253230"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3253230", 
          "o": "VALPROIC ACID"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0042291", 
          "o": "valproic acid"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0042291", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0131324"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0131324", 
          "o": "Valproic Acid"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/11118", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3254597"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3254597", 
          "o": "Valproic Acid"
        }
      ], 
      "ideal_answer": [
        "Yes, there is evidence to suggest that valproic acid (VPA) is associated with prolonged survival of glioblastoma patients. Several studies have indicated that VPA has radiosensitizing effects for gliomas and radioprotective influence on normal brain tissue or hippocampal neurons."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014635", 
        "http://www.biosemantics.org/jochem#4271063", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005909", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4271063", 
        "http://www.disease-ontology.org/api/metadata/DOID:3068", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013534", 
        "http://www.disease-ontology.org/api/metadata/DOID:3073", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016019", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015996"
      ], 
      "type": "yesno", 
      "id": "5884755ce56acf5176000007", 
      "snippets": [
        {
          "offsetInBeginSection": 978, 
          "offsetInEndSection": 1152, 
          "text": "For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1255, 
          "offsetInEndSection": 1372, 
          "text": "This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 571, 
          "offsetInEndSection": 1042, 
          "text": "Several in vivo and in vitro studies have indicated that VPA has radiosensitizing effects for gliomas and radioprotective influence on normal brain tissue or hippocampal neurons. The results of several retrospective studies have also indicated potential benefit to improve survival of patients with GBM. Moreover, the promising treatment results of a phase 2 trial of concurrent radiation therapy, temozolomide, and VPA for patients with GBM have been recently reported. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26925628", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 102, 
          "offsetInEndSection": 368, 
          "text": "While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that the widely used anti-convulsant agent, valproic acid (VPA) may significantly prolong survival in GBM patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648357", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1851, 
          "offsetInEndSection": 1955, 
          "text": " Additionally, VPA may result in improved outcomes compared to historical data and merits further study.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26194676", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1015, 
          "offsetInEndSection": 1247, 
          "text": "Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 239, 
          "offsetInEndSection": 335, 
          "text": "Several clinical studies have reported that valproic acid could prolong survival of GBM patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25066904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 102, 
          "offsetInEndSection": 367, 
          "text": "While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that the widely used anti-convulsant agent, valproic acid (VPA) may significantly prolong survival in GBM patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648357", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Valproic acid use during radiation therapy for glioblastoma associated with improved survival.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523186", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1032, 
          "offsetInEndSection": 1333, 
          "text": "Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1016, 
          "offsetInEndSection": 1249, 
          "text": "Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 92, 
          "offsetInEndSection": 740, 
          "text": "Several uncontrolled retrospective case series and a post hoc analysis of the registration trial for temozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes in patients with newly diagnosed glioblastoma.To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation T", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 239, 
          "offsetInEndSection": 336, 
          "text": "Several clinical studies have reported that valproic acid could prolong survival of GBM patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25066904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1001, 
          "offsetInEndSection": 1420, 
          "text": "Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93).VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 537, 
          "text": "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown.We investigated the in vitro and in vivo effects of pretreating glioma cells with temozolomide and VPA as an immunization strategy to boost an adaptive immune response in a syngeneic mouse model.Temozolomide and VPA induced autophagy in GL261 glioma cells, and caused tumor antigen-specific T-cells to become activated effector T-cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the effect of the direct interaction of Ikaros and Foxp1 in B-lymphocytes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27588474"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1825588", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20756491"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20756491", 
          "o": "IKAROS"
        }
      ], 
      "ideal_answer": [
        "The effect of the direct interaction of Ikaros and Foxp1 in B-lymphocytesis is modulation of expression of the G protein-coupled receptor G2A.", 
        "Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia."
      ], 
      "exact_answer": [
        [
          "Modulation of expression of the G protein-coupled receptor G2A."
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001402", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D060151", 
        "http://www.biosemantics.org/jochem#4250484", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051740", 
        "http://www.uniprot.org/uniprot/FOXP1_MOUSE", 
        "http://www.uniprot.org/uniprot/FOXP1_RAT"
      ], 
      "type": "factoid", 
      "id": "58853667e56acf5176000015", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 114, 
          "offsetInEndSection": 555, 
          "text": "We describe a novel physical and functional interaction between the proteins, which requires the central zinc finger domain of Ikaros. The Ikaros-Foxp1 interaction is abolished by deletion of this region, which corresponds to the IK6 isoform that is commonly associated with high-risk acute lymphoblastic leukemia (ALL). We also identify the Gpr132 gene, which encodes the orphan G protein-coupled receptor G2A, as a novel target for Foxp1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1047, 
          "offsetInEndSection": 1216, 
          "text": "Our results reveal a novel effect of Ikaros haploinsufficiency on Foxp1 functioning, and identify G2A as a potential modulator of the cell cycle in Ikaros-deleted B-ALL.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1040, 
          "offsetInEndSection": 1209, 
          "text": "Our results reveal a novel effect of Ikaros haploinsufficiency on Foxp1 functioning, and identify G2A as a potential modulator of the cell cycle in Ikaros-deleted B-ALL.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1047, 
          "offsetInEndSection": 1217, 
          "text": "Our results reveal a novel effect of Ikaros haploinsufficiency on Foxp1 functioning, and identify G2A as a potential modulator of the cell cycle in Ikaros-deleted B-ALL..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which syndrome is caused by deletion of Pds5b in mice?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17652350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19412548"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1442161", 
          "o": "Gene Deletion"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0039082", 
          "o": "Syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0039082", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0121946"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0121946", 
          "o": "Syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/989712", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3242053"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3242053", 
          "o": "Syndrome"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1511760", 
          "o": "Deletion"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1442161", 
          "o": "http://linkedlifedata.com/resource/umls/label/A10802767"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A10802767", 
          "o": "Deletion"
        }
      ], 
      "ideal_answer": [
        "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome", 
        "Mice lacking sister chromatid cohesion protein Pds5b exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome.", 
        "mice lacking sister chromatid cohesion protein pds5b exhibit developmental abnormalities reminiscent of cornelia de lange syndrome.", 
        "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome.", 
        "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome. "
      ], 
      "exact_answer": [
        [
          "Cornelia de Lange syndrome."
        ]
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/PDS5B_MOUSE", 
        "http://www.uniprot.org/uniprot/PDS5B_RAT", 
        "http://amigo.geneontology.org/amigo/term/GO:0090695"
      ], 
      "type": "factoid", 
      "id": "5889eb503b87a8a73800000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652350", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 298, 
          "offsetInEndSection": 364, 
          "text": "Pds5B mutant mice have developmental abnormalities resembling CdLS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412548", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652350", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 296, 
          "offsetInEndSection": 460, 
          "text": "Pds5B mutant mice have developmental abnormalities resembling CdLS; however the role of Pds5A in mammals and the association of PDS5 proteins with CdLS are unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412548", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 298, 
          "offsetInEndSection": 462, 
          "text": "Pds5B mutant mice have developmental abnormalities resembling CdLS; however the role of Pds5A in mammals and the association of PDS5 proteins with CdLS are unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412548", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652350", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the inheritance of Barth syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25776009", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16847078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12749056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8884581", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11975944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8487269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17353728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19037987", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12112112", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9345098", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8434619", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24751896", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16857210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21987083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24342716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21068380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25185984", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23523468", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24093814", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23031367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21932011"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0574083", 
          "o": "Barth Syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0574083", 
          "o": "http://linkedlifedata.com/resource/umls/label/A12001922"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A12001922", 
          "o": "BARTH SYNDROME"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0574083", 
          "o": "Barth Syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20801255"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20801255", 
          "o": "Barth syndrome"
        }, 
        {
          "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name", 
          "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/137", 
          "o": "Barth_syndrome"
        }
      ], 
      "ideal_answer": [
        "Barth syndrome (BTHS) has an X-linked recessive pattern of inheritance."
      ], 
      "exact_answer": [
        [
          "X-linked recessive pattern of inheritance"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056889", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050476", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040582", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"
      ], 
      "type": "factoid", 
      "id": "58d900428acda3452900000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "Barth syndrome (BTHS) is an X-linked recessive disease primarily affecting males.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25776009", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 974, 
          "offsetInEndSection": 1097, 
          "text": "The results of our study should not only be applicable to BTHS families, but also to families with other X-linked diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25776009", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 256, 
          "text": "Barth syndrome, an X-linked disorder that is characterized by cardiomyopathy, neutropenia, skeletal myopathy, and growth delay, is caused by mutations in the taffazin gene at Xq28 that result in cardiolipin deficiency and abnormal mitochondria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2300, 
          "offsetInEndSection": 2553, 
          "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 247, 
          "offsetInEndSection": 418, 
          "text": "Mutations in the G4.5 gene result in a wide spectrum of severe infantile X-linked cardiomyopathic phenotypes including Barth syndrome with dilated cardiomyopathy and INVM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12749056", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 755, 
          "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 595, 
          "offsetInEndSection": 749, 
          "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "OBJECTIVE: Barth syndrome is a rare, X-linked recessive disorder that affects only boys.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17353728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 125, 
          "offsetInEndSection": 236, 
          "text": "Barth syndrome, an X-linked mitochondrial cardioskeletal myopathy, was diagnosed by genetic testing at autopsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19037987", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Barth syndrome is an X-linked cardiomyopathy with neutropenia and 3-methylglutaconic aciduria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9345098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Barth syndrome is an X-linked cardiac and skeletal mitochondrial myopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12112112", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2265, 
          "offsetInEndSection": 2517, 
          "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 753, 
          "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 530, 
          "offsetInEndSection": 685, 
          "text": "Although the cardiomyopathy was familial in two siblings, two of three cases were female, ruling out Barth syndrome (with sex-linked recessive inheritance)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975944", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "Barth syndrome is an X-linked genetic disorder caused by mutations in the tafazzin (taz) gene and characterized by dilated cardiomyopathy, exercise intolerance, chronic fatigue, delayed growth, and neutropenia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2265, 
          "offsetInEndSection": 2518, 
          "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 754, 
          "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 530, 
          "offsetInEndSection": 686, 
          "text": "Although the cardiomyopathy was familial in two siblings, two of three cases were female, ruling out Barth syndrome (with sex-linked recessive inheritance).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975944", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 687, 
          "text": "Although the cardiomyopathy was familial in two siblings, two of three cases were female, ruling out Barth syndrome (with sex-linked recessive inheritance).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975944", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2265, 
          "offsetInEndSection": 2519, 
          "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Cryptococcus neoformans a frequent cause of isolated skin infections in immunocompromised individuals", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26246081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27852678", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12602722", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12219115"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0010414", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18683550"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18683550", 
          "o": "cryptococcus neoformans"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0010416", 
          "o": "Cryptococcus neoformans"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0010416", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0043970"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0010414", 
          "o": "http://linkedlifedata.com/resource/umls/label/A8355137"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A8355137", 
          "o": "Infection by Cryptococcus neoformans"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0010414", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0560486"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0560486", 
          "o": "Infection by Cryptococcus neoformans"
        }
      ], 
      "ideal_answer": [
        "Primary cutaneous cryptococcosis (PCC) without systemic infection is rare."
      ], 
      "exact_answer": "no", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003455", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003454", 
        "http://www.disease-ontology.org/api/metadata/DOID:12053", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012874", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003453"
      ], 
      "type": "yesno", 
      "id": "58e120036fddd3e83e00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 10, 
          "offsetInEndSection": 284, 
          "text": " Cryptococcus is an opportunistic yeast with a worldwide distribution that primarily causes significant infections in immunocompromised individuals, generally by affecting the respiratory tract. But primary cutaneous cryptococcosis (PCC) without systemic infection is rare. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Cryptococcus is a ubiquitous fungus and is known for causing meningitis and cutaneous infections in immunocompromised individuals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27852678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 215, 
          "text": "Cryptococcus neoformans is an encapsulated yeast that can cause primary pulmonary infections or disseminate and cause infections of the central nervous system, meninges, skin, and bone in the immunocompromised host.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12602722", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 189, 
          "text": "The authors report a male patient, a seller with no detected immunosuppression, with an extensive ulcerated skin lesion localized on the left forearm, caused by Cryptococcus neoformans var.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12219115", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mechanism of action of Pictilisib?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26733612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26830312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26976426", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27044711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27048952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27012832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27573562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27565810", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27155741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25370471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24754926", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26965285", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27489350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27529512"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Pictilisib acts by inhibiting PI3K. It is used for breast cancer treatment."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
      ], 
      "type": "summary", 
      "id": "5884fed0e56acf5176000011", 
      "snippets": [
        {
          "offsetInBeginSection": 367, 
          "offsetInEndSection": 696, 
          "text": "EXPERIMENTAL DESIGN: Antiestrogen-sensitive and antiestrogen-resistant ER(+) human breast cancer cell lines and mice bearing PIK3CA-mutant xenografts were treated with the antiestrogen fulvestrant, the PI3K inhibitor GDC-0941 (pictilisib; varied doses/schedules that provided similar amounts of drug each week), or combinations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1383, 
          "offsetInEndSection": 1834, 
          "text": "These strategies include first-line therapy with high-dose fulvestrant or everolimus (in combination with exemestane or letrozole or with other endocrine therapies), use of the PI3K inhibitors (e.g., buparlisib, alpelisib, pictilisib, taselisib), entinostat, CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib), and novel selective estrogen receptor degradation agents that may enhance the targeting of acquired mutations in the ESR1 gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830312", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 201, 
          "text": "Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976426", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 201, 
          "offsetInEndSection": 458, 
          "text": "This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976426", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 894, 
          "offsetInEndSection": 1100, 
          "text": "In contrast to parental cells, resistant cells were sensitive to growth inhibition and apoptosis induced by the class I PI3K inhibitor, GDC-0941 (pictilisib), which also induced FOXO1 nuclear translocation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27044711", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 57, 
          "offsetInEndSection": 429, 
          "text": "Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26 metabolites, including amino acids, acylcarnitines, and phosphatidylcholines, were decreased in mice bearing PTEN-deficient tumors compared with non-tumor-bearing controls and in addition were increased following dosing with class I PI3K inhibitor pictilisib (GDC-0941).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "The PI3K inhibitor pictilisib plus anastrozole suppresses luminal B breast cancer proliferation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 136, 
          "offsetInEndSection": 194, 
          "text": "Pictilisib is an oral inhibitor of multiple PI3K isoforms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27155741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Pictilisib (GDC-0941) is an oral class I phosphatidylinositol-3-phosphate kinase inhibitor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27565810", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754926", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370471", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 563, 
          "text": "PURPOSE: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).PATIENTS AND METHODS: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "The PI3K inhibitor pictilisib plus anastrozole suppresses luminal B breast cancer proliferation. <CopyrightInformation>\u00a92016 American Association for Cancer Research.</C", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 665, 
          "text": "Understanding the temporal response and pharmacodynamic effects of PI3K inhibition in ER(+) breast cancer will provide a rationale for treatment scheduling to maximize therapeutic index.Antiestrogen-sensitive and antiestrogen-resistant ER(+) human breast cancer cell lines and mice bearing PIK3CA-mutant xenografts were treated with the antiestrogen fulvestrant, the PI3K inhibitor GDC-0941 (pictilisib; varied doses/schedules that provided similar amounts of drug each week), or combinations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 352, 
          "offsetInEndSection": 926, 
          "text": "The objectives of these studies were to visualize and compare by matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry the brain and tumor distribution of the phosphatidylinositol 3-kinase (PI3K) inhibitors pictilisib (GDC-0941, 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine) and GNE-317 [5-(6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine] in U87 and GS2 orthotopic models of GBM, models that exhibit differing blood-brain barrier characteristics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754926", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 707, 
          "offsetInEndSection": 918, 
          "text": "Treating Mx1-Cre, Kras(D12) mice with GDC-0941 (also referred to as pictilisib), an orally bioavailable inhibitor of class I PI3K isoforms, reduced leukocytosis, anemia and splenomegaly while extending survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26965285", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1383, 
          "offsetInEndSection": 1874, 
          "text": "These strategies include first-line therapy with high-dose fulvestrant or everolimus (in combination with exemestane or letrozole or with other endocrine therapies), use of the PI3K inhibitors (e.g., buparlisib, alpelisib, pictilisib, taselisib), entinostat, CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib), and novel selective estrogen receptor degradation agents that may enhance the targeting of acquired mutations in the ESR1 gene. <CopyrightInformation>Copyright \u00a9 2015.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830312", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 195, 
          "text": "Pictilisib is an oral inhibitor of multiple PI3K isoforms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27155741", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are sirtuins?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26463981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26796034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26961318"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Seven sirtuins have been identified in humans, and their functions currently surpass their originally identified role as histone deacetylase and chromatin silencers to encompass nutrient sensing and metabolic function. All seven sirtuins require NAD(+) in order to carry out their enzymatic activity, and thus become activated in conditions of nutrient depletion, starvation, and cellular stress."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58e2651c6fddd3e83e000013", 
      "snippets": [
        {
          "offsetInBeginSection": 179, 
          "offsetInEndSection": 577, 
          "text": " seven sirtuins have been identified in humans, and their functions currently surpass their originally identified role as histone deacetylase and chromatin silencers to encompass nutrient sensing and metabolic function. All seven sirtuins require NAD(+) in order to carry out their enzymatic activity, and thus become activated in conditions of nutrient depletion, starvation, and cellular stress. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463981", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Sirtuins are NAD-dependent lysine deacylases that play critical roles in cellular regulation and are implicated in human diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26796034", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 92, 
          "offsetInEndSection": 160, 
          "text": "Sirtuins are NAD+ -dependent class III histone deacetylases (HDACs) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26961318", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which miRNA is targeted by SRY/Sox9?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25580223", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23389731", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23446346"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon", 
        "recently, the sex determining region y ( sry) and the cerebellar degeneration-related protein 1 ( cdr1as) rna transcripts have been described to function as a new class of post-transcriptional regulatory rnas that behave as circular endogenous rna sponges for the micro rnas (mirnas) mir-138 and mir-7, respectively.", 
        "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively.", 
        "Does the linear Sry transcript function as a ceRNA for miR-138?. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1 (HIF-1), and overexpression of SOX4 and HIF-1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138. Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. ", 
        ", the sex determining region y ( sry) and the cerebellar degeneration-related protein 1 ( cdr1as) rna transcripts have been described to function as a new class of post-transcriptional regulatory rnas that behave as circular endogenous rna sponges for the micro rnas (mirnas) mir-138 and mir-7 , respectively . ", 
        "Does the linear Sry transcript function as a ceRNA for miR-138?. Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1 (HIF-1), and overexpression of SOX4 and HIF-1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. ", 
        "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. Metastasis is the major factor affecting patient survival in ovarian cancer. MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs.", 
        "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. Epidermal growth factor receptor acted as the downstream molecule of SOX4 by way of direct transcriptional control, whereas Slug was the downstream molecule of HIF-1\u00ce\u00b1 by way of proteasome-mediated degradation.", 
        "Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u00ce\u00b1 (HIF-1\u00ce\u00b1), and overexpression of SOX4 and HIF-1\u00ce\u00b1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon.", 
        "Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. ", 
        "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively.  it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", 
        "Does the linear Sry transcript function as a ceRNA for miR-138? Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively."
      ], 
      "exact_answer": [
        [
          "mir-138"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58de18e48acda3452900002a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "Does the linear Sry transcript function as a ceRNA for miR-138?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580223", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 317, 
          "text": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580223", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 682, 
          "offsetInEndSection": 834, 
          "text": " it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580223", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 497, 
          "offsetInEndSection": 742, 
          "text": "Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389731", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1105, 
          "offsetInEndSection": 1308, 
          "text": "We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which technique led to the elucidation of the role of HOXD10 in regulating lymphatic endothelial responses to VEGF-C?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27199372"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1415684", 
          "o": "HOXD10"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5032383335380014", 
          "o": "HOXD10"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5032383335380014", 
          "o": "HOXD10"
        }
      ], 
      "ideal_answer": [
        "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C.", 
        "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C", 
        "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C. "
      ], 
      "exact_answer": [
        [
          "DeepCAGE"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042582", 
        "http://amigo.geneontology.org/amigo/term/GO:0036328", 
        "http://www.uniprot.org/uniprot/VEGFC_HUMAN", 
        "http://www.uniprot.org/uniprot/VEGFC_MOUSE", 
        "http://www.uniprot.org/uniprot/VEGFC_RAT", 
        "http://www.uniprot.org/uniprot/HXD10_LAGLA", 
        "http://www.uniprot.org/uniprot/HXD10_PANTR", 
        "http://www.uniprot.org/uniprot/HXD10_SAGLB", 
        "http://www.uniprot.org/uniprot/HXD10_CHICK", 
        "http://www.uniprot.org/uniprot/HXD10_HETFR", 
        "http://www.uniprot.org/uniprot/HXD10_HUMAN", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004729", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042442", 
        "http://www.biosemantics.org/jochem#4263666", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040262"
      ], 
      "type": "factoid", 
      "id": "5881f627713cbdfd3d000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27199372", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27199372", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27199372", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is Obeticholic Acid used for treatment of Primary Biliary Cholangitis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27825634", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27406083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27589928", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27621676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27700211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27532829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27906472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27468093", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26312413"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C2825352", 
          "o": "Obeticholic Acid"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C2825352", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17691068"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A17691068", 
          "o": "OBETICHOLIC ACID"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0087111", 
          "o": "http://linkedlifedata.com/resource/umls/label/A10762572"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A10762572", 
          "o": "Treatment"
        }
      ], 
      "ideal_answer": [
        "Yes, obeticholic acid is a farnesoid-X receptor agonist that is approved for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:0060643", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019468"
      ], 
      "type": "yesno", 
      "id": "5884722ee56acf5176000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 48, 
          "text": "Obeticholic acid in primary biliary cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 330, 
          "text": "In a double-blind, randomized, placebo-controlled study including 217 patients with primary biliary cholangitis, the authors show that obeticholic acid (a potent farnesoid X agonist) administered with ursodeoxycholic acid or as monotherapy significantly decreases serum alkaline phosphatase and bilirubin when compared to placebo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 453, 
          "text": "Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 238, 
          "offsetInEndSection": 400, 
          "text": "Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has recently been licenced by the FDA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27589928", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1142, 
          "offsetInEndSection": 1363, 
          "text": "OCA will be the first stratified therapy introduced in PBC, however confirmatory trial and real life data are needed to confirm that suggestive biochemical improvements are matched by improvement in key clinical outcomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27589928", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621676", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 972, 
          "offsetInEndSection": 1466, 
          "text": "A series of clinical trials of OCA in PBC, primarily in combination with UDCA, have established that OCA leads to significant reductions in serum alkaline phosphatase that are predicted to lead to improved clinical outcomes, while dose-dependent pruritus has been the most common adverse effect. On the basis of these studies, OCA was given conditional approval by the US Food and Drug Administration with plans to establish the long-term clinical efficacy of OCA in patients with advanced PBC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621676", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1246, 
          "offsetInEndSection": 1394, 
          "text": "Although obeticholic acid was approved by the FDA for the treatment of PBC in May 2016, this development occurred after the symposium presentation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27700211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2330, 
          "offsetInEndSection": 2511, 
          "text": "While several agents are being studied in combination with UDCA, monotherapy with the novel agent obeticholic acid, a farnesoid X receptor agonist, has also shown promising results.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27700211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 452, 
          "text": "Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Obeticholic acid for the treatment of primary biliary cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906472", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532829", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 513, 
          "offsetInEndSection": 654, 
          "text": "This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Obeticholic acid for the treatment of primary biliary cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906472", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 49, 
          "text": "Obeticholic acid in primary biliary cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532829", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 515, 
          "offsetInEndSection": 656, 
          "text": "This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What alternate indication has Vanoxerine been repositioned for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26616666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19817928", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27108936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25684233"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0164200", 
          "o": "vanoxerine"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0164200", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17685361"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A17685361", 
          "o": "VANOXERINE"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0164200", 
          "o": "vanoxerine"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0164200", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0294723"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0294723", 
          "o": "vanoxerine"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0556030", 
          "o": "repositioning"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0556030", 
          "o": "repositioning"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0556030", 
          "o": "http://linkedlifedata.com/resource/umls/label/A15558315"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A15558315", 
          "o": "Repositioned"
        }
      ], 
      "ideal_answer": [
        "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction and can potential treat atrial fibrillation", 
        "vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
        "Vanoxerine 's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
        "vanoxerine's were strongly frequency-dependent and repositioned it for treatment of atrial fibrillation and flutter. . has been in clinical trials for parkinsonism , depression and cocaine addiction but lacked efficacy. . ", 
        "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. ", 
        "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
        "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy."
      ], 
      "exact_answer": [
        [
          "atrial fibrillation and flutter"
        ]
      ], 
      "concepts": [
        "http://www.biosemantics.org/jochem#4151584", 
        "http://www.biosemantics.org/jochem#4001200", 
        "http://www.biosemantics.org/jochem#4258722", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4151584", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4001200", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4258722", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056687", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001145"
      ], 
      "type": "factoid", 
      "id": "58c9a8fe02b8c6095300002a", 
      "snippets": [
        {
          "offsetInBeginSection": 272, 
          "offsetInEndSection": 399, 
          "text": "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 55, 
          "text": "Vanoxerine: cellular mechanism of a new antiarrhythmic.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817928", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 231, 
          "offsetInEndSection": 294, 
          "text": "Therefore, we proposed that vanoxerine might be antiarrhythmic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "Vanoxerine is a promising, new, investigational antiarrhythmic drug.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 396, 
          "text": "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 245, 
          "offsetInEndSection": 308, 
          "text": "Therefore, we proposed that vanoxerine might be antiarrhythmic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1592, 
          "offsetInEndSection": 1674, 
          "text": "Vanoxerine has characteristics of a potentially effective and safe antiarrhythmic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817928", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "BACKGROUND: Vanoxerine is a promising, new, investigational antiarrhythmic drug.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Vanoxerine, a new drug for terminating atrial fibrillation and flutter.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 164, 
          "text": "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108936", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1420, 
          "offsetInEndSection": 1535, 
          "text": "Oral vanoxerine converted AF/AFL to SR at a high rate, was well tolerated, and caused no ventricular proarrhythmia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684233", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the applicability of the No Promoter Left Behind method?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26530723"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing promoter architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", 
        "Promoters have diverse regulatory architectures and thus activate genes differently. No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements."
      ], 
      "exact_answer": [
        [
          "Learning de novo promoter architectures from genome-wide transcription start sites."
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011401", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018507", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005786"
      ], 
      "type": "factoid", 
      "id": "588f341594c1512c50000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "No Promoter Left Behind (NPLB): learn de novo promoter architectures from genome-wide transcription start sites.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 472, 
          "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 234, 
          "offsetInEndSection": 457, 
          "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 459, 
          "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "No Promoter Left Behind (NPLB): learn de novo promoter architectures from genome-wide transcription start sites", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "No Promoter Left Behind (NPLB): learn de novo promoter architectures from genome-wide transcription start sites.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 460, 
          "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which mutated genes are associated with isolated ectopia lentis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26653794", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25900864", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25975359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22736615", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22539873", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19200529", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24406422", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18079676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16765689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22950452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20702823", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22871183", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21051722", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21989719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25654236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20141359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22219643", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19390640", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17679947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23426735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20082464"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1705285", 
          "o": "http://linkedlifedata.com/resource/umls/label/A19043125"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A19043125", 
          "o": "Mutated"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1851286", 
          "o": "Ectopia lentis isolated"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1851286", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18467573"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1705285", 
          "o": "mutation"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1705285", 
          "o": "mutation"
        }
      ], 
      "ideal_answer": [
        "Isolated ectopia lentis (EL) is caused by mutation in genes:\n1) ADAMTSL4 and \n2) Fibrillin-1 (FBN1)."
      ], 
      "exact_answer": [
        [
          "ADAMTSL4"
        ], 
        [
          "Fibrillin-1", 
          "FBN1"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004479"
      ], 
      "type": "list", 
      "id": "58d8d8108acda34529000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "A founder mutation in ADAMTSL4 causes early-onset bilateral ectopia lentis among Jews of Bukharian origin.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653794", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 421, 
          "text": "The term isolated ectopia lentis (EL; subluxation or dislocation of the human crystalline lens) is applied to patients with EL, without skeletal features and in the absence of aortic root dilatation. To date, the only gene shown to cause autosomal-recessive isolated EL is ADAMTSL4. Here we report a novel founder mutation in ADAMTSL4 gene in children of Bukharian Jewish origin presenting with early-onset bilateral EL. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653794", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Early onset ectopia lentis due to a FBN1 mutation with non-penetrance.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Isolated ectopia lentis is usually autosomal dominant and commonly due to the mutations of FBN1 gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 635, 
          "offsetInEndSection": 810, 
          "text": "In conclusion, we report on a case of early-onset autosomal dominant isolated ectopia lentis caused by FBN1 mutation that has previously been reported only in Marfan syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "ADAMTSL4-associated isolated ectopia lentis: Further patients, novel mutations and a detailed phenotype description.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975359", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "ADAMTSL4 mutations seem to be the most common cause of isolated ectoplia lentis (EL) and thus are important concerning the differential diagnosis of connective tissue syndromes with EL as main feature. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "A genotype-phenotype comparison of ADAMTSL4 and FBN1 in isolated ectopia lentis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 168, 
          "text": "To describe the genotype-phenotype relationship of a cohort of consecutive patients with isolated ectopia lentis (EL) secondary to ADAMTSL4 and FBN1 mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1389, 
          "offsetInEndSection": 1769, 
          "text": "ADAMTSL4 is the most important known causative gene in isolated EL. Mutations in ADAMTSL4 appear to cause earlier manifestation of EL and are associated with increased axial length as compared to FBN1. We suggest that ADAMTSL4 be screened in all patients with isolated EL and that physicians be vigilant for the more severe ocular phenotype associated with mutations in this gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "A novel FBN1 mutation in a Chinese family with isolated ectopia lentis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539873", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 101, 
          "text": "To identify the genetic defect in an autosomal dominant isolated ectopia lentis (EL) family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 974, 
          "offsetInEndSection": 1144, 
          "text": "A novel mutation of FBN1 results in an arginine to cysteine residue (p.R974C) substitution, which is responsible for the patients with isolated EL in this Chinese family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "A homozygous mutation in ADAMTSL4 causes autosomal-recessive isolated ectopia lentis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200529", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Isolated ectopia lentis is usually autosomal dominant and commonly due to the mutations of FBN1 gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "To examine the fibrillin-1 (FBN1) gene for mutations in members of a Chinese family with isolated ectopia lentis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Ophthalmic findings in a family with early-onset isolated ectopia lentis and the p.Arg62Cys mutation of the fibrillin-1 gene (FBN1).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Craniosynostosis with ectopia lentis and a homozygous 20-base deletion in ADAMTSL4.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22871183", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "ADAMTSL4-associated isolated ectopia lentis: Further patients, novel mutations and a detailed phenotype description", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975359", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1200, 
          "offsetInEndSection": 1509, 
          "text": "Our study presented detailed clinical manifestations, including some novel ophthalmic findings, such as pupillary abnormality, different types of glaucoma, and progressive hyperopia.Ophthalmic findings and the p.Arg62Cys mutation of FBN1 gene were reported in a family with early-onset isolated ectopia lentis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 204, 
          "text": "To examine the fibrillin-1 (FBN1) gene for mutations in members of a Chinese family with isolated ectopia lentis.Clinically relevant laboratory investigation.Family members underwent clinical examinations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Ophthalmic findings in a family with early-onset isolated ectopia lentis and the p.Arg62Cys mutation of the fibrillin-1 gene (FBN1)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 335, 
          "offsetInEndSection": 920, 
          "text": "The 65 exons of FBN1 were amplified by polymerase chain reaction and screened for mutations by a combination of denaturing high-performance liquid chromatography analysis and direct DNA sequencing.A mutation, c.184C-->T in exon 2 of FBN1, which results in substitution of arginine by cysteine at position 62 of the fibrillin-1 protein (p.R62C) in all affected family members but in none of the unaffected individuals.A recurrent mutation of FBN1 gene resulted in an arginine-to-cysteine residue (p.R62C), is responsible for the patients with isolated ectopia lentis in a Chinese family", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Isolated ectopia lentis is usually autosomal dominant and commonly due to the mutations of FBN1 gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 672, 
          "offsetInEndSection": 846, 
          "text": "CONCLUSIONS: The results emphasize the association of ADAMTSL4 null mutations with isolated ectopia lentis and the presence of a founder mutation in the European population. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051722", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 740, 
          "offsetInEndSection": 1052, 
          "text": "Herein we show a consanguineous family that carries a novel homozygous splice mutation IVS4-1G>A/IVS4-1G>A in ADAMTSL4 responsible for isolated autosomal recessive EL, thus confirming the involvement of this gene in this condition and underlining the major role of ADAMTS proteases in zonular fibers homeostasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Two novel FBN1 mutations associated with ectopia lentis and marfanoid habitus in two Chinese families.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19390640", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Novel FBN1 mutations associated with predominant ectopia lentis and marfanoid habitus in Chinese patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17679947", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 402, 
          "text": "FBN1 mutations are associated with multiple clinical phenotypes, including Marfan syndrome (MFS), MASS phenotype, and familial ectopia lentis, but rarely with isolated aortic aneurysm and dissection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20082464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 387, 
          "text": "This was correlated with Sanger sequencing of ADAMTSL4 and FBN1 genes.Seventeen patients were examined, including one with ectopia lentis et pupillae.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 619, 
          "offsetInEndSection": 739, 
          "text": "Recently, ADAMTSL4 has been shown to be responsible for isolated autosomal recessive ectopia lentis in an inbred family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Confirmation of ADAMTSL4 mutations for autosomal recessive isolated bilateral ectopia lentis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141359", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "A recurrent FBN1 mutation in an autosomal dominant ectopia lentis family of Indian origin.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18079676", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1558, 
          "offsetInEndSection": 1737, 
          "text": "We suggest that ADAMTSL4 be screened in all patients with isolated EL and that physicians be vigilant for the more severe ocular phenotype associated with mutations in this gene..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "A homozygous mutation in ADAMTSL4 causes autosomal-recessive isolated ectopia lentis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200529", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "Recurrent FBN1 mutation (R62C) in a Chinese family with isolated ectopia lentis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "A genotype-phenotype comparison of ADAMTSL4 and FBN1 in isolated ectopia lentis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1385, 
          "offsetInEndSection": 1514, 
          "text": "Ophthalmic findings and the p.Arg62Cys mutation of FBN1 gene were reported in a family with early-onset isolated ectopia lentis..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Ophthalmic findings in a family with early-onset isolated ectopia lentis and the p.Arg62Cys mutation of the fibrillin-1 gene (FBN1).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 756, 
          "offsetInEndSection": 926, 
          "text": "A recurrent mutation of FBN1 gene resulted in an arginine-to-cysteine residue (p.R62C), is responsible for the patients with isolated ectopia lentis in a Chinese family..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does the word ovine refers to goats?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25755186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23903827", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11578130"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Ovine refers to sheep."
      ], 
      "exact_answer": "no", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D034561", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012756"
      ], 
      "type": "yesno", 
      "id": "58e186fd6fddd3e83e00000f", 
      "snippets": [
        {
          "offsetInBeginSection": 147, 
          "offsetInEndSection": 320, 
          "text": "Jaagsiekte sheep retrovirus (JSRV) is the causative agent of ovine pulmonary adenocarcinoma (OPA), a transmissible lung cancer of sheep that has rarely been found in goats. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 304, 
          "text": "In sheep, a bronchiolo-alveolar carcinoma, known as ovine pulmonary carcinoma (OPC), is caused by jaagsiekte sheep retrovirus (JSRV), an exogenous type D retrovirus. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11578130", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does GATA-1 regulate ribosomal protein genes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24453067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19587786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10224082"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins.", 
        "mutations in exon 2 interfere with the synthesis of the full-length isoform of gata-1 and lead to the production of a shortened isoform, gata-1s.", 
        "yes", 
        "in exon 2 interfere with the synthesis of the full-length isoform of gata-1 and lead to the production of a shortened isoform , gata-1s these mutations have been found in patients with diamond-blackfan anemia (dba) , a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. . of the corresponding transcription factors are of particular interest , as they are housekeeping genes or show a direct link to hematopoiesis , tumorigenesis or leukemia (e.g gata-1/2 , pu.1 , mzf-1). . ", 
        "These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1). ", 
        "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1). ", 
        "These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. The Ribosomal protein S19 gene locus (RPS19) has been linked to two kinds of red cell aplasia, Diamond-Blackfan Anemia (DBA) and Transient Erythroblastopenia in Childhood (TEC).", 
        "These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g.", 
        "Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1). Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58e782fd3e8b6dc87c000006", 
      "snippets": [
        {
          "offsetInBeginSection": 127, 
          "offsetInEndSection": 451, 
          "text": "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1248, 
          "offsetInEndSection": 1453, 
          "text": "Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587786", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 885, 
          "offsetInEndSection": 1028, 
          "text": "Deletion of PKC1 relieves the repression of both ribosomal protein and rRNA genes that occurs in response to a defect in the secretory pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10224082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1197, 
          "offsetInEndSection": 1360, 
          "text": "This stress is monitored by Pkc1p, which initiates a signal transduction pathway that leads to repression of transcription of the rRNA and ribosomal protein genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10224082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1361, 
          "offsetInEndSection": 1578, 
          "text": "The importance of the transcription of the 137 ribosomal protein genes to the economy of the cell is apparent from the existence of at least three distinct pathways that can effect the repression of this set of genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10224082", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene mutations cause the Marfan syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25812041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26503076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27906200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24668922", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19159394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9649943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10633129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8882780", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21034599", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24078565", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19328768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21211293", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21883168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12413333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11251996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8008028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23684891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8180508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18377530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23653584", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11175294", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19839986", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16799921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18435798", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8941093", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10756346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15861007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11826022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9401003", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10189088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7870075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23121584", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10721679", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18412115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1569206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20538085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22221020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17701892", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12402346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19353630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19161152", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10694921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10766875", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1406753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10441700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15287423", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18388785", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12651868", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8841521", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8405806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12511552", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3354620", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23552953", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21909107", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7611299"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0596611", 
          "o": "Gene Mutation"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0596611", 
          "o": "Gene Mutation"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0596611", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7647895"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7647895", 
          "o": "Gene Mutation"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0596611", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7850263"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7850263", 
          "o": "Gene Mutation"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0024796", 
          "o": "Marfan Syndrome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0024796", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0431931"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0596611", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18566680"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18566680", 
          "o": "gene mutations"
        }
      ], 
      "ideal_answer": [
        "Marfan syndrome (MFS) is an autosomal dominant disorder caused by mutations in the fibrillin 1 gene (FBN1)."
      ], 
      "exact_answer": [
        [
          "fibrillin 1 gene", 
          "FBN1"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008382", 
        "http://www.disease-ontology.org/api/metadata/DOID:14323", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796"
      ], 
      "type": "factoid", 
      "id": "58d8e6818acda3452900000a", 
      "snippets": [
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 126, 
          "text": "The diagnostic criteria of Marfan syndrome (MFS) highlight the importance of a FBN1 mutation test in diagnosing MFS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25812041", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "A marked decrease in heart rate variability in Marfan syndrome patients with confirmed FBN1 mutations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 199, 
          "text": "The studies on heart rate variability (HRV), a key predictor of all-cause mortality, in Marfan syndrome (MS), up to now have not been reported, especially in patients with FBN1 mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 208, 
          "offsetInEndSection": 315, 
          "text": "Among 18 MS patients with the phenotype of MS meeting inclusion criteria 15 have had a FBN1 gene mutation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 513, 
          "offsetInEndSection": 637, 
          "text": "Heart rates in MS patients with the FBN1 mutation were increased in both the supine position and orthostatic test (p<0.001).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 847, 
          "offsetInEndSection": 985, 
          "text": "A marked decrease in HRV, documented in the study, may be an important clinical feature in MS patients with confirmed FBN1 gene mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Evaluating the quality of Marfan genotype-phenotype correlations in existing FBN1 databases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906200", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 102, 
          "text": "Genetic FBN1 testing is pivotal for confirming the clinical diagnosis of Marfan syndrome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Novel FBN1 gene mutation and maternal germinal mosaicism as the cause of neonatal form of Marfan syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24668922", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Marfan syndrome (MFS) is an autosomal dominant disorder caused by mutations in the fibrillin 1 gene (FBN1). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24668922", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 227, 
          "offsetInEndSection": 491, 
          "text": "While mutations causing classic manifestations of Marfan syndrome have been identified throughout the FBN1 gene, the six previously characterized mutations resulting in the severe, perinatal lethal form of Marfan syndrome have clustered in exons 24-32 of the gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "[Screening of FBN1 gene mutations in a family with Marfan syndrome].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211293", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "To identify FBN1 gene mutations in a Chinese family with Marfan syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211293", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Identification of fibrillin-1 gene mutations in Marfan syndrome by high-resolution melting analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19328768", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 51, 
          "offsetInEndSection": 458, 
          "text": "Three diagnostic classifications comprising first, Marfan genotype with a causative FBN1 gene mutation; second, Marfan phenotype with clinical criteria of the original Ghent nosology (Ghent-1); and third, phenotype with clinical criteria of its current revision (Ghent-2) in 300 consecutive persons referred for confirmation or exclusion of Marfan syndrome (150 men, 150 women aged 35 \u00b1 13 years) were used.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21883168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159394", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 85, 
          "offsetInEndSection": 155, 
          "text": "Marfan syndrome type 1 (MFS1) is caused by mutations in the FBN1 gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Fibrillin gene (FBN1) mutations in Japanese patients with Marfan syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721679", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 116, 
          "offsetInEndSection": 222, 
          "text": "Mutations in FBN1, TGFBR1, TGFBR2 are known to cause Marfan syndrome (MIM 154700), a pleiotropic disorder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538085", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175294", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1088, 
          "offsetInEndSection": 1345, 
          "text": "We conclude that fibrillin gene defects cause familial Marfan syndrome, that mutations in the EGF-like motif of the fibrillin gene are not uniformly associated with severe disease, and that fibrillin genotype is not the sole determinant of Marfan phenotype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1569206", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Mutations of the fibrillin gene (FBN1) are known to cause classical Marfan's syndrome, ectopia lentis and neonatal Marfan's syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7870075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 50, 
          "text": "Severe Marfan syndrome due to FBN1 exon deletions.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18412115", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "BACKGROUND: Mutations in the FBN1 gene are the cause of the Marfan syndrome, an autosomal dominant disorder with skeletal, ocular, and cardiovascular complications.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8941093", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 454, 
          "offsetInEndSection": 696, 
          "text": "It is still difficult to use modern genetic testing for diagnosis because Marfan syndrome can be caused by many different mutations in FBN1, a large gene with 65 coding segments, while mutations in other genes can cause overlapping phenotypes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121584", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 292, 
          "text": "The studies on heart rate variability (HRV), a key predictor of all-cause mortality, in Marfan syndrome (MS), up to now have not been reported, especially in patients with FBN1 mutations.Among 18 MS patients with the phenotype of MS meeting inclusion criteria 15 have had a FBN1 gene mutation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Mutations in the gene encoding fibrillin-1 (FBN1), a component of the extracellular microfibril, cause Marfan syndrome (MFS)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22221020", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Mutations in the fibrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of overlapping phenotypes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17701892", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Mutations in the gene encoding fibrillin-1 (FBN1) cause Marfan syndrome (MFS) and other related connective tissue disorders", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Mutations in the FBN1 gene cause Marfan syndrome (MFS) and have been associated with a wide range of milder overlapping phenotypes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19353630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "The aim of this study was to establish a national database of mutations in the fibrillin-1 (FBN1) gene that cause Marfan syndrome (MFS) in the Taiwanese population", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19839986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Fibrillin-1 gene (FBN1) mutations cause Marfan syndrome (MFS), an inherited connective tissue disorder with autosomal dominant transmission", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18435798", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "Mutations in the gene encoding fibrillin 1 (FBN1) cause Marfan syndrome (MFS), and related connective tissue disorders", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19161152", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "Neonatal Marfan syndrome caused by an exon 25 mutation of the fibrillin-1 gene.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15287423", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Functional pulmonary atresia in a patient with neonatal Marfan syndrome caused by a c.3602G>A mutation in exon 29 of the FBN1 gene.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388785", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "Mutations in the gene for fibrillin-1 (FBN1) cause Marfan syndrome, an autosomal dominant disorder of connective tissue with prominent manifestations in the skeletal, ocular, and cardiovascular system. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175294", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "It has been firmly established that mutations in the gene for fibrillin 1, FBN1, cause Marfan syndrome (MFS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11826022", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 118, 
          "offsetInEndSection": 282, 
          "text": "Mutations in the fibrillin-1 gene (FBN1) cause Marfan syndrome and related connective tissue disorders (fibrillinopathies) that show autosomal dominant inheritance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12651868", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 394, 
          "offsetInEndSection": 623, 
          "text": "It is known that mutations in the fibrillin gene cause a heterogenous connective tissue disease called Marfan syndrome [2], so information on mechanical properties of microfibrils or their role in tissue function would be useful.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8841521", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1727, 
          "offsetInEndSection": 1856, 
          "text": "Mutations in the fibrillin gene located on human chromosome 15 have been strongly implicated as the cause of the Marfan syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8405806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Mutations in the FBN1 gene cause Marfan syndrome (MFS) and have been associated with a wide range of milder overlapping phenotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19353630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 261, 
          "text": "Mutations within the fibrillin-1 gene cause Marfan syndrome (MFS), a heritable disease of connective tissue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12511552", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 878, 
          "offsetInEndSection": 1013, 
          "text": "These data speak against the hypothesis that mutations in one or more of these 3 fibrillar collagens cause the classic Marfan syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3354620", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 777, 
          "offsetInEndSection": 1074, 
          "text": "By WES and filtering with a mining tool, a novel FBN1 missense variant was found in patient 1 and his mother, who both showed clinical features of Marfan syndrome by thorough anthropometric assessment, and a novel EYA1 missense variant as a probable cause of the renal malformation in the patient.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23552953", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Mutations in the fibrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of overlapping phenotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17701892", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 695, 
          "offsetInEndSection": 781, 
          "text": "FBN1 mutations cause Marfan syndrome, whose major cardiovascular complication is TAAD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21909107", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Marfan syndrome is a multisystem disorder of connective tissue that is inherited in an autosomal dominant fashion, and results from mutation of the FBN1 gene on human chromosome 15.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121584", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 201, 
          "text": "Mutations in the gene for fibrillin-1 (FBN1) cause Marfan syndrome, an autosomal dominant disorder of connective tissue with prominent manifestations in the skeletal, ocular, and cardiovascular system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175294", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 537, 
          "offsetInEndSection": 661, 
          "text": "We here report 22 novel and 9 recurrent mutations in the FBN1 gene in 36 patients with clinical features of Marfan syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 125, 
          "offsetInEndSection": 195, 
          "text": "The fibrillin gene is the site of mutations causing Marfan's syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8008028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Fibrillin-1 gene (FBN1) mutations cause Marfan syndrome (MFS), an inherited connective tissue disorder with autosomal dominant transmission.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18435798", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 198, 
          "offsetInEndSection": 344, 
          "text": "FBN1 at 15q21.1 was found to cause Marfan syndrome in 1991, and in 2004 TGFBR2 at 3p24.1 was newly identified as the Marfan syndrome type II gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7611299", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Mutations in the gene encoding fibrillin-1 (FBN1) cause Marfan syndrome (MFS) and other related connective tissue disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 540, 
          "text": "Mutations in the gene coding for fibrillin-1, FBN1, are known to cause Marfan syndrome, and have been identified in almost all exons of FBN1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10189088", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Mutations in the gene encoding fibrillin-1 (FBN1), a component of the extracellular microfibril, cause the Marfan syndrome (MFS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7611299", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "The aim of this study was to establish a national database of mutations in the fibrillin-1 (FBN1) gene that cause Marfan syndrome (MFS) in the Taiwanese population.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19839986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 229, 
          "offsetInEndSection": 493, 
          "text": "While mutations causing classic manifestations of Marfan syndrome have been identified throughout the FBN1 gene, the six previously characterized mutations resulting in the severe, perinatal lethal form of Marfan syndrome have clustered in exons 24-32 of the gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 358, 
          "text": "Mutations in the fibrillin-1 (FBN1) gene, on chromosome 15q21.1, have been found to cause Marfan syndrome, a dominantly inherited disorder characterised by clinically variable skeletal, ocular, and cardiovascular abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401003", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "Mutations in the gene for fibrillin-1 (FBN1) have been shown to cause Marfan syndrome, an autosomal dominant disorder of connective tissue characterised by pleiotropic manifestations involving primarily the ocular, skeletal, and cardiovascular systems.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10633129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 149, 
          "offsetInEndSection": 332, 
          "text": "Through a number of investigational approaches, the gene encoding for fibrillin, the FBN1 gene on chromosome 15, has been identified as the defective gene causing the Marfan syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8180508", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the indication of ARCALYST?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22096352", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19649332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19707454"
      ], 
      "triples": [], 
      "ideal_answer": [
        "In February 2008, Regeneron received Orphan Drug approval from the Food and Drug Administration for rilonacept in the treatment of two cryopyrin-associated periodic syndromes (CAPS) disorders, namely, familial cold-induced autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), for children and adults 12 years and older."
      ], 
      "exact_answer": [
        [
          "cryopyrin-associated periodic syndromes (CAPS) disorders"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58df47f08acda3452900002f", 
      "snippets": [
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 775, 
          "text": "Rilonacept (Arcalyst(TM); Regeneron) is the first us Food and Drug Administration-approved treatment for familial cold autoinflammatory syndrome and Muckle-Wells syndrome and the first in a new line of drugs designed for longer-acting IL-1 blockade.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22096352", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 401, 
          "offsetInEndSection": 735, 
          "text": " In February 2008, Regeneron received Orphan Drug approval from the Food and Drug Administration for rilonacept in the treatment of two cryopyrin-associated periodic syndromes (CAPS) disorders, namely, familial cold-induced autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), for children and adults 12 years and older. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649332", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1271, 
          "offsetInEndSection": 1605, 
          "text": "In February, 2008, 'Orphan Drug' approval from the Food and Drug Administration (FDA) for rilonacept (IL-1 Trap/Arcalyst(), Regeneron Pharmaceuticals, Inc) was given for the treatment of two CAPS disorders, FCAS and MWS in adults and children 12 years and older, making rilonacept the first therapy approved for the treatment of CAPS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19707454", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is ChIPpeakAnno?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20459804"
      ], 
      "triples": [], 
      "ideal_answer": [
        "ChIPpeakAnno is a Bioconductor package within the statistical programming environment R that facilitates batch annotation of enriched peaks identified from ChIP-seq, ChIP-chip, cap analysis of gene expression (CAGE) or any experiments resulting in a large number of enriched genomic regions."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "587d13c0d673c3eb14000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459804", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 706, 
          "offsetInEndSection": 1011, 
          "text": "We have developed ChIPpeakAnno as a Bioconductor package within the statistical programming environment R to facilitate batch annotation of enriched peaks identified from ChIP-seq, ChIP-chip, cap analysis of gene expression (CAGE) or any experiments resulting in a large number of enriched genomic regions", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459804", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1719, 
          "offsetInEndSection": 2187, 
          "text": "ChIPpeakAnno enables batch annotation of the binding sites identified from ChIP-seq, ChIP-chip, CAGE or any technology that results in a large number of enriched genomic regions within the statistical programming environment R. Allowing users to pass their own annotation data such as a different Chromatin immunoprecipitation (ChIP) preparation and a dataset from literature, or existing annotation packages, such as GenomicFeatures and BSgenome, provides flexibility", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459804", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Signaling of which pathways is inhibited by Dupilumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26440137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27334730", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25645542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25542094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26308331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27637004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26454361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25006719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25482871", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23688323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27223113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24275927", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25214796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26967382", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26457448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27525671"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0037083", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7662356"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7662356", 
          "o": "Signaling"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1710082", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17472893"
        }
      ], 
      "ideal_answer": [
        "Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling. It is used for treatment of atopic or allergic diseases."
      ], 
      "exact_answer": [
        [
          "interleukin-4"
        ], 
        [
          "interleukin-13"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015398", 
        "http://amigo.geneontology.org/amigo/term/GO:0023052"
      ], 
      "type": "list", 
      "id": "5880b2a6c872c95565000004", 
      "snippets": [
        {
          "offsetInBeginSection": 724, 
          "offsetInEndSection": 1170, 
          "text": "This study reviewed all studies about any roles of IL-4 that can directly and indirectly be played in the development of pemphigus and IL-4 inhibition with interferons and dupilumab therapy were introduced as a novel pemphigus treatment for patients who are in relapse phase of the disease. Dupilumab was also introduced as a possible treatment for patients with severe pemphigus. It can directly inhibit IL-4 by targeting IL-4 \u03b1-chain receptor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 149, 
          "offsetInEndSection": 276, 
          "text": "OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "BACKGROUND: Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 936, 
          "offsetInEndSection": 1158, 
          "text": "Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1051, 
          "offsetInEndSection": 1337, 
          "text": "Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor \u03b1-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 249, 
          "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 450, 
          "offsetInEndSection": 614, 
          "text": "The world's first prospective controlled studies with the biologic human anti-IL4R antibody dupilumab for the indication \"atopic dermatitis\" were published in 2014.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645542", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 708, 
          "offsetInEndSection": 803, 
          "text": "An IL-4R antagonist, dupilumab, is the first drug that shows great promise in phase II trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542094", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 625, 
          "offsetInEndSection": 818, 
          "text": "Dupilumab, a humanized monoclonal antibody to the interteukin-4R is the first antibody (i.e. 'biological') with published efficacy shown in controlled prospective studies in atopic dermatitis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308331", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 271, 
          "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 240, 
          "offsetInEndSection": 368, 
          "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 242, 
          "text": "Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26454361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 742, 
          "offsetInEndSection": 974, 
          "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 174, 
          "text": "Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 91, 
          "offsetInEndSection": 271, 
          "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 101, 
          "offsetInEndSection": 684, 
          "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \ufffd, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 91, 
          "offsetInEndSection": 272, 
          "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 242, 
          "offsetInEndSection": 370, 
          "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 746, 
          "offsetInEndSection": 978, 
          "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 101, 
          "offsetInEndSection": 683, 
          "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \u00e1, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does the TOP2B/TOP2A expression ratio affect the response to AML chemotherapy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22627319"
      ], 
      "triples": [], 
      "ideal_answer": [
        "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia", 
        "among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the top2b/top2a ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (hr, 0.24; p=0.002) and overall survival (hr, 0.29; p=0.005).", 
        "yes", 
        "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia. Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype. Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005). ", 
        "Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", 
        "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005). Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", 
        "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58b67fae22d3005309000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1292, 
          "offsetInEndSection": 1496, 
          "text": "Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 763, 
          "offsetInEndSection": 964, 
          "text": "Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 965, 
          "offsetInEndSection": 1279, 
          "text": "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 935, 
          "offsetInEndSection": 1453, 
          "text": "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005).Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1283, 
          "offsetInEndSection": 1499, 
          "text": "CONCLUSION: Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1253, 
          "offsetInEndSection": 1458, 
          "text": "Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 937, 
          "offsetInEndSection": 1252, 
          "text": "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 735, 
          "offsetInEndSection": 936, 
          "text": "Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List the three main structures of the cytoskeleton.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26498781"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Fibrillar polymers-actin filaments, microtubules, and intermediate filaments-are major constituents of the cytoskeleton."
      ], 
      "exact_answer": [
        [
          "actin filaments"
        ], 
        [
          "microtubules"
        ], 
        [
          "intermediate filaments"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58e0035f6fddd3e83e000009", 
      "snippets": [
        {
          "offsetInBeginSection": 177, 
          "offsetInEndSection": 297, 
          "text": "Fibrillar polymers-actin filaments, microtubules, and intermediate filaments-are major constituents of the cytoskeleton,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26498781", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the genus for the common European honey bee?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27705831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27447542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18941909", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21960435", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27518068", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19909977", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26990560", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17897670"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The genus and species of the European honey bee is Apis mellifera."
      ], 
      "exact_answer": [
        [
          "Apis"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58e23ec66fddd3e83e000010", 
      "snippets": [
        {
          "offsetInBeginSection": 52, 
          "offsetInEndSection": 87, 
          "text": "European honey bee (Apis mellifera)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27447542", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 69, 
          "offsetInEndSection": 106, 
          "text": " European honey bees (Apis mellifera)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18941909", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 63, 
          "offsetInEndSection": 99, 
          "text": " European honey bees (Apis mellifera", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17897670", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 56, 
          "offsetInEndSection": 92, 
          "text": " European honey bees, Apis mellifera", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17897670", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the TAZ (G4.5) is located in humans?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25118650", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9345098", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23606313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12032589", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11735032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19261493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23031367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23398819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10407787"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20729485"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20729485", 
          "o": "TAZ gene"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "http://linkedlifedata.com/resource/umls/label/A6916046"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A6916046", 
          "o": "TAZ gene"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0086418", 
          "o": "http://linkedlifedata.com/resource/umls/label/A6958822"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20747487"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20747487", 
          "o": "G4.5"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "TAZ"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1336578", 
          "o": "TAZ"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0086418", 
          "o": "Man"
        }
      ], 
      "ideal_answer": [
        "TAZ gene (G4.5) is located on Xq28 in humans."
      ], 
      "exact_answer": [
        [
          "Xq28"
        ]
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/TAZ_HUMAN", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006801", 
        "http://www.uniprot.org/uniprot/TAZ_MACMU", 
        "http://www.uniprot.org/uniprot/TAZ_SAISC", 
        "http://www.uniprot.org/uniprot/TAZ_PANTR", 
        "http://www.uniprot.org/uniprot/TAZ_ERYPA", 
        "http://www.uniprot.org/uniprot/TAZ_PONPY"
      ], 
      "type": "factoid", 
      "id": "58d906b28acda3452900000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Tafazzin (EC 2.3.1.23) is a Phospholipid Transacylase involved in Cardiolipin remodeling on mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: Xq28) in human.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25118650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 208, 
          "text": "Barth syndrome is an X-linked cardiomyopathy with neutropenia and 3-methylglutaconic aciduria. Recently, mutations in the G4.5 gene, located in Xq28, have been described in four probands with Barth syndrome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9345098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 210, 
          "offsetInEndSection": 294, 
          "text": "The disorder is caused by mutations in the tafazzin (TAZ/G4.5) gene located on Xq28.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1506, 
          "offsetInEndSection": 1702, 
          "text": "Disabling mutations or deletions of the tafazzin (TAZ) gene, located at Xq28, cause the disorder by reducing remodeling of cardiolipin, a principal phospholipid of the inner mitochondrial membrane", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398819", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "The tafazzin gene (TAZ) is located at Xq28 and encodes a protein involved in the transacylation of cardiolipin, an essential mitochondrial phospholipid", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23031367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 294, 
          "text": "The disorder is caused by mutations in the tafazzin (TAZ/G4.5) gene located on Xq28", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 295, 
          "text": "The disorder is caused by mutations in the tafazzin (TAZ/G4.5) gene located on Xq28.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 95, 
          "offsetInEndSection": 207, 
          "text": "Recently, mutations in the G4.5 gene, located in Xq28, have been described in four probands with Barth syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9345098", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What do nerve-associated peripheral glial progenitors give rise to?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24925909"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0027757", 
          "o": "NERVE"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0027757", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20241247"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20241247", 
          "o": "NERVE"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0027740", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0006429"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0006429", 
          "o": "Nerve"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0027740", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0006426"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0006426", 
          "o": "Nerve"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0205100", 
          "o": "Peripheral"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0205100", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20244302"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0027740", 
          "o": "Nerves"
        }
      ], 
      "ideal_answer": [
        "Nerve-associated peripheral glial progenitors give rise to parasympathetic neurons. The parasympathetic system in mice--including trunk ganglia and the cranial ciliary, pterygopalatine, lingual, submandibular, and otic ganglia--arise from glial cells in nerves, not neural crest cells. The parasympathetic fate is induced in nerve-associated Schwann cell precursors at distal peripheral sites.", 
        "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.", 
        "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors. The parasympathetic fate is induced in nerve-associated Schwann cell precursors at distal peripheral sites."
      ], 
      "exact_answer": [
        [
          "Parasympathetic neurons"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009457", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009417", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009474", 
        "http://amigo.geneontology.org/amigo/term/GO:0010001"
      ], 
      "type": "factoid", 
      "id": "5881f9b65bf093691f000001", 
      "snippets": [
        {
          "offsetInBeginSection": 18, 
          "offsetInEndSection": 103, 
          "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 156, 
          "offsetInEndSection": 478, 
          "text": "We show that the parasympathetic system in mice--including trunk ganglia and the cranial ciliary, pterygopalatine, lingual, submandibular, and otic ganglia--arise from glial cells in nerves, not neural crest cells. The parasympathetic fate is induced in nerve-associated Schwann cell precursors at distal peripheral sites.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Neurodevelopment. Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 18, 
          "offsetInEndSection": 102, 
          "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Neurodevelopment. Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "How many topological associated domains are contained in the human Hox cluster?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24843030"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Initially, Hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks. Transcriptional activation is associated with a dynamic bi-modal 3D organization, whereby the genes switch autonomously from an inactive to an active compartment.", 
        "transcriptional activation is associated with a dynamic bi-modal 3d organization, whereby the genes switch autonomously from an inactive to an active compartment.", 
        ", hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks. . activation is associated with a dynamic bi-modal 3d organization , whereby the genes switch autonomously from an inactive to an active compartment. . ", 
        "Initially, Hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks. Transcriptional activation is associated with a dynamic bi-modal 3D organization, whereby the genes switch autonomously from an inactive to an active compartment. "
      ], 
      "exact_answer": [
        [
          "two", 
          "2"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58e793f53e8b6dc87c000008", 
      "snippets": [
        {
          "offsetInBeginSection": 422, 
          "offsetInEndSection": 543, 
          "text": "Initially, Hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24843030", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 544, 
          "offsetInEndSection": 706, 
          "text": "Transcriptional activation is associated with a dynamic bi-modal 3D organization, whereby the genes switch autonomously from an inactive to an active compartment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24843030", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Lennox-Gastaut Syndrome usually diagnosed in older adults?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26945476", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24659735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26166587", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8029151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22576075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20518600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20542434", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9400037"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography.", 
        "lennox-gastaut syndrome (lgs) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 hz) spike wave discharges on electroencephalography.", 
        " children with Lennox-Gastaut syndrome Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography"
      ], 
      "exact_answer": "no", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065768", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050561"
      ], 
      "type": "yesno", 
      "id": "58dbb4f08acda3452900001a", 
      "snippets": [
        {
          "offsetInBeginSection": 583, 
          "offsetInEndSection": 729, 
          "text": "We studied 15 LGS patients (mean age \u00b1 1 standard deviation [SD] = 28.7 \u00b1 10.6 years) and 17 healthy controls (mean age \u00b1 1 SD = 27.6 \u00b1 6.6 years)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26945476", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 91, 
          "offsetInEndSection": 129, 
          "text": " children with Lennox-Gastaut syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24659735", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26166587", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Clinical course and results of therapy were analysed in the group of 92 children, aged between 3 and 9 years, with diagnosed Lennox-Gastaut syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8029151", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 427, 
          "offsetInEndSection": 659, 
          "text": "We report the case of a 27-year-old man with a neurodevelopmental syndrome due to a 15q duplication, with intellectual disability, psychiatric disturbances, and an epileptic phenotype diagnosed as late-onset Lennox-Gastaut syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22576075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 206, 
          "text": "Lennox-Gastaut Syndrome is a severe childhood epilepsy syndrome characterised by the diagnostic triad of a slow spike and wave pattern on electroencephalogram, multiple seizure types and developmental delay", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20542434", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 427, 
          "offsetInEndSection": 660, 
          "text": "We report the case of a 27-year-old man with a neurodevelopmental syndrome due to a 15q duplication, with intellectual disability, psychiatric disturbances, and an epileptic phenotype diagnosed as late-onset Lennox-Gastaut syndrome..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22576075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "The Lennox-Gastaut syndrome, a severe form of epilepsy that usually begins in early childhood, is difficult to treat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9400037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 400, 
          "text": "The Lennox-Gastaut syndrome is an age-specific disorder, characterised by epileptic seizures, a characteristic electroencephalogram (EEG), psychomotor delay and behaviour disorders. It occurs more frequently in males and onset is usually before the age of eight, with a peak between three and five years. Late cases occurring in adolescence and early adulthood have rarely been reported. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19588340", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which treatment methods were compared in the EXCEL Trial?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25583761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26159652", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23995725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22941121", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22075415", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22511269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21547994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27639738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25983143", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21796086"
      ], 
      "triples": [], 
      "ideal_answer": [
        "EXCEL trial compared Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization."
      ], 
      "exact_answer": [
        [
          "Everolimus Eluting Stent"
        ], 
        [
          "Coronary Artery Bypass Surgery"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017428", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002986", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017326"
      ], 
      "type": "list", 
      "id": "5880b583c872c95565000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "AIMS: To prospectively validate the SYNTAX Score II and forecast the outcomes of the randomized Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) Trial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1385, 
          "offsetInEndSection": 1665, 
          "text": "Based on 4-year mortality predictions in EXCEL, clinical characteristics shifted long-term mortality predictions either in favour of PCI (older age, male gender and COPD) or CABG (younger age, lower creatinine clearance, female gender, reduced left ventricular ejection fraction).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 463, 
          "offsetInEndSection": 797, 
          "text": "Given that the completed randomized trials did not include contemporary DESs, the upcoming results of the ongoing trials evaluating the performance of new-generation DES compared with CABG (such as the EXCEL trial), may further help to clarify the current role and future recommendations of PCI for left main coronary artery disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26159652", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 686, 
          "text": "The ongoing EXCEL trial will help elucidate the role of ULMCA PCI in the treatment of left main disease compared with coronary artery bypass graft surgery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995725", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1151, 
          "offsetInEndSection": 1412, 
          "text": "The ongoing Evaluation of XIENCE V Everolimus Eluting Stent System Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is expected to provide a better answer on the optimal treatment strategy for LMCAD patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22941121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 496, 
          "text": "The Evaluation of Xience Prime or Xience V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is a multicenter, ongoing trial conducted in patients with left main disease and SYNTAX score \u2264 32 to establish the presumptive advantage of percutaneous coronary intervention (PCI) versus bypass surgery in patients with less complex coronary artery disease than those enrolled in the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22075415", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 965, 
          "offsetInEndSection": 1095, 
          "text": "The EXCEL trial will address the value of PCI in relation to CABG for the treatment of ULMCA stenosis in more than 2000 patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22511269", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 478, 
          "text": "OBJECTIVES: The aim of this study is to verify the study hypothesis of the EXCEL trial by comparing percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in an EXCEL-like population of patients.BACKGROUND: The upcoming EXCEL trial will test the hypothesis that left main patients with SYNTAX score \u2264 32 experience similar rates of 3-year death, myocardial infarction (MI), or cerebrovascular accidents (CVA) following revascularization by PCI or CABG.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1403, 
          "offsetInEndSection": 1562, 
          "text": "CONCLUSIONS: In an EXCEL-like cohort of patients with left main disease, there seems to be a clinical equipoise between PCI and CABG in terms of death/MI/CVA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "The aim of this study is to verify the study hypothesis of the EXCEL trial by comparing percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in an EXCEL-like population of patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 730, 
          "text": "To prospectively validate the SYNTAX Score II and forecast the outcomes of the randomized Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) Trial.Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization is a prospective, randomized multicenter trial designed to establish the efficacy and safety of percutaneous coronary intervention (PCI) with the everolimus-eluting stent compared with coronary artery bypass graft (CABG) surgery in subjects with unprotected left-main coronary artery (ULMCA) disease and low-intermediate anatomical SYNTAX scores (&lt;33).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 326, 
          "text": "OBJECTIVES: The aim of this study is to verify the study hypothesis of the EXCEL trial by comparing percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in an EXCEL-like population of patients.BACKGROUND: The upcoming EXCEL trial will test the hypothesis that left main patients with SYNTAX score ?", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 679, 
          "offsetInEndSection": 902, 
          "text": "The results of the ongoing EXCEL trial, which compares left main percutaneous coronary intervention with drug-eluting stents and CABG, will provide insight regarding the ideal revascularization strategy for these patients..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21796086", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 463, 
          "offsetInEndSection": 796, 
          "text": "Given that the completed randomized trials did not include contemporary DESs, the upcoming results of the ongoing trials evaluating the performance of new-generation DES compared with CABG (such as the EXCEL trial), may further help to clarify the current role and future recommendations of PCI for left main coronary artery disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26159652", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 363, 
          "offsetInEndSection": 904, 
          "text": "The introduction of the newer-generation drug-eluting stents (DES) -with documented improvements in both safety and efficacy- has prompted the interventional community to design two new dedicated randomised trials comparing CABG and PCI: the NOBLE (Coronary Artery Bypass Grafting Vs Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis) and EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25983143", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 965, 
          "offsetInEndSection": 1094, 
          "text": "The EXCEL trial will address the value of PCI in relation to CABG for the treatment of ULMCA stenosis in more than 2000 patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22511269", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1108, 
          "offsetInEndSection": 1368, 
          "text": "The ongoing Evaluation of XIENCE V Everolimus Eluting Stent System Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is expected to provide a better answer on the optimal treatment strategy for LMCAD patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22941121", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe ATR-16 syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24631100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17598130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9375730", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10631133", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18076105", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8460633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15921166", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10872473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8606626"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0795917", 
          "o": "http://linkedlifedata.com/resource/umls/label/A11992244"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A11992244", 
          "o": "ATR-16 SYNDROME"
        }
      ], 
      "ideal_answer": [
        "ATR-16 syndrome is due to alterations on chromosome 16p13.3, and is usually accompanied by alpha-thalassemia, mild-moderate mental retardation, dysmorphic facial features, skeletal and genitourinary malformations."
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:225", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"
      ], 
      "type": "summary", 
      "id": "588623153b87a8a738000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 213, 
          "text": "ATR-16 syndrome is due to alterations on chromosome 16p13.3, and is usually accompanied by alpha-thalassemia, mild-moderate mental retardation, dysmorphic facial features, skeletal and genitourinary malformations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24631100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "Alpha thalassemia retardation associated with chromosome16 (ATR-16 syndrome) is defined as a contiguous gene syndrome resulting from haploinsufficiency of the alpha-globin gene cluster and genes involved in mental retardation (MR). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17598130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 498, 
          "offsetInEndSection": 652, 
          "text": "This is the fifth reported case of the ATR-16 syndrome (alpha-thalassemia retardation-16) not complicated by duplication or deletion of other chromosomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9375730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "Familial mental retardation syndrome ATR-16 due to an inherited cryptic subtelomeric translocation, t(3;16)(q29;p13.3).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10631133", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the results of inactivated ANGPLT3?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24798233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22062970"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia"
      ], 
      "exact_answer": [
        [
          "Recessive hypolipidemia"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58dfd70c6fddd3e83e000002", 
      "snippets": [
        {
          "offsetInBeginSection": 681, 
          "offsetInEndSection": 895, 
          "text": "Although it appears by now that the main lipid pathways have been uncovered, and that only modulators or adaptor proteins such as those encoded by LDLRAP1, APOA5, ANGPLT3/4, and PCSK9 are currently being discovered", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24798233", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 142, 
          "offsetInEndSection": 355, 
          "text": "Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 364, 
          "offsetInEndSection": 493, 
          "text": " 4 related individuals with primary hypolipidemia were found to be compound heterozygotes for ANGPTL3 loss-of-function mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1703, 
          "offsetInEndSection": 1823, 
          "text": "Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What percentage of rheumatoid arthritis patients are responsive to anti-TNF therapy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24040234", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22044414"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. A substantial proportion of Rheumatoid Arthritis patients (approximately 30-40%) fail to respond to anti-TNF therapies.", 
        "treatment strategies blocking tumor necrosis factor (anti-tnf) have proven very successful in patients with rheumatoid arthritis (ra), showing beneficial effects in approximately 50-60% of the patients.", 
        "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. ", 
        "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. ", 
        "strategies blocking tumor necrosis factor (anti-tnf) have proven very successful in patients with rheumatoid arthritis (ra) , showing beneficial effects in approximately 50-60% of the patients. . this , a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies . ", 
        "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. ", 
        "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. The introduction of anti-TNF therapy has dramatically improved the outlook for patients suffering from a number of inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease.", 
        "The introduction of anti-TNF therapy has dramatically improved the outlook for patients suffering from a number of inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease. Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", 
        "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", 
        "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies.  Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", 
        "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies."
      ], 
      "exact_answer": [
        [
          "50-60%"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58e79e703e8b6dc87c00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 344, 
          "text": "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044414", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040234", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease is treated with semaglutide?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26694823", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27835045", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27817160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27921428", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25475122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27633186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26358288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26308095", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27042424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27863704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26642233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27432074", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22675341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27183953"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0012634", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0049608"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0049608", 
          "o": "Disease"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1022004", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3147522"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3147522", 
          "o": "Disease"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0012634", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18683747"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18683747", 
          "o": "disease"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0012634", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0015569"
        }
      ], 
      "ideal_answer": [
        "Semaglutide is glucagon-like peptide-1 receptor agonist that is being used for the treatment of type 2 diabetes mellitus."
      ], 
      "exact_answer": [
        [
          "Type 2 diabetes mellitus", 
          "TYPE 2 DIABETES"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:4", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019468"
      ], 
      "type": "factoid", 
      "id": "5880c42fc872c95565000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 741, 
          "text": "INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly being used for the treatment of type 2 diabetes mellitus, but consideration of benefits and potential adverse events is required. This review examines the state of glycemic control, weight loss, blood pressure, and tolerability, as well as the current debate about the safety of GLP-1 RAs, including risk of pancreatitis, pancreatic cancer, and thyroid cancer.METHODS: A MEDLINE search (2010-2015) identified publications that discussed longer-acting GLP-1 RAs. Search terms included GLP-1 receptor agonists, liraglutide, exenatide, lixisenatide, semaglutide, dulaglutide, albiglutide, efficacy, safety, pancreatitis, pancreatic cancer, and thyroid cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26694823", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 365, 
          "offsetInEndSection": 872, 
          "text": " Seven trials have been published that have established CV safety for three DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin), three GLP-1 receptor agonists (liraglutide, lixisenatide, and semaglutide), and one sodium-glucose cotransporter-2 inhibitor (empagliflozin). Three of those studies also established superiority with liraglutide, empagliflozin, and semaglutide at reducing the composite primary endpoint of major CV events (CV death, nonfatal myocardial infarction, and nonfatal stroke). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27835045", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 727, 
          "text": "RECENT FINDINGS: In response to guidance issued by the Food and Drug Administration, thousands of patients have been enrolled in large randomized trials evaluating the cardiovascular effects of the three newest diabetes drug classes: glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose cotransporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Two studies of GLP-1 receptor agonists-one of liraglutide and one of semaglutide-have shown cardiovascular benefit relative to placebo, and one study of the SGLT-2 inhibitor empagliflozin has shown benefit.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27817160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "New antidiabetic drugs are being developed today that expand the range of pharmacological intervention, in particular for patients with type 2 diabetes (imeglimin, semaglutide, dulaglutide, FGF 21 analogue).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27921428", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D), on the bioavailability of a combined oral contraceptive was investigated. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25475122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2040, 
          "offsetInEndSection": 2365, 
          "text": "Conclusions In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27633186", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 201, 
          "offsetInEndSection": 526, 
          "text": "Postmenopausal women with T2D (n\u2009=\u200943) on diet/exercise\u2009\u00b1\u2009metformin received ethinylestradiol (0.03\u2009mg)/levonorgestrel (0.15\u2009mg) once daily for 8 days before (semaglutide-free) and during (steady-state 1.0\u2009mg) semaglutide treatment (subcutaneous once weekly; dose escalation: 0.25\u2009mg 4 weeks; 0.5\u2009mg 4 weeks; 1.0\u2009mg 5 weeks).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25475122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27633186", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What condition is usually represented by the acronym SUDEP?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26038597", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26387918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19713869", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25499158", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22191982", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19909334", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22042178", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19130900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25600783", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23962523", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16421121", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12862502", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19232547", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17433051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15824334", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25323494", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23099115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25253292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24236903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15129839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19666211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19623466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24348119", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21737136", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26924854", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27131289"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The acronym SUDEP refers to  Sudden Unexpected Death in Epilepsy", 
        "Sudden Unexpected Death in Epilepsy (SUDEP)", 
        "Sudden Unexpected Death in Epilepsy (SUDEP). sudden unexpected death in epilepsy (SUDEP),. ", 
        " sudden unexpected death in epilepsy (SUDEP), Sudden Unexpected Death in Epilepsy (SUDEP)"
      ], 
      "exact_answer": [
        [
          "Sudden Unexpected Death in Epilepsy (SUDEP)"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58dbb8968acda3452900001b", 
      "snippets": [
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 160, 
          "text": "Sudden Unexpected Death in Epilepsy (SUDEP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26038597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 211, 
          "text": " sudden unexpected death in epilepsy (SUDEP),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26387918", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 186, 
          "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause of death, and most cases usually occur in patients with intractable, longstanding epilepsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232547", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "Sudden unexpected death in epilepsy (SUDEP): what do patients think?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25499158", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "OBJECTIVES: Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality in epilepsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25499158", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 504, 
          "offsetInEndSection": 582, 
          "text": "In 11 patients cause of death was sudden unexpected death in epilepsy (SUDEP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22042178", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 124, 
          "offsetInEndSection": 334, 
          "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign condition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23962523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17433051", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 89, 
          "offsetInEndSection": 296, 
          "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy die suddenly, almost certainly during a seizure and with no other identified cause of death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24236903", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Epilepsy, the commonest serious neurological condition, is associated with an increased risk in premature deaths, including an estimated 500 sudden unexpected deaths (SUDEP) per year in the UK.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15129839", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19623466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to study in humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348119", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask, don't tell?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16421121", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 276, 
          "text": "Many individuals with epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy (SUDEP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19909334", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "The baboon represents a natural model for genetic generalized epilepsy and sudden unexpected death in epilepsy (SUDEP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26924854", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of a seemingly healthy individual with epilepsy, usually occurring during, or immediately after, a tonic-clonic seizure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737136", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 236, 
          "text": "This condition is called sudden unexpected death in epilepsy (SUDEP), and it accounts for a large proportion of deaths among people with epilepsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19713869", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 124, 
          "offsetInEndSection": 335, 
          "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign condition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23962523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 45, 
          "text": "Sudden unexpected death in epilepsy (SUDEP) i", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22191982", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 86, 
          "offsetInEndSection": 130, 
          "text": " sudden unexpected death in epilepsy (SUDEP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19130900", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 25, 
          "offsetInEndSection": 70, 
          "text": "sudden unexpected death in epilepsy (SUDEP) f", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600783", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 44, 
          "text": "udden unexpected death in epilepsy (SUDEP) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12862502", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 40, 
          "offsetInEndSection": 88, 
          "text": "sudden and unexpected death in epilepsy (SUDEP) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17178458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 53, 
          "text": "Sudden unexpected death in epilepsy (SUDEP) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25647769", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 70, 
          "offsetInEndSection": 113, 
          "text": "sudden unexpected death in epilepsy (SUDEP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824334", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 45, 
          "text": "udden unexpected death in epilepsy (SUDEP) i", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25323494", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 53, 
          "text": "Sudden unexplained death in epilepsy (SUDEP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099115", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 44, 
          "text": "udden unexpected death in epilepsy (SUDEP) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139807", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 201, 
          "text": " sudden unexpected death in epilepsy (SUDEP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 105, 
          "text": "udden unexpected death in epilepsy (SUDEP) is the leading cause for death in individuals with epilepsy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131289", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which proteins does the yeast Cleavage and Polyadenylation Complex contain?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25877920", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20226668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19049464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18951092", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23514951"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The proteins Nrd1, Rap1, Trf4, Rrp6, Ssu72, Cstf64, Pcf11 and PAP are the major components of the 3' cleavage and polyadenylation complex."
      ], 
      "exact_answer": [
        [
          "Nrd1"
        ], 
        [
          "Rap1"
        ], 
        [
          "Trf4"
        ], 
        [
          "Rrp6"
        ], 
        [
          "Ssu72"
        ], 
        [
          "PAP"
        ], 
        [
          "Cstf64"
        ], 
        [
          "Pcf11"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58add7699ef3c34033000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "Gene loops have been described in different organisms from yeast to human and form through interaction between components of the transcription pre-initiation complex and Ssu72, a member of the 3' end cleavage and polyadenylation complex", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23514951", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 364, 
          "text": "A large cleavage and polyadenylation complex containing the major poly(A) polymerase Pap1 produces mRNA 3' ends, whereas those of nonpolyadenylated snoRNAs in yeast are formed either by endonucleolytic cleavage or by termination, followed by trimming by the nuclear exosome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951092", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 582, 
          "offsetInEndSection": 814, 
          "text": "Poly(A) tails are added by Pap1 to both forms, whereas the alternative poly(A) polymerase Tfr4 adenylates major precursors and processing intermediates to facilitate further polyadenylation by Pap1 and maturation by the exosome/Rrp6", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951092", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 816, 
          "offsetInEndSection": 911, 
          "text": "A more important role of Trf4/TRAMP, however, is to enhance Nrd1 association with snoRNA genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951092", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 551, 
          "offsetInEndSection": 844, 
          "text": "Screening crude natural product extracts with this technology has resulted in the identification of a novel family of antifungal natural products, named the parnafungins, which inhibit the enzyme polyadenosine polymerase (PAP), a key component of the mRNA cleavage and polyadenylation complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19049464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 717, 
          "offsetInEndSection": 884, 
          "text": "We show that phosphorylation of TFIIB at serine 65 regulates the interaction between TFIIB and the CstF-64 component of the CstF 3' cleavage and polyadenylation comple", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20226668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 167, 
          "offsetInEndSection": 400, 
          "text": "We now show that Pcf11, a component of the cleavage and polyadenylation complex (CPAC), is also generally required for NRD-dependent transcription termination through the action of its C-terminal domain (CTD)-interacting domain (CID)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877920", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 398, 
          "offsetInEndSection": 560, 
          "text": "Like the yeast counterpart, mammalian Ssu72 associates with TFIIB and the yeast cleavage/polyadenylation factor Pta1, and exhibits intrinsic phosphatase activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659578", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 560, 
          "offsetInEndSection": 772, 
          "text": "We also provide evidence that Pti1p probably acts by uncoupling cleavage and polyadenylation, and functions in coordination with the Nrd1p-dependent pathway for 3' end formation of non-polyadenylated transcripts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12773397", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 400, 
          "offsetInEndSection": 562, 
          "text": "Like the yeast counterpart, mammalian Ssu72 associates with TFIIB and the yeast cleavage/polyadenylation factor Pta1, and exhibits intrinsic phosphatase activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659578", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease can be categorized using the Koos grading system?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26967786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27513938", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25811349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24797568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23160632", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27453796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15179293", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26606668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25181431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24987677", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21665381"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0012634", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0049608"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0049608", 
          "o": "Disease"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1022004", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3147522"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3147522", 
          "o": "Disease"
        }
      ], 
      "ideal_answer": [
        "Koos grading system is used for vestibular schwannoma."
      ], 
      "exact_answer": [
        [
          "vestibular schwannoma"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:4", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
      ], 
      "type": "factoid", 
      "id": "5886519c3b87a8a738000007", 
      "snippets": [
        {
          "offsetInBeginSection": 636, 
          "offsetInEndSection": 789, 
          "text": "The patients had Koos Grade I or II tumors and American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Class D hearing status preoperatively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26967786", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 250, 
          "offsetInEndSection": 378, 
          "text": "METHODS: This is a retrospective review of 22 patients with VS Koos grade III and IV who were treated with STR followed by SRS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27513938", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 483, 
          "offsetInEndSection": 585, 
          "text": " VS was characterized by its size (Koos classification) and the presence or not of a cystic component.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811349", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 624, 
          "offsetInEndSection": 788, 
          "text": "MAIN OUTCOME MEASURES: All data recorded were reviewed to access age, sex, tumor type, and tumor size according to the Koos classification and presenting symptoms. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Facial nerve preservation surgery for koos grade 3 and 4 vestibular schwannomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181431", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Safety and Efficacy of Gamma Knife Radiosurgery for the Management of Koos Grade 4 Vestibular Schwannomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26606668", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 368, 
          "offsetInEndSection": 509, 
          "text": "In all 333 patients microsurgical vestibular schwannoma (Koos grade 1: 12, grade 2: 34, grade 3: 62, and grade 4: 225) removal was performed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24987677", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "Facial nerve preservation surgery for koos grade 3 and 4 vestibular schwannomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181431", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 195, 
          "offsetInEndSection": 293, 
          "text": "To report, in a retrospective study, outcomes for large Koos grade 3 and 4 vestibular schwannomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Safety and Efficacy of Gamma Knife Radiosurgery for the Management of Koos Grade 4 Vestibular Schwannomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26606668", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the inheritance of the glucose-6-phosphate dehydrogenase (G6PD) deficiency?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15226563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10066026", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1634454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6350992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/631693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1188317", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10698963", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25116429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12169625", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24865682", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11271380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24460025", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1953691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12737943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11261779", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24943486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26275698"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://purl.uniprot.org/uniprot/P11413", 
          "o": "http://purl.uniprot.org/uniprot/P11413"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017757", 
          "o": "G6PD"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_503131343133004B", 
          "o": "G6PD"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_503131343133004B", 
          "o": "G6PD"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0017757", 
          "o": "http://linkedlifedata.com/resource/umls/label/A8256485"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
          "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", 
          "o": "http://purl.uniprot.org/uniprot/P11413"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", 
          "o": "Glucose-6-phosphate 1-dehydrogenase"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://purl.uniprot.org/uniprot/P11413", 
          "o": "G6PD_HUMAN"
        }
      ], 
      "ideal_answer": [
        "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has a recessive X-linked inheritance."
      ], 
      "exact_answer": [
        [
          "recessive X-linked inheritance"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005955", 
        "http://www.disease-ontology.org/api/metadata/DOID:2862", 
        "http://www.uniprot.org/uniprot/G6PD_CRIGR", 
        "http://www.uniprot.org/uniprot/G6PD_DIDVI", 
        "http://www.uniprot.org/uniprot/G6PD_TAKRU", 
        "http://www.uniprot.org/uniprot/G6PD_MACRO", 
        "http://www.uniprot.org/uniprot/G6PD_BOSIN", 
        "http://www.uniprot.org/uniprot/G6PD_HUMAN", 
        "http://www.uniprot.org/uniprot/G6PD_HELPY", 
        "http://www.uniprot.org/uniprot/G6PD_HELPJ", 
        "http://www.uniprot.org/uniprot/G6PD_HAEIN", 
        "http://www.uniprot.org/uniprot/G6PD_GLUOX", 
        "http://www.uniprot.org/uniprot/G6PD_ENCCU", 
        "http://www.uniprot.org/uniprot/G6PD_EMENI", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005954", 
        "http://www.uniprot.org/uniprot/G6PD_AGGAC", 
        "http://www.uniprot.org/uniprot/G6PD_ZYMMO", 
        "http://www.uniprot.org/uniprot/G6PD_NOSP7", 
        "http://www.uniprot.org/uniprot/G6PD_CYBJA", 
        "http://www.uniprot.org/uniprot/G6PD_BUCAI", 
        "http://www.uniprot.org/uniprot/G6PD_BUCAP", 
        "http://www.uniprot.org/uniprot/G6PD_CERCA", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042843"
      ], 
      "type": "factoid", 
      "id": "58c6635f02b8c60953000023", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226563", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1050, 
          "offsetInEndSection": 1317, 
          "text": " The high manifestation of G6PD deficiency in women may be due to the preferential expression of the G6PD-deficient gene and X-inactivation of the normal gene, and/or to the presence of an 'enhancer' gene that makes the expression of the G6PD deficiency more likely. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10066026", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 461, 
          "offsetInEndSection": 605, 
          "text": "Study of the deficiency pattern amongst family members of the enzyme deficient subjects confirmed the X-linked inheritance of G-6-PD deficiency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1634454", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 639, 
          "text": " The investigation of the patient's whole family showed the typical recessive X-linked inheritance of this enzyme-defect. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6350992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 297, 
          "text": "After having described in detail the pathophysiology, symptomatology, X-chromosomal inheritance and some laboratory methods in detecting G-6-PD-deficiency by demonstrating a case of favism (Schulz et al. 1977), the authors now discuss the particularities of the enzyme deficiency in the newborn. T", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/631693", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 185, 
          "offsetInEndSection": 327, 
          "text": "The genetic pattern is consistent with x-linked recessive inheritance and the defect is associated with drug (primaquine) induced haemolysis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1188317", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "UNLABELLED: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive disorder in which haemolytic anaemia is the major symptom.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11271380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities, and it has a significant prevalence in the male population (X chromosome linked).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865682", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226563", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive genetic defect that can cause hemolytic crisis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by a mutation in the G6PD gene on Xq28.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 161, 
          "offsetInEndSection": 297, 
          "text": "Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive hereditary disease characterised by abnormally low levels of G6PD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943486", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which deep learning-based algorithms are used for enhancer prediction?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27929098", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25378307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27490187", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27329130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26091399"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0086222", 
          "o": "Enhancer"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0086222", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7570315"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7570315", 
          "o": "Enhancer"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0086222", 
          "o": "Enhancer"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0205125", 
          "o": "DEEP"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0205125", 
          "o": "http://linkedlifedata.com/resource/umls/label/A20250446"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A20250446", 
          "o": "DEEP"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0205125", 
          "o": "DEEP"
        }
      ], 
      "ideal_answer": [
        "EP-DNN and DEEP."
      ], 
      "exact_answer": [
        [
          "EP-DNN"
        ], 
        [
          "DEEP"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069550"
      ], 
      "type": "list", 
      "id": "587d30fb31b33e8760000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "EP-DNN: A Deep Neural Network-Based Global Enhancer Prediction Algorithm", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "We present EP-DNN, a protocol for predicting enhancers based on chromatin features, in different cell types", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 64, 
          "text": "DEEP: a general computational framework for predicting enhancers", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378307", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 671, 
          "offsetInEndSection": 1145, 
          "text": " In this study we developed DEEP, a novel ensemble prediction framework. DEEP integrates three components with diverse characteristics that streamline the analysis of enhancer's properties in a great variety of cellular conditions. In our method we train many individual classification models that we combine to classify DNA regions as enhancers or non-enhancers. DEEP uses features derived from histone modification marks or attributes coming from sequence characteristics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378307", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 869, 
          "offsetInEndSection": 1080, 
          "text": " in this paper, we use recent state-of-the-art Deep Learning methods and develop a deep neural network (DNN)-based architecture, called EP-DNN, to predict the presence and types of enhancers in the human genome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2349, 
          "offsetInEndSection": 2583, 
          "text": "In this paper, we developed EP-DNN, which has high accuracy of prediction, with validation rates above 90\u00a0% for the operational region of enhancer prediction for all four cell lines that we studied, outperforming DEEP-ENCODE and RFECS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 307, 
          "text": "We present EP-DNN, a protocol for predicting enhancers based on chromatin features, in different cell types. Specifically, we use a deep neural network (DNN)-based architecture to extract enhancer signatures in a representative human embryonic stem cell type (H1) and a differentiated lung cell type (IMR90)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 570, 
          "offsetInEndSection": 810, 
          "text": "We find that EP-DNN has superior accuracy with a validation rate of 91.6%, relative to 85.3% for DEEP-ENCODE and 85.5% for RFECS, for a given number of enhancer predictions and also scales better for a larger number of enhancer predictions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "PEDLA: predicting enhancers with a deep learning-based algorithmic framework.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329130", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 65, 
          "text": "DEEP: a general computational framework for predicting enhancers.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378307", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "PEDLA: predicting enhancers with a deep learning-based algorithmic framework.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329130", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "EP-DNN: A Deep Neural Network-Based Global Enhancer Prediction Algorithm.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 342, 
          "offsetInEndSection": 616, 
          "text": "We developed a deep learning-based algorithmic framework named PEDLA (https://github.com/wenjiegroup/PEDLA), which can directly learn an enhancer predictor from massively heterogeneous data and generalize in ways that are mostly consistent across various cell types/tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329130", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Beta-Thalassemia is associated with a mutation or deletion of the gene that codes for alpha globin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25230702"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains", 
        "beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains.", 
        "Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of -globin chains. ", 
        "Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains."
      ], 
      "exact_answer": "no", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017086", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055544"
      ], 
      "type": "yesno", 
      "id": "58dbbbf08acda3452900001d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230702", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "The beta-thalassemia syndromes are a heterogeneous group of genetic disorders characterized by reduced or absent expression of the beta-globin gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9056561", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is diphosphatidylglycerol (cardiolipin) a phospholipid of the mitochondrial membranes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24007978", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7459841", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6807345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6717095", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3548756", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3668386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3718705", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7378435", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6257342", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2397096", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6509920", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9370332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1247555", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9843887", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16971584", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1550861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26028302", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7794966", 
        "http://www.ncbi.nlm.nih.gov/pubmed/4322761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21599656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8143741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1213878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24443516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23200781", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26301254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24769127", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25843549", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26396268", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24905496", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20637181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20336283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22634369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25182746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8977117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15460113"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0202177", 
          "o": "Phospholipid"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0007188", 
          "o": "http://linkedlifedata.com/resource/umls/label/A17997459"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A17997459", 
          "o": "Cardiolipins"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/2083", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3130515"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3130515", 
          "o": "Cardiolipins"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0007188", 
          "o": "cardiolipin"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/2083", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3130514"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3130514", 
          "o": "Cardiolipin"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0007188", 
          "o": "cardiolipin"
        }
      ], 
      "ideal_answer": [
        "Yes, diphosphatidylglycerol (cardiolipin) is a phospholipid of the mitochondrial membranes."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.biosemantics.org/jochem#4001026", 
        "http://www.biosemantics.org/jochem#4244279", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051336", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4244279", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002308", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008566", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008928", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008563"
      ], 
      "type": "yesno", 
      "id": "58d90f228acda3452900000f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 341, 
          "text": "A unique organelle for studying membrane biochemistry is the mitochondrion whose functionality depends on a coordinated supply of proteins and lipids. Mitochondria are capable of synthesizing several lipids autonomously such as phosphatidylglycerol, cardiolipin and in part phosphatidylethanolamine, phosphatidic acid and CDP-diacylglycerol.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24007978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 372, 
          "offsetInEndSection": 474, 
          "text": "A small decrease of diphosphatidylglycerol also occurred in the hepatoma mitochondria inner membrane. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7459841", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 492, 
          "offsetInEndSection": 624, 
          "text": "Diphosphatidylglycerol was confined to the mitochondrial fraction, where it represented about 7% of the total phosphoacylglycerols. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6807345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 401, 
          "text": "Mitochondrial membranes were isolated from the myocardium of young (4-month-old) and aged (33-month-old) male Long-Evans rats and compared in terms of cholesterol content and phospholipid and fatty acid composition. In aged rats, as compared to young, the major observations include: markedly higher cholesterol content; increased percentage of sphingomyelin and diphosphatidylglycerol (cardiolipin); ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6717095", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 445, 
          "offsetInEndSection": 632, 
          "text": "The polyglycerophosphatides (typified by diphosphatidylglycerol) were apparently synthesized in situ by intramitochondrial membrane-bound enzymes using CDP-diglycerides as intermediates. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3548756", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 538, 
          "offsetInEndSection": 875, 
          "text": "Both the mitochondrial and microsomal fractions contained significant proportions of solvent front phospholipid (SFP) and whereas the mitochondrial SFP displayed the relatively unsaturated fatty acid composition characteristic of diphosphatidylglycerol (cardiolipin), the fatty acids of the microsomal SFP were distinctly more saturated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6509920", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 456, 
          "offsetInEndSection": 764, 
          "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 295, 
          "text": "The enzyme responsible for the conversion of phosphatidylglycerol to diphosphatidylglycerol (cardiolipin) in the presence of cytidine diphosphate diacylglycerol is firmly associated with mitochondrial membranes and is not extracted with hypotonic or hypertonic media or with nonionic detergents.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6257342", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 347, 
          "text": "The mechanism of cardiolipin (diphosphatidylglycerol) biosynthesis was examined in mitochondria and outer and inner mitochondrial membranes prepared from guinea pig and rat livers to determine whether this formation from phosphatidylglycerol was absolutely dependent on cytidinediphosphodiglyceride, as previously reported for intact mitochondria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 454, 
          "offsetInEndSection": 597, 
          "text": "In isolated mitochondrial outer membranes, cardiolipin (diphosphatidylglycerol) increased CPT1 activity 4-fold and the Km for carnitine 6-fold.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21599656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 457, 
          "offsetInEndSection": 765, 
          "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 499, 
          "offsetInEndSection": 615, 
          "text": "90% or more of the phospholipid, cardiolipin was found in the mitochondrial membranes of wild type and petite yeast.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4322761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 629, 
          "offsetInEndSection": 760, 
          "text": "Furthermore, the same mechanism for the biosynthesis of cardiolipin was operational in the outer and inner mitochondrial membranes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 346, 
          "text": "The mechanism of cardiolipin (diphosphatidylglycerol) biosynthesis was examined in mitochondria and outer and inner mitochondrial membranes prepared from guinea pig and rat livers to determine whether this formation from phosphatidylglycerol was absolutely dependent on cytidinediphosphodiglyceride, as previously reported for intact mitochondria", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 65, 
          "offsetInEndSection": 246, 
          "text": "Cardiolipin (CL) is a key phospholipid in mitochondrial membranes, playing important roles in maintaining the functional integrity and dynamics of mitochondria in animals and yeasts", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24443516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Cardiolipin, the specific phospholipid of mitochondria, is involved in the biogenesis, the dynamics, and the supramolecular organization of mitochondrial membranes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200781", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Cardiolipin (CL), the signature phospholipid of mitochondrial membranes, is crucial for both mitochondrial function and cellular processes outside of the mitochondria", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26301254", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 231, 
          "text": "Since it has been recognized that mitochondria are crucial not only for energy metabolism but also for other cellular functions, there has been a growing interest in cardiolipin, the specific phospholipid of mitochondrial membranes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 72, 
          "offsetInEndSection": 259, 
          "text": "Cardiolipin, the main anionic phospholipid in mitochondrial membranes, is expected to be a determinant in this adaptive mechanism since it modulates the activity of most membrane proteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 457, 
          "offsetInEndSection": 764, 
          "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 247, 
          "offsetInEndSection": 530, 
          "text": "Cardiolipin is normally localized to the inner mitochondrial membrane; however, when cardiolipin becomes externalized to the surface of dysregulated mitochondria, it promotes inflammasome activation and stimulates the elimination of damaged or nonfunctional mitochondria by mitophagy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26396268", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 454, 
          "offsetInEndSection": 598, 
          "text": "In isolated mitochondrial outer membranes, cardiolipin (diphosphatidylglycerol) increased CPT1 activity 4-fold and the Km for carnitine 6-fold. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21599656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Increasing levels of cardiolipin differentially influence packing of phospholipids found in the mitochondrial inner membrane.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24905496", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 261, 
          "offsetInEndSection": 440, 
          "text": "Here, we used Saccharomyces cerevisiae subjected to conditions that affect mitochondrial metabolism as a model to determine the possible role of cardiolipin in stress adaptation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 290, 
          "offsetInEndSection": 684, 
          "text": "This decline of respiration was attributed to a progressive diminution of the number of mitochondria in copper-treated cells, based on the demonstration of the concomitant decline of (1) cardiolipin (diphosphatidylglycerol) and cytochrome aa3 (cytochrome oxidase), two specific markers of mitochondrial inner membrane, and (2) fumarase activity, a specific marker of mitochondrial matrix space.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977117", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 327, 
          "offsetInEndSection": 477, 
          "text": "Diphosphatidylglycerol (DPG) or cardiolipin, a specific component of the inner mitochondrial membrane, represents about 4% of the total lipid content.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15460113", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 348, 
          "offsetInEndSection": 628, 
          "text": "Experimental results confirmed that the biosynthesis of cardiolipin, from the membrane-bound radioactive phosphatidylglycerol in intact mitochondria isolated from guinea pig and rat liver, was absolutely dependent on CDP-diglycerides and required the addition of divalent cations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 561, 
          "offsetInEndSection": 776, 
          "text": "We have shown that decrease of cardiolipin in mitochondrial membrane occurs early during ischemia, and only during the irreversible phase of ischemia are phosphatidylethanolamine and phosphatidylcholine broken down.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7378435", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Partial purification of diphosphatidylglycerol synthetase from liver mitochondrial membranes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6257342", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 372, 
          "offsetInEndSection": 473, 
          "text": "A small decrease of diphosphatidylglycerol also occurred in the hepatoma mitochondria inner membrane.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7459841", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Have studies shown that there is no link between DNA methylation patterns and Post Traumatic Stress Disorder?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26361058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26447678", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21306736", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19793403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21714072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22332656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27886370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21508515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26305478", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25065861"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Studies do show a correlation of PTSD-related accelerated aging in DNA methylation patterns."
      ], 
      "exact_answer": "no", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:2055", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013313", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040921", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019175"
      ], 
      "type": "yesno", 
      "id": "58e2422c6fddd3e83e000011", 
      "snippets": [
        {
          "offsetInBeginSection": 918, 
          "offsetInEndSection": 1502, 
          "text": "Using pre-deployment SKA2 methylation levels and childhood trauma exposure, we found that the previously published suicide prediction rule significantly predicted post-deployment PTSD symptoms (AUC=0.66, 95% CI: 0.53-0.79) with an optimal sensitivity of 0.81 and specificity of 0.91. Permutation analysis using random methylation loci supported these findings. Together, these data establish the importance of SKA2 for cortisol stress responsivity and the development of PTSD and provide further evidence that SKA2 is a promising biomarker for stress-related disorders including PTSD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361058", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1126, 
          "offsetInEndSection": 1307, 
          "text": " Results provide novel support for PTSD-related accelerated aging in DNAm and extend the evidence base of known DNAm age correlates to the domains of neural integrity and cognition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26447678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "We investigated serum DNA methylation patterns in genomic repetitive elements, LINE-1 and Alu, for post-traumatic stress disorder (PTSD) cases and controls who were US military service members recently deployed to Afghanistan or Iraq.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 97, 
          "offsetInEndSection": 321, 
          "text": "In light of its role in glucocorticoid receptor transactivation, we investigated whether SKA2 DNA methylation influences cortisol stress reactivity and is involved in the development of post-traumatic stress disorder (PTSD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361058", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1398, 
          "offsetInEndSection": 1579, 
          "text": "These results suggest that alterations in global methylation pattern are involved in behavioural adaptation to environmental stress and pinpoint Dlgap2 as a possible target in PTSD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 286, 
          "text": "Here we examined whether there was a link between an established rat model of post-traumatic stress disorder (PTSD) and Bdnf DNA methylation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306736", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 287, 
          "text": "We investigated serum DNA methylation patterns in genomic repetitive elements, LINE-1 and Alu, for post-traumatic stress disorder (PTSD) cases and controls who were US military service members recently deployed to Afghanistan or Iraq.Cases (n = 75) had a postdeployment diagnosis of PTSD", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "DNA methylation in repetitive elements and post-traumatic stress disorder: a case-control study of US military service members", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 288, 
          "text": "Here we examined whether there was a link between an established rat model of post-traumatic stress disorder (PTSD) and Bdnf DNA methylation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306736", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "DNA methylation in repetitive elements and post-traumatic stress disorder: a case-control study of US military service members.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "AIM: We investigated serum DNA methylation patterns in genomic repetitive elements, LINE-1 and Alu, for post-traumatic stress disorder (PTSD) cases and controls who were US military service members recently deployed to Afghanistan or Iraq. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1221, 
          "offsetInEndSection": 1398, 
          "text": "Together, these results suggest that psychosocial stress may alter global and gene-specific DNA methylation patterns potentially associated with peripheral immune dysregulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21714072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "DNA methylation in vulnerability to post-traumatic stress in rats: evidence for the role of the post-synaptic density protein Dlgap2.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793403", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 763, 
          "offsetInEndSection": 885, 
          "text": "Subjects with PTSD showed a higher DNA methylation of four CpG sites at the BDNF promoter compared with those without PTSD", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27886370", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1427, 
          "offsetInEndSection": 1606, 
          "text": "Cumulatively, the data suggest that epigenetic variation at SKA2 mediates vulnerability to suicidal behaviors and PTSD through dysregulation of the HPA axis in response to stress.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305478", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is POLD3 essential for mouse development?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27524497"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1427199", 
          "o": "POLD3"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5131353035340028", 
          "o": "POLD3"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5131353035340028", 
          "o": "POLD3"
        }, 
        {
          "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
          "s": "http://linkedlifedata.com/resource/#_5131353035340028", 
          "o": "POLD3"
        }
      ], 
      "ideal_answer": [
        "Yes. The Pold3 gene encodes a subunit of the Pol\u03b4 DNA polymerase complex. Pold3 orthologs are not essential in Saccharomyces cerevisiae or chicken DT40 cells, but the Schizosaccharomyces pombe ortholog is essential. POLD3 also has a specialized role in the repair of broken replication forks, suggesting that POLD3 activity could be particularly relevant for cancer cells enduring high levels of DNA replication stress. In mouse, POLD3 is essential for development and is also required for viability in adult animals.", 
        "yes"
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5883b8e6e56acf5176000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 528, 
          "text": "The Pold3 gene encodes a subunit of the Pol\u03b4 DNA polymerase complex. Pold3 orthologs are not essential in Saccharomyces cerevisiae or chicken DT40 cells, but the Schizosaccharomyces pombe ortholog\u00a0is essential. POLD3 also has a specialized role in the repair of broken replication forks, suggesting that POLD3 activity could be particularly relevant for cancer cells enduring high levels of DNA replication stress. We report here that POLD3 is essential for mouse development and is also required for viability in adult animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 412, 
          "offsetInEndSection": 525, 
          "text": "We report here that POLD3 is essential for mouse development and is also required for viability in adult animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 415, 
          "offsetInEndSection": 528, 
          "text": "We report here that POLD3 is essential for mouse development and is also required for viability in adult animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524497", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mechanism of action of Romosozumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26989807", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27510350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25669441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25799662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26232375", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26082665", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26277199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24665957", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27641143", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24835636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24382002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27487526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24272917", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26529924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26451332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27569204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24842796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26768288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26557374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25432357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24490672", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24870844", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24433088"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Romosozumab is humanized monoclonal antibody to sclerostin. It inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. This dual effect of romosozumab leads to rapid and substantial increases in areal bone mineral density as measured by dual-energy X-ray absorptiometry. It is developed for osteoporosis treatment."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
      ], 
      "type": "summary", 
      "id": "5880e089c872c9556500000b", 
      "snippets": [
        {
          "offsetInBeginSection": 416, 
          "offsetInEndSection": 681, 
          "text": "The current review will focus on emerging treatments of osteoporosis with the potential of enhanced anabolic effects (romosozumab and abaloparatide) or uncoupling of resorption and formation (odanacatib and romosozumab) as well as the effect of combination therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989807", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1245, 
          "offsetInEndSection": 1443, 
          "text": "Newer anabolic agents are imminent and include an analogue of parathyroid hormone-related protein, abaloparatide, and a humanised monoclonal antibody to an inhibitor of bone formation, romosozumab. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27510350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 895, 
          "offsetInEndSection": 1022, 
          "text": " Several humanized monoclonal antibodies to sclerostin, including romosozumab and blosozumab, are now in clinical development. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25669441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 216, 
          "text": "Romosozumab, an antibody raised against sclerostin, is a promising bone anabolic agent.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25799662", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "Romosozumab inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. This dual effect of romosozumab leads to rapid and substantial increases in areal bone mineral density (aBMD) as measured by dual-energy X-ray absorptiometry (DXA). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26232375", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 976, 
          "offsetInEndSection": 1146, 
          "text": "Phase I and II studies of the two humanized sclerostin monoclonal antibodies, romosozumab and blosozumab, both of which have had positive effects on bone mineral density.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082665", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1142, 
          "offsetInEndSection": 1368, 
          "text": "Romosozumab, an anti-sclerosin antibody, and abaloparatide, a PTH-related peptide analog, are at present in advanced stages of clinical evaluation, so far demonstrating efficaciousness together with a favorable safety profile.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26277199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 277, 
          "offsetInEndSection": 621, 
          "text": "Advances in understanding the mechanisms of action of this signaling molecule have led to the development of a pharmacological inhibitor of sclerostin with potential clinical applications as an osteoanabolic drug for the treatment of osteoporosis.Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Update on romosozumab : a humanized monoclonal antibody to sclerostin.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272917", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 539, 
          "offsetInEndSection": 653, 
          "text": "AREAS COVERED: Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 81, 
          "offsetInEndSection": 167, 
          "text": "The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24382002", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Romosozumab (formerly AMG 785/CDP7851) is a monoclonal antibody that blocks sclerostin from inhibiting osteoblast maturation and function. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272917", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 217, 
          "text": "Romosozumab, an antibody raised against sclerostin, is a promising bone anabolic agent. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25799662", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 606, 
          "offsetInEndSection": 775, 
          "text": "Phase II clinical trials with anti-sclerostin antibodies, romosozumab and blosozumab, demonstrated a marked increase in bone mineral density after one year of treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26529924", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 652, 
          "offsetInEndSection": 1022, 
          "text": "Similar to preclinical animal studies with sclerostin antibodies, initial clinical studies show that romosozumab increases bone formation and bone mineral density.EXPERT OPINION: Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 291, 
          "offsetInEndSection": 651, 
          "text": "Advances in understanding the mechanisms of action of this signaling molecule have led to the development of a pharmacological inhibitor of sclerostin with potential clinical applications as an osteoanabolic drug for the treatment of osteoporosis.AREAS COVERED: Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Romosozumab (formerly AMG 785/CDP7851) is a monoclonal antibody that blocks sclerostin from inhibiting osteoblast maturation and function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272917", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 81, 
          "offsetInEndSection": 564, 
          "text": "The monoclonal antibody romosozumab binds to sclerostin and increases bone formation.METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24382002", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 788, 
          "offsetInEndSection": 980, 
          "text": "Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Romosozumab is a humanized immunoglobulin G  monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26502199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27111262", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23212598", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25709077", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25049338", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19016483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23706842", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15915097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22475888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25007537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17224720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11891997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27418378", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9122295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12798257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19268914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16324899", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18396192", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10954063", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16600574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11555345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11552771", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18436427", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19282141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16317314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25763455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15076016", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22209270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23103549", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21034691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19506776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24216181"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "Symptoms"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0788385"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0788385", 
          "o": "SYMPTOMS"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "Symptoms"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "http://linkedlifedata.com/resource/umls/label/A11838788"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A11838788", 
          "o": "Symptoms"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C1457887", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7164206"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7164206", 
          "o": "Symptoms"
        }
      ], 
      "ideal_answer": [
        "Davidson Trauma Scale is used for evaluation of post-traumatic stress disorder."
      ], 
      "exact_answer": [
        [
          "post-traumatic stress disorder", 
          "PTSD"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013568", 
        "http://www.disease-ontology.org/api/metadata/DOID:4", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
      ], 
      "type": "factoid", 
      "id": "58861d413b87a8a738000002", 
      "snippets": [
        {
          "offsetInBeginSection": 539, 
          "offsetInEndSection": 1221, 
          "text": "Besides, to study its scores' evidence of convergent, discriminant, and predictive validity in relation to other resilience questionnaires (Connor Davidson Resilience Scale 10-item version, Situated Subjective Resilience Questionnaire for Adults and Resiliency Questionnaire for Adults) and to variables such as emotions (Modified Differential Emotions Scale), coping (Person-situation Coping Questionnaire for Adults), anxiety and depression (Hospital Anxiety and Depression Scale), posttraumatic growth (Posttraumatic Growth Inventory), perceived stress (Perceived Stress Scale) and posttraumatic stress (Davidson Trauma Scale), correlation and regression analyses were conducted.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26502199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1441, 
          "offsetInEndSection": 1796, 
          "text": "Using the normalized population mean of 50 on the SF-36 MH domain score as a cut-off, positive predictive values were 16 and 55% for substantial depression; 20 and 68% for substantial anxiety (Depression Anxiety Stress Scales and HADS, respectively); and 40, 44, and 67% for substantial PTSD symptoms (IES-R, IES, and Davidson Trauma Scale, respectively).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111262", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 248, 
          "offsetInEndSection": 714, 
          "text": "METHOD: A randomly selected representative sample of inmates in the Puerto Rico correctional system (N = 1,179) was assessed with the Spanish-language Wender Utah Rating Scale (WURS); the Composite International Diagnostic Interview (CIDI) modules for lifetime/current major depression disorder (MDD), generalized anxiety disorder (GAD), and SUD; the Davidson Trauma Scale (DTS; posttraumatic stress disorder [PTSD]); and self-reports of in-site high-risk behaviors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212598", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 662, 
          "offsetInEndSection": 1295, 
          "text": "After correcting for multiple comparisons, no significant effects were observed on any of the outcomes among the NHW sample; however, within the NHB sample, significant gene \u00d7 environment (G \u00d7 E) interactions were observed for lifetime PTSD (P = .0029) and PTSD symptom severity (P = .0009). In each case, the APOE \u03b54 allele had no effect on the outcomes when combat exposure was low; however, when combat exposure was high, an additive effect was observed such that \u03b54 homozygotes exposed to high levels of combat reported the highest rates of PTSD (92%) and the worst symptom severity scores on the Davidson Trauma Scale (M = 79.5)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709077", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Early prognostic screening for posttraumatic stress disorder with the Davidson Trauma Scale and the SPAN.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19016483", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 271, 
          "text": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11891997", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 404, 
          "text": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates.Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25763455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 186, 
          "text": "Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15076016", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 272, 
          "text": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11891997", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 527, 
          "offsetInEndSection": 718, 
          "text": "Symptoms were assessed at sequential time points by the Structured Interview for PTSD (SIP), a clinician interview based assessment, and a self-report scale, the Davidson Trauma Scale (DTS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10954063", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 427, 
          "text": "The present study focused on platelet serotonin (5-HT) concentration and symptoms of comorbid depression in war veterans with or without PTSD.PTSD and depression were evaluated using Clinician Administered PTSD Scale, Davidson Trauma Scale, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12798257", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 768, 
          "text": "Although rates of trauma and PTSD are higher in those with bipolar disorder than in the general population, little is known about differences across bipolar subtypes.Using the NIMH STEP-BD dataset (N=3158), this study evaluated whether there were baseline differences in the prevalence of PTSD between participants with bipolar disorder I (BDI) and bipolar disorder II (BDII), using the MINI and the Davidson Trauma Scale.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706842", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 213, 
          "offsetInEndSection": 542, 
          "text": "We also investigated the interaction between the genetic variants to determine whether these variables and the interactions between the variables influenced the severity of PTSD symptoms.PTSD symptoms were quantitatively assessed using the Davidson Trauma Scale (DTS) in 150 participants from an at-risk South African population.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1378, 
          "offsetInEndSection": 1733, 
          "text": "Using the normalized population mean of 50 on the SF-36 MH domain score as a cut-off, positive predictive values were 16 and 55% for substantial depression; 20 and 68% for substantial anxiety (Depression Anxiety Stress Scales and HADS, respectively); and 40, 44, and 67% for substantial PTSD symptoms (IES-R, IES, and Davidson Trauma Scale, respectively).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111262", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 672, 
          "text": "The Davidson Trauma Scale was completed at 1 (n = 145), 6 (n = 106), 12 (n = 94), and 24 (n = 66) months postdischarge to assess symptoms of PTSD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21034691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "The Davidson Trauma Scale (DTS) is a validated, 17-item, brief global assessment scale for posttraumatic stress disorder (PTSD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18396192", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 177, 
          "offsetInEndSection": 423, 
          "text": "Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16600574", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the Mis18 protein?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25202874", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21911481", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22540025", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25569776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24269809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19217403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24774534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27239045", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24789708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27670610", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21768289", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26343758"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", 
        "the mis18 complex has been identified as a critical factor for the centromeric localization of a histone h3 variant, centromeric protein a (cenp-a), which is responsible for the specification of centromere identity in the chromosome.", 
        "The Mis18 complex is a critical player in determining when and where centromeres are built. The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome. Eukaryotic chromosomes segregate by attaching to microtubules of the mitotic spindle through a chromosomal microtubule binding site called the kinetochore. Centromeres are important structural constituents of chromosomes that ensure proper chromosome segregation during mitosis by providing defined sites for kinetochore attachment. Centromeres contain specialized chromatin that includes the centromere-specific histone H3 variant, spCENP-A/Cnp1.", 
        "Mis16 and Mis18 form a complex and maintain the deacetylated state of histones specifically in the central core of centromeres. A fundamental process in centromere establishment is the incorporation of the histone variant CENP-A into centromeric chromatin, which provides a binding platform for the other centromeric proteins. CENP-A nucleosome assembly requires the Mis18 complex and the CENP-A chaperone HJURP. Thus, CENP-C provides a link between existing CENP-A chromatin and the proteins required for new CENP-A nucleosome assembly. The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome. This is a critical step that is essential for proper centromere function and maintaining the integrity of the genome.", 
        "Kinetochores assemble on a specialized chromosomal locus termed the centromere, which is characterized by the replacement of histone H3 in centromeric nucleosomes with the essential histone H3 variant CENP-A (centromere protein A). The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome. Further, we demonstrate Mis18\u00ce\u00b1's crucial role for epigenetic regulation of centromeric chromatin by reinforcing centromeric localization of DNMT3A/3B. Mis18\u00ce\u00b1 interacts with DNMT3A/3B, and this interaction is critical for maintaining DNA methylation and hence regulating epigenetic states of centromeric chromatin. Together, our findings uncover the functional mechanism of Mis18\u00ce\u00b1 and its pivotal role in mammalian cell cycle. The Mis18 complex is a critical player in determining when and where centromeres are built.", 
        "Together, our findings uncover the functional mechanism of Mis18\u03b1 and its pivotal role in mammalian cell cycle. The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", 
        "Mis16 and Mis18 are required for CENP-A loading and histone deacetylation at centromeres Here we report identification of five fission yeast centromere proteins, Mis14-18. Mis14 is recruited to kinetochores independently of CENP-A, and, conversely, CENP-A does not require Mis14 to associate with centromeres. In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway. Mis16 and Mis18 form a complex and maintain the deacetylated state of histones specifically in the central core of centromeres. Mis16 and Mis18 are the most upstream factors in kinetochore assembly as they can associate with kinetochores in all kinetochore mutants except for mis18 and mis16, respectively."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58af11e67125859353000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Mis16 and Mis18 are required for CENP-A loading and histone deacetylation at centromeres", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 335, 
          "text": "Here we report identification of five fission yeast centromere proteins, Mis14-18. Mis14 is recruited to kinetochores independently of CENP-A, and, conversely, CENP-A does not require Mis14 to associate with centromeres.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 336, 
          "offsetInEndSection": 476, 
          "text": "In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 559, 
          "offsetInEndSection": 866, 
          "text": "Mis16 and Mis18 form a complex and maintain the deacetylated state of histones specifically in the central core of centromeres. Mis16 and Mis18 are the most upstream factors in kinetochore assembly as they can associate with kinetochores in all kinetochore mutants except for mis18 and mis16, respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 508, 
          "offsetInEndSection": 640, 
          "text": "The Mis18 complex, and, in particular, its member M18BP1 was shown to be essential for both incorporation and maintenance of CENP-A.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540025", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 513, 
          "offsetInEndSection": 599, 
          "text": " CENP-A nucleosome assembly requires the Mis18 complex and the CENP-A chaperone HJURP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911481", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Roles of Mis18\u03b1 in epigenetic regulation of centromeric chromatin and CENP-A loading", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 300, 
          "offsetInEndSection": 514, 
          "text": "Here, we generated Mis18\u03b1 conditional knockout mice and found that Mis18\u03b1 deficiency resulted in lethality at early embryonic stage with severe defects in chromosome segregation caused by mislocalization of CENP-A.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 515, 
          "offsetInEndSection": 664, 
          "text": "Further, we demonstrate Mis18\u03b1's crucial role for epigenetic regulation of centromeric chromatin by reinforcing centromeric localization of DNMT3A/3B", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 666, 
          "offsetInEndSection": 827, 
          "text": "Mis18\u03b1 interacts with DNMT3A/3B, and this interaction is critical for maintaining DNA methylation and hence regulating epigenetic states of centromeric chromatin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 829, 
          "offsetInEndSection": 1003, 
          "text": "Mis18\u03b1 deficiency led to reduced DNA methylation, altered histone modifications, and uncontrolled noncoding transcripts in centromere region by decreased DNMT3A/3B enrichment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1005, 
          "offsetInEndSection": 1116, 
          "text": "Together, our findings uncover the functional mechanism of Mis18\u03b1 and its pivotal role in mammalian cell cycle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 51, 
          "text": "Centromere licensing: Mis18 is required to Polo-ver", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202874", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "The Mis18 complex is a critical player in determining when and where centromeres are built", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202874", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 793, 
          "offsetInEndSection": 972, 
          "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "Mis16 and Mis18 are subunits of a protein complex required for incorporation of the histone H3 variant CenH3 (Cnp1/CENP-A) into centromeric chromatin in Schizosaccharomyces pombe and mammals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19217403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "The Mis18 proteins (Mis18\u03b1, Mis18\u03b2, and M18BP1) are pivotal to the deposition of CENP-A at the centromere during cell cycle progression and are indispensable for embryonic development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27670610", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 471, 
          "text": "Although Mis18\u03b1 and Mis18\u03b2 are highly homologous proteins, we find that their conserved YIPPEE domains mediate distinct interactions that are essential to link new CENP-A deposition to existing centromeres.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239045", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 796, 
          "offsetInEndSection": 975, 
          "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 335, 
          "offsetInEndSection": 651, 
          "text": "Ectopically targeted CENP-A chromatin at the LacO array was sufficient to direct the assembly of a functional centromere as indicated by the recruitment of the constitutive centromere-associated network proteins, the microtubule-binding protein NDC80, and the formation of stable kinetochore-microtubule attachments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21768289", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 64, 
          "offsetInEndSection": 208, 
          "text": "Replication-independent incorporation of CENP-A at centromeres depends on its chaperone HJURP(Scm3), and Mis18 in vertebrates and fission yeast.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 932, 
          "offsetInEndSection": 1261, 
          "text": "Our findings suggest that Eic1 serves a function analogous to that of Mis18BP1(KNL2), thus representing the functional counterpart of Mis18BP1(KNL2) in fission yeast that connects with a module within the CCAN/Mis6/Ctf19 complex to allow the temporally regulated recruitment of the Mis18/Scm3(HJURP) Cnp1(CENP-A) loading factors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 77, 
          "offsetInEndSection": 215, 
          "text": "Here, we show that Mis18\u00e2, a component of Mis18 complex governing CENP-A localization, is a new substrate of \u00e2TrCP-containing SCF complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269809", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "Schizosaccharomyces pombe centromere protein Mis19 links Mis16 and Mis18 to recruit CENP-A through interacting with NMD factors and the SWI/SNF complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774534", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 108, 
          "offsetInEndSection": 245, 
          "text": "The fission yeast Schizosaccharomyces pombe and mammalian Mis16 and Mis18 form a complex essential for CENP-A recruitment to centromeres.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774534", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 796, 
          "offsetInEndSection": 1227, 
          "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A. Searches for distant homologs point to an evolutionary relationship of CULT, yippee, and Mis18 to proteins sharing a common fold, which consists of two four-stranded \u03b2-meanders packing at a roughly right angle and coordinating a zinc ion at their apex", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Schizosaccharomyces pombe centromere protein Mis19 links Mis16 and Mis18 to recruit CENP-A through interacting with NMD factors and the SWI/SNF complex", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774534", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 336, 
          "offsetInEndSection": 475, 
          "text": "In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "Eic1 links Mis18 with the CCAN/Mis6/Ctf19 complex to promote CENP-A assembly.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Mis16 and Mis18 are required for CENP-A loading and histone deacetylation at centromeres.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 773, 
          "offsetInEndSection": 932, 
          "text": "No Mis18BP1(KNL2) orthologue has been identified in fission yeast, consequently it remains unknown how the key Cnp1(CENP-A) loading factor Mis18 is recruited. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 336, 
          "offsetInEndSection": 477, 
          "text": "In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 213, 
          "offsetInEndSection": 451, 
          "text": "In fission yeast, Scm3sp and the Mis18 complex, composed of Mis16, Eic1, and Mis18, function as a CENP-A(Cnp1)-specific chaperone and a recruiting factor, respectively, and together ensure accurate delivery of CENP-A(Cnp1) to centromeres.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343758", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 796, 
          "offsetInEndSection": 1228, 
          "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A. Searches for distant homologs point to an evolutionary relationship of CULT, yippee, and Mis18 to proteins sharing a common fold, which consists of two four-stranded \u03b2-meanders packing at a roughly right angle and coordinating a zinc ion at their apex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 773, 
          "offsetInEndSection": 931, 
          "text": "No Mis18BP1(KNL2) orthologue has been identified in fission yeast, consequently it remains unknown how the key Cnp1(CENP-A) loading factor Mis18 is recruited.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 514, 
          "offsetInEndSection": 599, 
          "text": "CENP-A nucleosome assembly requires the Mis18 complex and the CENP-A chaperone HJURP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911481", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 474, 
          "offsetInEndSection": 716, 
          "text": "We find that Mis18\u03b1 directly interacts with the N terminus of Mis18BP1, whereas Mis18\u03b2 directly interacts with CENP-C during G1 phase, revealing that these proteins have evolved to serve distinct functions in centromeres of higher eukaryotes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239045", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are hepadnaviral minichromosomes free of nucleosomes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21331901", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3023620", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8380890", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8649399", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1337883"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned.", 
        "In vitro assembled minichromosomes were able to replicate efficiently in vitro, when the DNA was preincubated with T-antigen, a cytosolic S100 extract and three deoxynucleoside triphosphates prior to chromatin assembly, indicating that the origin has to be free of nucleosomes for replication initiation. The transcriptionally inactive locus is covered by an array of positioned nucleosomes extending over 1,400 bp. In minichromosomes with a (mu)LCR or DNase I-hypersensitive site 2 (HS2) which actively transcribe the epsilon-globin gene, the nucleosome at the promoter is altered or disrupted while positioning of nucleosomes in the rest of the locus is retained. Viral minichromosomes were found to exist in at least two defined structures covered with 11 or 12 nucleosomes, leaving open gaps accessible for interactions with other host factors. Minichromosomes from both preparations contain the full complement of nucleosomes, but salt treatment removes histone H1 and a fraction of nonhistone chromatin proteins. This double-stranded DNA serves as a template for replication as well as transcription and is assembled into host nucleosomes, yielding circular viral minichromosomes. In contrast, the replicated untreated minichromosomes were found to be densely packed with nucleosomes, indicating that an assembly of new nucleosomes occurred during in vitro replication.", 
        "Several nucleosome-protected sites in a region of the DHBV genome [nucleotides (nt) 2000 to 2700], known to harbor various cis transcription regulatory elements, were consistently identified in all DHBV-positive liver samples. In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings.", 
        "nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned. In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58e3d1743e8b6dc87c000001", 
      "snippets": [
        {
          "offsetInBeginSection": 556, 
          "offsetInEndSection": 782, 
          "text": "Several nucleosome-protected sites in a region of the DHBV genome [nucleotides (nt) 2000 to 2700], known to harbor various cis transcription regulatory elements, were consistently identified in all DHBV-positive liver samples.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 783, 
          "offsetInEndSection": 1024, 
          "text": "In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1054, 
          "offsetInEndSection": 1160, 
          "text": "nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 232, 
          "offsetInEndSection": 593, 
          "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 212, 
          "offsetInEndSection": 554, 
          "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 291, 
          "offsetInEndSection": 497, 
          "text": "Mature SV40 minichromosomes are estimated to contain about 27 nucleosomes (error +/- 2), except for those molecules with a nucleosome-free gap, which are interpreted to contain 25 nucleosomes (error +/- 2).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3023620", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 591, 
          "offsetInEndSection": 791, 
          "text": "In vitro replication in the presence of protein-free competitor DNA shows that replicating trypsinized minichromosomes do not lose nucleosomes and replicating competitor DNA does not gain nucleosomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8649399", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 595, 
          "offsetInEndSection": 795, 
          "text": "In vitro replication in the presence of protein-free competitor DNA shows that replicating trypsinized minichromosomes do not lose nucleosomes and replicating competitor DNA does not gain nucleosomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8649399", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 599, 
          "offsetInEndSection": 793, 
          "text": "We conclude that in both cases parental nucleosomes are transferred to progeny DNA, and, in addition, that an assembly of new nucleosomes occurs during the replication of native minichromosomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1337883", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 657, 
          "offsetInEndSection": 845, 
          "text": "In contrast, the replicated untreated minichromosomes were found to be densely packed with nucleosomes, indicating that an assembly of new nucleosomes occurred during in vitro replication.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8380890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 233, 
          "offsetInEndSection": 593, 
          "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 213, 
          "offsetInEndSection": 554, 
          "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 213, 
          "offsetInEndSection": 555, 
          "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 233, 
          "offsetInEndSection": 595, 
          "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Cri Du Chat associated with an expansion of a repeat with in the gene found on chromosome 5?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27144168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7896290", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1606717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21045963", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7757083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9718678", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24556499", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9464278", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2988137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/995018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11810654", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23455788", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7762563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9284926", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7713510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16953888"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0008668", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18590602"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18590602", 
          "o": "5 chromosome"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0008668", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7569590"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7569590", 
          "o": "Chromosome 5"
        }
      ], 
      "ideal_answer": [
        "Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5.", 
        "cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5.", 
        "Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5", 
        "syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5 . ", 
        "Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5. "
      ], 
      "exact_answer": "no", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003410", 
        "http://www.disease-ontology.org/api/metadata/DOID:12580"
      ], 
      "type": "yesno", 
      "id": "58dbba438acda3452900001c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 192, 
          "offsetInEndSection": 571, 
          "text": "The typical cri du chat syndrome, due to 5p15.2 deletion, includes severe intellectual disability, facial dysmorphisms, neonatal hypotonia and pre- and post-natal growth retardation, whereas more distal deletions in 5p15.3 lead to cat-like cry and speech delay and produce the clinical picture of the atypical cri du chat syndrome, with minimal or absent intellectual impairment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556499", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Cri-du-chat is a human contiguous gene deletion syndrome resulting from hemizygous deletions of chromosome 5p.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9464278", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Cri-du-chat is a chromosomal deletion syndrome characterized by partial deletion of the short arm of chromosome 5.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7896290", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 188, 
          "offsetInEndSection": 322, 
          "text": "The karyotype showed a terminal deletion of the short arm of chromosome 5 including the critical region 5p15 for cri du chat syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11810654", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 804, 
          "offsetInEndSection": 938, 
          "text": "Fewer than 1 in 200 of cri du chat syndrome cases are due to recombination aneusomy arising from a parental inversion of chromosome 5.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1606717", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Molecular approach to analyzing the human 5p deletion syndrome, cri du chat.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2988137", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Cri-du-chat is a human contiguous gene deletion syndrome resulting from hemizygous deletions of chromosome 5p", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9464278", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "The cri du chat syndrome (CdCS) is a chromosomal deletion syndrome associated with a partial deletion of the short (p) arm of chromosome 5", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23455788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "The cri-du-chat syndrome is a contiguous gene syndrome that results from a deletion of the short arm of chromosome 5 (5p).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7762563", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Cri-du-chat syndrome is associated with a deletion of the short arm of chromosome 5.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9284926", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "The deletion of the short arm of chromosome 5 is associated with the cri-du-chat syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7713510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "The Cri du Chat syndrome (CdCS) is a genetic disease resulting from a deletion of variable size occurring on the short arm of chromosome 5 (5p-).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953888", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Cri-du-chat is a well described partial aneusomy resulting from deletion of the short arm of chromosome 5.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7757083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "Cri-du-chat syndrome is caused by haploinsufficiency of the genes on the distal part of the short arm of chromosome 5, and characteristic features include microcephaly, developmental delays, and a distinctive high-pitched mewing cry.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21045963", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 461, 
          "offsetInEndSection": 578, 
          "text": "The pathological condition of cri du chat syndrome is due to the cytogenetic deletion of band p15.2 of chromosome 5. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9718678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 695, 
          "offsetInEndSection": 875, 
          "text": " Karyotype analysis indicated that the patient has carried a terminal deletion in 5p. FISH with Cri du Chat syndrome region probe confirmed that D5S23 and D5S721 loci are deleted. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450488", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the roles of Smyd3 in zebrafish?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21887258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27377701", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25997738"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0043457", 
          "o": "Danio rerio"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0043457", 
          "o": "Danio rerio"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0043457", 
          "o": "Danio rerio"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0043457", 
          "o": "http://linkedlifedata.com/resource/umls/label/A7574572"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A7574572", 
          "o": "Zebrafish"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0043457", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0134867"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0134867", 
          "o": "Zebrafish"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0043457", 
          "o": "http://linkedlifedata.com/resource/umls/label/A18687609"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A18687609", 
          "o": "zebrafish"
        }
      ], 
      "ideal_answer": [
        "Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish. Transcripts of smyd3 are expressed in zebrafish embryos at all developmental stages and knockdown of smyd3 in embryos resulted in pericardial edema and defects in the trunk structure. In addition, these phenotypes are associated with abnormal expression of three heart-chamber markers including cmlc2, amhc and vmhc, and abnormal expression of myogenic regulatory factors including myod and myog."
      ], 
      "exact_answer": [
        [
          "The development of cardiac muscle"
        ], 
        [
          "The development of skeletal muscle"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015027", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D029961", 
        "http://www.uniprot.org/uniprot/SMYD3_MOUSE", 
        "http://www.uniprot.org/uniprot/SMYD3_HUMAN", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011495", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018482"
      ], 
      "type": "list", 
      "id": "5883a25d7ffa0d4374000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 704, 
          "offsetInEndSection": 1237, 
          "text": "We here show that transcripts of smyd3 were expressed in zebrafish embryos at all developmental stages examined and that knockdown of smyd3 in embryos resulted in pericardial edema and defects in the trunk structure. In addition, these phenotypes were associated with abnormal expression of three heart-chamber markers including cmlc2, amhc and vmhc, and abnormal expression of myogenic regulatory factors including myod and myog. These data suggest that Smyd3 plays an important role in the development of heart and skeletal muscle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 700, 
          "offsetInEndSection": 916, 
          "text": "We here show that transcripts of smyd3 were expressed in zebrafish embryos at all developmental stages examined and that knockdown of smyd3 in embryos resulted in pericardial edema and defects in the trunk structure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 465, 
          "offsetInEndSection": 717, 
          "text": "We find both smyd3 and setd7 are highly expressed within developing zebrafish heart and knock-down of these genes led to severe defects in cardiac morphogenesis without altering the expressions pattern of heart markers, including cmlc2, vmhc, and amhc.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25997738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 238, 
          "offsetInEndSection": 378, 
          "text": "SMYD1, SMYD2, SMYD3, and SMYD4 have been found to play critical roles in carcinogenesis and/or the development of heart and skeletal muscle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377701", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 240, 
          "offsetInEndSection": 380, 
          "text": "SMYD1, SMYD2, SMYD3, and SMYD4 have been found to play critical roles in carcinogenesis and/or the development of heart and skeletal muscle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377701", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1135, 
          "offsetInEndSection": 1238, 
          "text": "These data suggest that Smyd3 plays an important role in the development of heart and skeletal muscle..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which enzyme is inhibited by ribociclib?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26303211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26642065", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27017286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27810861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27336726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27729458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27717303", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25941111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27542767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26390342", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27496135", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26995305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26830312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26896604", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27087139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26053278", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25876993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27030077", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25848011"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Ribociclib is inhibitor of cyclin D-cyclin-dependent kinase 4/6 (CDK 4/6). It is used for breast cancer treatment."
      ], 
      "exact_answer": [
        [
          "cyclin D-cyclin-dependent kinase 4/6", 
          "CDK4/6"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798"
      ], 
      "type": "factoid", 
      "id": "5880dba9c872c95565000009", 
      "snippets": [
        {
          "offsetInBeginSection": 411, 
          "offsetInEndSection": 587, 
          "text": "Three CDK 4/6 inhibitors have been investigated for the treatment of HR(+) breast cancer, including palbociclib (PD 0332991), ribociclib (LEE011), and abemaciclib (LY2835219). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26303211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 472, 
          "offsetInEndSection": 761, 
          "text": "The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1054, 
          "offsetInEndSection": 1405, 
          "text": "SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1339, 
          "offsetInEndSection": 1512, 
          "text": "Currently, three selective CDK4/6 inhibitors have been approved or are in late-stage development: palbociclib (PD-0332991), ribociclib (LEE011), and abemaciclib (LY2835219).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27017286", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 276, 
          "text": "The combination of antiestrogen therapy and ribociclib, an investigational CDK4/6 inhibitor, led to improved outcomes in women with metastatic HR-positive, HER2-negative breast cancer, according to findings presented at a meeting of the European Society for Medical Oncology. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 353, 
          "text": "OBJECTIVES: Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). This study assessed the biological activity of ribociclib (LEE011; CDK4/6 inhibitor) plus letrozole compared with single-agent letrozole in the presurgical setting", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 406, 
          "offsetInEndSection": 559, 
          "text": "Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 547, 
          "offsetInEndSection": 803, 
          "text": "After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell cycle analysis, Ki67 immunostaining, timelapse microscopy and xenograft studies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 274, 
          "offsetInEndSection": 635, 
          "text": "Methods In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717303", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 522, 
          "offsetInEndSection": 795, 
          "text": "Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941111", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 874, 
          "offsetInEndSection": 1102, 
          "text": "Targeted inhibition of CDK4/6 pathway by small-molecule inhibitors palbociclib (PD-0332991) and ribociclib (LEE011) resulted in inhibition of cell-cycle progression, amelioration of kidney injury, and improved overall survival. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848011", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which histone mutations have been associated with pediatric gliomas?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26376656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27135271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23907119", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23715325", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23603901", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27622066", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23417712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25170156", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25525250", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23539183", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24285547", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25200322", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23429371", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25401693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27048880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27444975"
      ], 
      "triples": [], 
      "ideal_answer": [
        "About 80% of Diffuse intrinsic pontine glioma (DIPG) cases and 70% of midline glioblastomas contain a mutation at one allele of the H3F3A gene (encoding histone H3 variant H3.3), replacing the lysine 27 with methionine (K27M). Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome. Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1)", 
        ", approximately 30% of pediatric high grade gliomas (pedhgg) including gbm and dipg harbor a lysine 27 mutation (k27m) in histone 3.3 (h3.3) which is correlated with poor outcome and was shown to influence ezh2 function . the h3f3a mutant allele found in high-grade pediatric glioma by real-time pcr . studies on high-grade pediatric gbm have identified two recurrent mutations (k27m and g34r/v) in genes encoding histone h3 (h3f3a for h3.3 and hist1h3b for h3.1) . has been reported recently that about 80% of dipg cases and 70% of midline glioblastomas contain a mutation at one allele of the h3f3a gene (encoding histone h3 variant h3.3) , replacing the lysine 27 with methionine (k27m). . , discuss vaccine treatment for children diagnosed with malignant glioma , through targeting epha2 , il-13r\u03b12 and/or histone h3 k27m , while in adults , treatments with rintega , prophage series g-100 and dendritic cells are explored. . studies have identified a lys 27-to-methionine (k27m) mutation at one allele of h3f3a , one of the two genes encoding histone h3 variant h3.3 , in 60% of high-grade pediatric glioma cases. . new studies show that the known histone h3 alteration p.lys27met in pediatric glioma leads to globally diminished trimethylation at histone h3 lysine 27 . were able to discern the h3f3a k27m mutation in a newly obtained pediatric brainstem glioblastoma sample whose h3.3 status was not known previously , and in three other dipg samples as well as paraffin embedded samples these results demonstrate that have developed a new reliable procedure for detecting the h3f3a k27m mutation in pediatric glioblastoma patient samples. . ", 
        "Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1). Two new studies show that the known histone H3 alteration p.Lys27Met in pediatric glioma leads to globally diminished trimethylation at histone H3 lysine 27. These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis.", 
        "Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1) Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases."
      ], 
      "exact_answer": [
        [
          "K27M in H3F3A"
        ], 
        [
          "G34R/V in HIST1H3B"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58a6c94860087bc10a00002a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 355, 
          "text": " It has been reported recently that about 80% of DIPG cases and 70% of midline glioblastomas contain a mutation at one allele of the H3F3A gene (encoding histone H3 variant H3.3), replacing the lysine 27 with methionine (K27M).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 356, 
          "offsetInEndSection": 481, 
          "text": "In order to facilitate diagnosis of DIPG patients, a quick and reliable method to identify the H3F3A K27M mutation is needed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1040, 
          "offsetInEndSection": 1240, 
          "text": "Using this optimized real-time PCR assay, we analyzed eleven samples, two of which containing H3F3A K27M mutation, and found that these two samples were differentially amplified from the nine others. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1253, 
          "offsetInEndSection": 1629, 
          "text": "we were able to discern the H3F3A K27M mutation in a newly obtained pediatric brainstem glioblastoma sample whose H3.3 status was not known previously, and in three other DIPG samples as well as paraffin embedded samples. These results demonstrate that we have developed a new reliable procedure for detecting the H3F3A K27M mutation in pediatric glioblastoma patient samples.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 512, 
          "offsetInEndSection": 739, 
          "text": "Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27135271", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 72, 
          "offsetInEndSection": 240, 
          "text": "Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 504, 
          "offsetInEndSection": 620, 
          "text": "Genome-wide studies using ChIP-seq on H3.3K27M patient samples indicate a global reduction of H3K27me3 on chromatin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 621, 
          "offsetInEndSection": 788, 
          "text": "Remarkably, we also found a dramatic enrichment of H3K27me3 and EZH2 (the catalytic subunit H3K27 methyltransferase) at hundreds of gene loci in H3.3K27M patient cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 158, 
          "text": "Two new studies show that the known histone H3 alteration p.Lys27Met in pediatric glioma leads to globally diminished trimethylation at histone H3 lysine 27. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23715325", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 795, 
          "offsetInEndSection": 924, 
          "text": "These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 568, 
          "text": "Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13R\u03b12 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622066", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Histone H3 lysine(27)-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "Sequencing of pediatric gliomas has identified missense mutations Lys27Met (K27M) and Gly34Arg/Val (G34R/V) in genes encoding histone H3.3 (H3F3A) and H3.1 (HIST3H1B).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539183", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 213, 
          "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 397, 
          "offsetInEndSection": 648, 
          "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 455, 
          "text": "Exon sequencing has identified a mutation in K27M of the histone H3.3 gene (H3F3A K27M and G34R/V) in about 20% of pediatric glioblastomas, but it remains to be seen whether these mutations can be considered specific for pediatric diffuse high-grade astrocytomas or also occur in other pediatric brain tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429371", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 400, 
          "offsetInEndSection": 650, 
          "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 71, 
          "offsetInEndSection": 253, 
          "text": "Recent sequencing studies have shown that ~30\u00a0% of pediatric GBM and ~80\u00a0% of diffuse intrinsic pontine gliomas show K27M mutations in the H3F3A gene, a variant encoding histone H3.3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200322", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Histone H3 lysine(27)-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Sequencing of pediatric gliomas has identified missense mutations Lys27Met (K27M) and Gly34Arg/Val (G34R/V) in genes encoding histone H3.3 (H3F3A) and H3.1 (HIST3H1B)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539183", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 454, 
          "text": "Exon sequencing has identified a mutation in K27M of the histone H3.3 gene (H3F3A K27M and G34R/V) in about 20% of pediatric glioblastomas, but it remains to be seen whether these mutations can be considered specific for pediatric diffuse high-grade astrocytomas or also occur in other pediatric brain tumors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429371", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Pediatric brainstem gliomas often harbor oncogenic K27M mutation of histone H3.3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25401693", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 194, 
          "text": "Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 118, 
          "offsetInEndSection": 386, 
          "text": "We established a Drosophila animal model for the pathogenic histone H3K27M mutation and show that its overexpression resembles polycomb repressive complex 2 (PRC2) loss-of-function phenotypes, causing derepression of PRC2 target genes and developmental perturbations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 71, 
          "offsetInEndSection": 254, 
          "text": "Recent sequencing studies have shown that ~30\u00a0% of pediatric GBM and ~80\u00a0% of diffuse intrinsic pontine gliomas show K27M mutations in the H3F3A gene, a variant encoding histone H3.3.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200322", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 298, 
          "offsetInEndSection": 604, 
          "text": "Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 500, 
          "offsetInEndSection": 1070, 
          "text": "Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function.The present study investigated the correlation of expression of EZH2 and other PRC2 genes (EZH1, SUZ12, EED) with overall survival of pediatric GBM patients and the cytotoxic impact of EZH2 inhibition by the novel agent Tazemetostat in pediatric GBM/DIPG cells harboring either a H3.3 mutation or a H3 wildtype.EZH2 gene expression does not c", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27135271", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 400, 
          "offsetInEndSection": 651, 
          "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 940, 
          "offsetInEndSection": 1352, 
          "text": "Important insights have also been uncovered in the field of pediatric glioma, including the identification of recurrent mutation, fusion, and/or duplication events of the BRAF, FGFR1, MYB, and MYBL1 genes in pediatric low-grade gliomas, mutations affecting histone components (H3F3A p.K27M or p.G34) in pediatric high-grade gliomas, and aggressive subsets developing in midline central nervous system structures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27444975", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1139, 
          "offsetInEndSection": 1261, 
          "text": "K27M-H3.3 is universally associated with short survival in DIPG, while patients wild-type for H3.3 show improved survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1481, 
          "offsetInEndSection": 1704, 
          "text": "Taken together, our results suggest that mutations disrupting the histone code at H3K36, including H3.3 G34R/V, IDH1 and/or SETD2 mutations, are central to the genesis of hemispheric HGGs in older children and young adults.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23417712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1168, 
          "offsetInEndSection": 1284, 
          "text": "Gliomas with H3F3A K27M from pediatric or young adult patients had similar, characteristic DNA methylation profiles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285547", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1141, 
          "offsetInEndSection": 1263, 
          "text": "K27M-H3.3 is universally associated with short survival in DIPG, while patients wild-type for H3.3 show improved survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 656, 
          "offsetInEndSection": 794, 
          "text": "Moreover, the gain of H3K27me3 and Ezh2 at gene promoters alters the expression of genes that are associated with various cancer pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is it feasible to obtain DNA read lengths that exceed 30 Kb?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27587671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27712583", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25977818"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The emergence and development of so called third generation sequencing platforms such as PacBio has permitted exceptionally long reads (over 20\u2009kb) to be generated but not yet read length >30 Kb."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58dff5776fddd3e83e000008", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 368, 
          "text": "Single-molecule, real-time sequencing (SMRT) developed by Pacific BioSciences produces longer reads than secondary generation sequencing technologies such as Illumina. The long read length enables PacBio sequencing to close gaps in genome assembly, reveal structural variations, and identify gene isoforms with higher accuracy in transcriptomic sequencing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27587671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 214, 
          "offsetInEndSection": 513, 
          "text": " Third-generation sequencing, with read lengths>10 kb, will improve the assembly of complex genomes, but these techniques require high-molecular-weight genomic DNA (gDNA), and gDNA extraction protocols used for obtaining smaller fragments for short-read sequencing are not suitable for this purpose.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27712583", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 383, 
          "text": "The emergence and development of so called third generation sequencing platforms such as PacBio has permitted exceptionally long reads (over 20\u2009kb) to be generated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25977818", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is osteocrin expressed exclusively in the bone?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27830782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17951249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15923362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14523025"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No, Osteocrin (Ostn) has been detected in the bones and the brain."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58df73bd38f7f3e93a000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Evolution of Osteocrin as an activity-regulated factor in the primate brain.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830782", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 390, 
          "offsetInEndSection": 601, 
          "text": "Here we use transcriptional profiling of human fetal brain cultures to identify an activity-dependent secreted factor, Osteocrin (OSTN), that is induced by membrane depolarization of human but not mouse neurons.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Osteocrin (Ostn) is a recently discovered secreted protein produced by cells of the osteoblast lineage that shows a well conserved homology with members of the natriuretic peptide (NP) family. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17951249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Osteocrin (Ostn), a bone-active molecule, has been shown in animals to be highly expressed in cells of the osteoblast lineage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15923362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14523025", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is  Achondroplasia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25823796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24365319", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20624921"
      ], 
      "triples": [
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0001080", 
          "o": "Achondroplasia"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0001080", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0385394"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0385394", 
          "o": "ACHONDROPLASIA"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0001080", 
          "o": "Achondroplasia"
        }, 
        {
          "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name", 
          "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/21", 
          "o": "Achondroplasia"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0001080", 
          "o": "http://linkedlifedata.com/resource/umls/label/A0018520"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/umls/label/A0018520", 
          "o": "Achondroplasia"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
          "s": "http://linkedlifedata.com/resource/rxnorm/id/1024318", 
          "o": "http://linkedlifedata.com/resource/rxnorm/label/3105017"
        }, 
        {
          "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
          "s": "http://linkedlifedata.com/resource/rxnorm/label/3105017", 
          "o": "Achondroplasia"
        }, 
        {
          "p": "http://www.w3.org/2000/01/rdf-schema#label", 
          "s": "http://linkedlifedata.com/resource/umls/id/C0001080", 
          "o": "Achondroplasia"
        }
      ], 
      "ideal_answer": [
        "Achondrogenesis type II also known as  Achondroplasia  is an autosomal-dominant disease leading to severe micromelic dwarfism", 
        "achondrogenesis type ii is an autosomal-dominant disease leading to severe micromelic dwarfism.", 
        "Achondrogenesis type II is an autosomal-dominant disease leading to severe micromelic dwarfism.", 
        "achondrogenesis type ii is an autosomal-dominant disease to severe micromelic dwarfism. . ", 
        "Achondrogenesis type II is an autosomal-dominant disease leading to severe micromelic dwarfism. "
      ], 
      "exact_answer": [
        [
          "An autosomal dominant form of dwarfism"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000130", 
        "http://www.disease-ontology.org/api/metadata/DOID:4480"
      ], 
      "type": "factoid", 
      "id": "58cefcfb8acda34529000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Achondrogenesis type II is an autosomal-dominant disease leading to severe micromelic dwarfism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25823796", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Physical basis behind achondroplasia, the most common form of human dwarfism", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20624921", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Achondroplasia is the best described and most common form of the congenital short-limbed dwarfing conditions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24365319", 
          "endSection": "abstract"
        }
      ]
    }
  ]
}